var title_f43_13_44240="Prenatal ultrasound fetal pelvic kidney";
var content_f43_13_44240=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound fetal pelvic kidney",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 409px; height: 361px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right pelvic kidney next to the bladder and blood flow to both kidneys on color Doppler seen. The left kidney and bladder locations appear normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tulin Ozcan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_13_44240=[""].join("\n");
var outline_f43_13_44240=null;
var title_f43_13_44241="Sources of CVC infection";
var content_f43_13_44241=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sources of intravenous catheter-related infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 438px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Major sources of intravenous catheter-related infection include skin colonization with migration of microorganisms along intracutaneous tract (wound infection or infection of fibrin sheath); intraluminal colonization of device or hub; hematogenous seeding from remote focus elsewhere (infection of fibrin sheath); or the delivery of contaminated infusate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_13_44241=[""].join("\n");
var outline_f43_13_44241=null;
var title_f43_13_44242="Shoulder ROM with cane PI";
var content_f43_13_44242=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F75309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F75309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Shoulder ROM with cane",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 591px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Hold a cane (or dowel) with two hands. The arms should be held down with the elbows against the body and the thumbs on the front of the cane (away from the body).",
"    <br/>",
"    (B-C) Lift cane with both hands above head, keeping arms and back straight. Reach back until you feel a stretch in the shoulders (this should not hurt). Hold for 5 seconds. Lower the arms and rest. Repeat 10 times.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_13_44242=[""].join("\n");
var outline_f43_13_44242=null;
var title_f43_13_44243="Abnormal involuntary movement scale";
var content_f43_13_44243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F51103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F51103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Abnormal involuntary movement scale",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 764px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_13_44243=[""].join("\n");
var outline_f43_13_44243=null;
var title_f43_13_44244="Foscarnet: An overview";
var content_f43_13_44244=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Foscarnet: An overview",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/13/44244/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/13/44244/contributors\">",
"     Martin Rodriguez, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/13/44244/contributors\">",
"     Kimon C Zachary, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/13/44244/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/13/44244/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/13/44244/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/13/44244/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/13/44244/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     Foscarnet",
"    </a>",
"    is principally used for the treatment of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    -resistant cytomegalovirus (CMV) infections in patients with the acquired immunodeficiency syndrome (AIDS) or in transplant recipients.",
"   </p>",
"   <p>",
"    The mechanisms of action, pharmacokinetics, and adverse effects will be reviewed here. Treatment of the specific clinical syndromes can be found on the appropriate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     Foscarnet",
"    </a>",
"    (trisodium phosphonoformate) is a pyrophosphate analog. It binds reversibly near the pyrophosphate-binding site of DNA polymerase (or reverse transcriptase) without requiring further modification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/1\">",
"     1",
"    </a>",
"    ]. After binding, the drug blocks the cleavage of the pyrophosphate moiety from deoxynucleotide triphosphates, in turn halting DNA chain elongation. Foscarnet selectively inhibits viral polymerase; inhibition of mammalian DNA polymerase requires a 100-fold greater concentration of foscarnet than that required to block cytomegalovirus (CMV) replication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SPECTRUM OF ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     Foscarnet",
"    </a>",
"    inhibits the replication, at least in vitro, of multiple herpes family viruses, hepatitis B virus, and the human immunodeficiency virus (HIV) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/1\">",
"     1",
"    </a>",
"    ]. Clinically, foscarnet is employed almost exclusively to treat infections with cytomegalovirus (CMV), particularly when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    cannot be used, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    -resistant herpes simplex virus (HSV) and varicella zoster virus (VZV).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MECHANISM OF RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    , unlike",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    , does not require intracellular phosphorylation for antiviral activity, thymidine kinase mutations in herpes simplex virus (HSV) or varicella-zoster virus (VZV) and UL97 phosphotransferase mutations in cytomegalovirus (CMV) do not confer resistance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=see_link\">",
"     \"Acyclovir: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/25/17815?source=see_link\">",
"     \"Ganciclovir and valganciclovir: An overview\"",
"    </a>",
"    .) Foscarnet resistance in CMV has been associated with mutations in the viral DNA polymerase gene in patients receiving prolonged therapy for AIDS-associated CMV retinitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations in the HIV reverse transcriptase gene conferring resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    have also been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     BASIC PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     Foscarnet",
"    </a>",
"    has poor oral bioavailability and is therefore administered intravenously. Serum levels following a given dose can vary considerably, perhaps owing to differing equilibria resulting from foscarnet deposition in bone and cartilage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/1\">",
"     1",
"    </a>",
"    ]. Foscarnet is not significantly metabolized and is excreted solely by the kidneys, mainly via glomerular filtration and tubular secretion; bone and cartilage uptake accounts for roughly 20 percent of administered drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peak concentrations with a regimen of 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    thrice daily or 90",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice daily range from about 400 to 700",
"    <span class=\"nowrap\">",
"     micromol/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/1\">",
"     1",
"    </a>",
"    ]. Elimination follows a three-phase pattern, with half-lives of about 1 h, 3 to 7 h, and 88 h [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clearance decreases with impaired renal function, and dose adjustment in patients with renal insufficiency is required.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     Foscarnet",
"    </a>",
"    is cleared by hemodialysis; concentrations in patients receiving 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    after dialysis were similar to those in patients with normal renal function receiving 90",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/1\">",
"     1",
"    </a>",
"    ]. A small study found vitreous concentrations roughly comparable to concomitant plasma levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific toxicities are somewhat difficult to measure, given that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    is used almost exclusively in patients with significant underlying illness who are often taking multiple medications. The most important adverse effects of foscarnet are decreased renal function, electrolyte abnormalities, and infusion-related nausea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the drug's manufacturer in a 1993 tabulation, 27 percent of 188 AIDS patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    in clinical trials experienced decreased renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. This impairment is usually reversible in persons with previously normal renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     Foscarnet",
"    </a>",
"    appears to be directly toxic to the renal tubular cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/8\">",
"     8",
"    </a>",
"    ]. Although tubular damage is probably the principal factor underlying foscarnet-induced renal dysfunction, the finding of crystals in the glomerular capillaries of three patients suggests that other mechanisms may contribute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The plasma creatinine concentration usually begins to rise after 6 to 15 days, the urinalysis is relatively bland, and biopsy tissue from a few patients has revealed acute tubular necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The primary tubular injury can also explain the frequent polyuria and polydipsia via interference with the action of antidiuretic hormone&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/13\">",
"     13",
"    </a>",
"    ]; in some cases, nephrogenic diabetes insipidus has occurred in the absence of an elevation in the plasma creatinine concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal toxicity appears to be reduced by concomitant saline (generally 0.5 to 1 L) administration. Administration of other nephrotoxic drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    along with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    may increase the risk of renal insufficiency substantially [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Electrolyte abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypocalcemia is a well-established effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    , possibly via complex formation between the drug and free calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/17\">",
"     17",
"    </a>",
"    ]. Hypomagnesemia is also commonly found and may contribute to the development of both hypocalcemia and hypokalemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/1,17\">",
"     1,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42580?source=see_link\">",
"     \"Signs and symptoms of magnesium depletion\"",
"    </a>",
"    .) Other electrolyte disturbances that may occur include hypophosphatemia, hypercalcemia, and hyperphosphatemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures have been associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    in AIDS clinical trials, but it is unclear whether this effect reflects direct toxicity, drug-induced hypocalcemia, or underlying conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Genital ulcerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genital ulcerations have been linked to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    therapy, and it is suspected that a topical toxic effect of the drug concentrated in urine is responsible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/1\">",
"     1",
"    </a>",
"    ]. These lesions are reversible and potentially preventable with careful urinary hygiene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia has been reported commonly in AIDS patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    , but, again, it is difficult to discern the degree of drug effect. Neutropenia, in contrast to the experience with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    , is uncommon with foscarnet therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Nausea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infusion-related nausea afflicts about a quarter of persons receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/1\">",
"     1",
"    </a>",
"    ]. This problem, combined with the requirement for concomitant hydration and need for electrolyte monitoring, make this drug more difficult to administer than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     USE IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     Foscarnet",
"    </a>",
"    has been assigned to Pregnancy Category C (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). Skeletal anomalies have been observed in rats, and there are no adequate studies in pregnant women. This drug should be used in pregnant patients only if the anticipated benefits clearly exceed the potential risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44244/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1563820\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"       Foscarnet",
"      </a>",
"      is a pyrophosphate analog that inhibits viral replication by selectively binding to viral DNA polymerase. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In vitro,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      inhibits the replication of multiple herpes family viruses, hepatitis B virus, and HIV. Clinically, foscarnet is used almost exclusively to treat patients with cytomegalovirus (CMV) infections, particularly when",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      cannot be used, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      -resistant herpes simplex virus (HSV) and varicella zoster virus (VZV). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Spectrum of activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unlike",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      does not require intracellular phosphorylation for antiviral activity; thus, thymidine kinase mutations in HSV or VZV and UL97 phosphotransferase mutations in CMV do not confer drug resistance to foscarnet. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mechanism of resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"       Foscarnet",
"      </a>",
"      has poor oral bioavailability and is therefore administered intravenously. Clearance decreases with impaired renal function; dose adjustment of foscarnet is required. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Basic pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important adverse effects of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      are decreased renal function, electrolyte abnormalities, and infusion-related nausea. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The development of renal insufficiency on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      is common among AIDS patients taking foscarnet, although renal impairment is usually reversible among patients with previously normal renal function. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Renal insufficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypocalcemia is a well-established effect of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      , possibly via complex formation between the drug and free calcium. Hypomagnesemia is also common and may contribute to the development of both hypocalcemia and hypokalemia. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Electrolyte abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"       Foscarnet",
"      </a>",
"      has been assigned to Pregnancy Category C. Skeletal anomalies have been observed in rats, and there are no adequate studies in pregnant women to assess toxicity or teratogenicity. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Use in pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44244/abstract/1\">",
"      Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994; 48:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44244/abstract/2\">",
"      Chou S, Marousek G, Guentzel S, et al. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis 1997; 176:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44244/abstract/3\">",
"      Chou S, Marousek G, Parenti DM, et al. Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. J Infect Dis 1998; 178:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44244/abstract/4\">",
"      Weinberg A, Jabs DA, Chou S, et al. Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis 2003; 187:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44244/abstract/5\">",
"      Meyer PR, Matsuura SE, Zonarich D, et al. Relationship between 3'-azido-3'-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase. J Virol 2003; 77:6127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44244/abstract/6\">",
"      Arevalo JF, Gonzalez C, Capparelli EV, et al. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J Infect Dis 1995; 172:951.",
"     </a>",
"    </li>",
"    <li>",
"     Astra Arcus. Foscarnet international prescribing information. March 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44244/abstract/8\">",
"      Trifillis AL, Cui X, Drusano GL. Use of human renal proximal tubule cell cultures for studying foscarnet-induced nephrotoxicity in vitro. Antimicrob Agents Chemother 1993; 37:2496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44244/abstract/9\">",
"      Maurice-Estepa L, Daudon M, Katlama C, et al. Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am J Kidney Dis 1998; 32:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44244/abstract/10\">",
"      Goldfarb DS, Coe FL. Foscarnet crystal deposition and renal failure. Am J Kidney Dis 1998; 32:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44244/abstract/11\">",
"      Berns JS, Cohen RM, Stumacher RJ, Rudnick MR. Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections. J Am Soc Nephrol 1991; 1:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44244/abstract/12\">",
"      Deray G, Martinez F, Katlama C, et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol 1989; 9:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44244/abstract/13\">",
"      Navarro JF, Quereda C, Quereda C, et al. Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. Am J Kidney Dis 1996; 27:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44244/abstract/14\">",
"      Farese RV Jr, Schambelan M, Hollander H, et al. Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis. Ann Intern Med 1990; 112:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44244/abstract/15\">",
"      Zaman MM, Burney S, Landman D, Quale JM. Rapid development of renal insufficiency with the simultaneous administration of amphotericin B and foscarnet. Clin Infect Dis 1996; 22:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44244/abstract/16\">",
"      Brady RC, Bernstein DI. Treatment of herpes simplex virus infections. Antiviral Res 2004; 61:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44244/abstract/17\">",
"      Guillaume MP, Karmali R, Bergmann P, Cogan E. Unusual prolonged hypocalcemia due to foscarnet in a patient with AIDS. Clin Infect Dis 1997; 25:932.",
"     </a>",
"    </li>",
"    <li>",
"     Physicians' Desk Reference, 52nd ed, Medical Economics Company, Montvale, NJ 1998.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8288 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-FB51BAF4EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_13_44244=[""].join("\n");
var outline_f43_13_44244=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1563820\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SPECTRUM OF ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MECHANISM OF RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      BASIC PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Electrolyte abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Genital ulcerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Nausea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      USE IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1563820\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8288\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8288|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\" title=\"table 1\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=related_link\">",
"      Acyclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/25/17815?source=related_link\">",
"      Ganciclovir and valganciclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42580?source=related_link\">",
"      Signs and symptoms of magnesium depletion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_13_44245="Beclomethasone (oral inhalation): Pediatric drug information";
var content_f43_13_44245=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Beclomethasone (oral inhalation): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30199?source=see_link\">",
"    see \"Beclomethasone (oral inhalation): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/17/26901?source=see_link\">",
"    see \"Beclomethasone (oral inhalation): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7990266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      QVAR&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7990267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      QVAR&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10481876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenal Corticosteroid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Inhalant (Oral)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10482266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30199?source=see_link\">",
"      see \"Beclomethasone (oral inhalation): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral inhalation (doses should be titrated to the lowest effective dose once asthma is controlled):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QVAR&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 5-11 years: Initial: 40 mcg twice daily; maximum dose: 80 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     No previous inhaled corticosteroids: Initial: 40-80 mcg twice daily; maximum dose: 320 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Previous inhaled corticosteroid use: Initial: 40-160 mcg twice daily; maximum dose: 320 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Therapeutic ratio between QVAR&reg; and other beclomethasone inhalers has not been established; when switching to QVAR&reg;, monitor patients for efficacy and adverse effects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIH Asthma Guidelines (NAEPP, 2007) (give in divided doses): HFA formulation (eg, QVAR&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 5-11 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     \"Low\" dose: 80-160 mcg/day (40 mcg/puff: 2-4 puffs/day or 80 mcg/puff: 1-2 puffs/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     \"Medium\" dose: &gt;160-320 mcg/day (40 mcg/puff: 4-8 puffs/day or 80 mcg/puff: 2-4 puffs/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     \"High\" dose: &gt;320 mcg/day (40 mcg/puff: &gt;8 puffs/day or 80 mcg/puff: &gt;4 puff/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     \"Low\" dose: 80-240 mcg/day (40 mcg/puff: 2-6 puffs/day or 80 mcg/puff: 1-3 puffs/day)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;\">",
"     \"Medium\" dose: &gt;240-480 mcg/day (40 mcg/puff: 6-12 puffs/day or 80 mcg/puff: 3-6 puffs/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     \"High\" dose: &gt;480 mcg/day (40 mcg/puff: &gt;12 puffs/day or 80 mcg/puff: 6 puffs/day)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7991812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, for oral inhalation, as dipropionate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     QVAR&reg;: 40 mcg/inhalation (7.3 g [DSC]) [chlorofluorocarbon free; contains ethanol; 100 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     QVAR&reg;: 40 mcg/inhalation (8.7 g) [chlorofluorocarbon free; contains ethanol; 120 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     QVAR&reg;: 80 mcg/inhalation (7.3 g [DSC]) [chlorofluorocarbon free; contains ethanol; 100 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     QVAR&reg;: 80 mcg/inhalation (8.7 g) [chlorofluorocarbon free; contains ethanol; 120 metered actuations]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7990269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10482267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prime canister before use. Use a spacer device for children 5-8 years of age;",
"     <b>",
"      Note:",
"     </b>",
"     Use of QVAR&reg; with a spacer device is not recommended in children &lt;5 years of age due to the decreased amount of medication that is delivered with increasing wait times; patients should be instructed to inhale immediately if using a spacer device. Rinse mouth after use to prevent",
"     <i>",
"      Candida",
"     </i>",
"     infection. Do not wash or put inhaler in water; mouthpiece may be cleaned with a dry tissue or cloth.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10481921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not store near heat or open flame; store QVAR&reg; so inhaler rests on concave end of canister (with plastic actuator on top); use Vanceril&reg; within 6 months after removal from moisture protective package",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10481912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-term (chronic) control of persistent bronchial asthma (FDA approved in ages &ge;5 years and adults);",
"     <b>",
"      not",
"     </b>",
"     indicated for the relief of acute bronchospasm. Also used to help reduce or discontinue oral corticosteroid therapy for asthma.",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F7991731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Dysphonia, headache, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylactic/anaphylactoid reactions; growth velocity reduction in children/adolescents; HPA function suppression; immediate and delayed hypersensitivity reactions (angioedema, bronchospasm, rash, urticaria); psychiatric and behavioral changes (such as aggressiveness, depression, sleep disturbances, psychomotor hyperactivity, suicidal ideation; more common in children); rarely glaucoma, increased intraocular pressure, and cataracts have been reported with inhaled corticosteroids",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10481913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to beclomethasone or any component; primary treatment of status asthmaticus or other acute episodes of bronchial asthma where intensive treatment is needed",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10481915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using higher than recommended dosages; suppression of HPA function, suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, hypercorticism (Cushing's syndrome), hyperglycemia, or glucosuria may occur. Use with extreme caution in patients with respiratory tuberculosis, untreated systemic infections, or ocular herpes simplex. Use with caution and monitor patients closely with hepatic dysfunction. Rare cases of increased IOP, glaucoma, or cataracts may occur.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10481914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after switching from systemic corticosteroids to aerosol steroids; several months may be required for full recovery of hypothalamic-pituitary-adrenal (HPA) function; patients receiving higher doses of systemic corticosteroids (eg, adults receiving &ge;20 mg of prednisone per day) may be at greater risk; during this period of HPA suppression, aerosol steroids do not provide the systemic glucocorticoid or mineralocorticoid activity needed to treat patients requiring stress doses (ie, patients with major stress such as trauma, surgery, or infections, or other conditions associated with severe electrolyte loss). When used at high doses or for a prolonged time, hypercorticism and HPA suppression (including adrenal crisis) may occur; use with inhaled or systemic corticosteroids (even alternate-day dosing) may increase risk of HPA suppression. Acute adrenal insufficiency may occur with abrupt withdrawal after long-term use or with stress; withdrawal and discontinuation of corticosteroids should be done carefully; patients with HPA axis suppression may require doses of systemic glucocorticosteroids prior to, during, and after unusual stress (eg, surgery). Immunosuppression may occur; patients may be more susceptible to infections; avoid exposure to chickenpox and measles. Switching from systemic corticosteroids to inhalation may unmask allergic conditions (such as eczema, conjunctivitis, and rhinitis) that were previously suppressed by systemic steroids. Bronchospasm may occur after use of inhaled asthma medications.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7991733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Orally Inhaled) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7991657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7991658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal reproduction studies following SubQ administration but not with oral inhalation. A decrease in fetal growth has not been observed with inhaled corticosteroid use during pregnancy. Inhaled corticosteroids are recommended for the treatment of asthma (most information available using budesonide) during pregnancy (NAEPP, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10482270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Check mucous membranes for signs of fungal infection. Monitor growth in pediatric patient. Monitor IOP with therapy &gt;6 weeks",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10482041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes and fibroblasts, reverses capillary permeability, and stabilizes lysosomal membranes at the cellular level to prevent or control inflammation",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10482192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Onset of action: Within 1-2 days in some patients; usually within 1-2 weeks; Maximum effect: 3-4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10482042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Readily absorbed; quickly hydrolyzed by pulmonary esterases to active metabolite, beclomethasone-17-monoproprionate (17-BMP), prior to absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Beclomethasone dipropionate (BDP): 20 L; 17-BMP: 424 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: BDP 87%; 17-BMP: 94% to 96%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: BDP is a prodrug (inactive) which undergoes rapid hydrolysis to 17-BMP (active monoester) during absorption; BDP is also metabolized in the liver via cytochrome P450 isoenzyme CYP3A4 to 17-BMP and two other less active metabolites: Beclomethasone-21-monopropionate (21-BMP) and beclomethasone (BOH)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, elimination: BDP: 0.5 hours; 17-BMP: 2.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: BDP: 0.5 hours; 17-BMP: 0.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Primary route of excretion is via feces (~60%); &lt;10% to 12% of oral dose excreted in urine as metabolites",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10482271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/17/26901?source=see_link\">",
"      see \"Beclomethasone (oral inhalation): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if condition being treated persists or worsens; do not decrease dose or discontinue without physician approval; may cause dry mouth; avoid spraying in eyes; avoid exposure to chicken pox or measles; if exposed, seek medical advice without delay; discard canister when labeled number of metered doses (sprays) have been used. QVAR&reg; may taste differently and have a different feeling during inhalation compared to other inhalers containing chlorofluorocarbons (CFCs). Rinse mouth after inhalation to decrease chance of oral candidiasis; report sore mouth or mouth lesions to physician",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10482272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If bronchospasm with wheezing occurs after use, a fast-acting bronchodilator may be used; discontinue orally inhaled corticosteroid and initiate alternative chronic therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     QVAR&reg;: Does not contain chlorofluorocarbons (CFCs), uses hydrofluoroalkane (HFA) as the propellant; is a solution formulation; uses smaller-size particles which results in a higher percent of drug delivered to the respiratory tract and lower recommended doses than other products. An open-label, randomized, multicenter, 12-month study in 300 asthmatic children 5-11 years of age indicated that QVAR&reg; provided long-term control of asthma at approximately half the dose compared with a CFC propelled beclomethasone MDI and spacer (Pedersen, 2002).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007; available at file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pedersen S, Warner J, Wahn U, et al, &ldquo;Growth, Systemic Safety, and Efficacy During 1 Year of Asthma Treatment With Different Beclomethasone Dipropionate Formulations: An Open-Label, Randomized Comparison of Extra Fine and Conventional Aerosols in Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2002, 109(6), file://www.pediatrics.org/cgi/content/full/109/6/e92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/13/44245/abstract-text/12042586/pubmed\" id=\"12042586\" target=\"_blank\">",
"        12042586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tinkelman DG, Reed CE, Nelson HS, et al, &ldquo;Aerosol Beclomethasone Dipropionate Compared With Theophylline as Primary Treatment of Chronic, Mild-to-Moderately Severe Asthma in Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1993, 92(1):64-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/13/44245/abstract-text/8516087/pubmed\" id=\"8516087\" target=\"_blank\">",
"        8516087",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wyatt R, Waschek J, Weinberger M, et al, &ldquo;Effects of Inhaled Beclomethasone Dipropionate and Alternate-Day Prednisone on Pituitary-Adrenal Function in Children With Chronic Asthma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1978, 299(25):1387-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/13/44245/abstract-text/362207/pubmed\" id=\"362207\" target=\"_blank\">",
"        362207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15948 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-88.81.100.162-4217E6CC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_13_44245=[""].join("\n");
var outline_f43_13_44245=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7990266\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7990267\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481876\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482266\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991812\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7990269\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482267\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481921\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481912\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991731\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481913\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481915\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481914\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298819\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991733\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991657\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991658\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482270\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482041\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482192\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482042\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482271\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10482272\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15948\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15948|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/39/21109?source=related_link\">",
"      Beclomethasone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/51/16180?source=related_link\">",
"      Beclomethasone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/34/7716?source=related_link\">",
"      Beclomethasone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30199?source=related_link\">",
"      Beclomethasone (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/17/26901?source=related_link\">",
"      Beclomethasone (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_13_44246="Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention";
var content_f43_13_44246=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/13/44246/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/13/44246/contributors\">",
"     Wendy Y Chen, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/13/44246/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/13/44246/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/13/44246/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/13/44246/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/13/44246/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women at high-risk for breast cancer, endocrine therapy can reduce the risk of invasive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in situ breast cancers.",
"   </p>",
"   <p>",
"    This topic will discuss the use of endocrine therapy in women at increased risk for breast cancer. Screening for breast cancer, surgical approaches to prevent breast cancer among high-risk women, and the risk factors for the development of breast cancer are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/49/41754?source=see_link\">",
"       \"Screening for breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=see_link\">",
"       \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2872?source=see_link\">",
"       \"Risk prediction models for breast cancer screening\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28954?source=see_link\">",
"       \"Factors that modify breast cancer risk in women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=see_link&amp;anchor=H2#H2\">",
"       \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\", section on 'Risk-reducing surgery'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9621357\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who are at an increased risk for breast cancer, we agree with guidelines from both the American Society of Clinical Oncology (ASCO) and the United States Preventive Services Task Force (USPSTF) and suggest endocrine therapy for breast cancer prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44246/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Selection criteria used in the breast cancer prevention trials to identify appropriate candidates are reasonably applied in clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44246/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age over 60 years",
"     </li>",
"     <li>",
"      Age over 35 years with a history of lobular carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS), or atypical proliferative lesion of the breast (atypical ductal or lobular hyperplasia) (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/14/44265?source=see_link\">",
"       \"Atypia and lobular carcinoma in situ: High risk lesions of the breast\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women between 35 and 59 years with a",
"      <a class=\"external\" href=\"file://www.cancer.gov/bcrisktool/\">",
"       Gail model",
"      </a>",
"      risk of breast cancer &ge;1.66 percent over five years",
"     </li>",
"     <li>",
"      Women with known BRCA1 or BRCA2 mutations who do not undergo prophylactic mastectomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although mastectomy is the only way to truly prevent breast cancer, it is only recommended in women at high risk due to germline mutations of BRCA1 or BRCA2; these women have a 50 percent or higher risk for developing breast cancer in their lifetime. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=see_link\">",
"     \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no data on the use of either the selective estrogen receptor modulators (SERMs) or aromatase inhibitors for breast cancer prevention in men. Given the low overall incidence of breast cancer in men and the lack of data to inform the benefits versus risks of chemoprevention, we recommend against the use of these agents in men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1328629\">",
"    <span class=\"h1\">",
"     TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemopreventative options include the use of selective estrogen receptor modulators (SERMs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    ) and the aromatase inhibitor,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44246/abstract/7\">",
"     7",
"    </a>",
"    ]. The data to support their administration are reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31421519\">",
"    <span class=\"h2\">",
"     Selective estrogen receptor modulators",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31421388\">",
"    <span class=\"h3\">",
"     Tamoxifen",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the normal breast and in breast cancer,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    blocks the effects of endogenous estrogen. In contrast, it produces estrogen-like effects in the uterus, bone, liver, and coagulation system. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/2/7210?source=see_link\">",
"     \"Mechanisms of action of selective estrogen receptor modulators\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41576?source=see_link\">",
"     \"Managing the side effects of tamoxifen\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the setting of primary prevention,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    reduces the risk of developing hormone-receptor positive breast cancer in both premenopausal and postmenopausal women, but does not impact overall survival. A 2009 meta-analysis of four randomized trials of tamoxifen versus placebo in both premenopausal and postmenopausal women confirmed that tamoxifen resulted in a reduction in the risk of ER-positive invasive breast cancer (risk ratio [RR] 0.70, 95% CI 0.59-0.82), although it had no effect on the risk of ER-negative breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44246/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concerns about potential serious adverse effects (eg, endometrial cancers or thromboembolic events) clearly impact a woman's decision to pursue",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    chemoprevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44246/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Although the risks of these events are significantly higher in women taking tamoxifen (compared to placebo), the overall incidence of these events is low. This was demonstrated in the NSABP P-1 trial. Compared to placebo, a five year course of tamoxifen resulted in [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44246/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increased in invasive endometrial cancer (2.24 versus 0.68 cases per 1000 women, RR 3.28, 95% CI 1.9-6.0). The risk of endometrial cancer was significantly increased only in women aged 50 years or older. In addition,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      was associated with three cases of uterine sarcoma, compared to one case diagnosed among women taking placebo.",
"     </li>",
"     <li>",
"      A trend towards higher stroke rates (1.75 versus 1.23 cases per 1000 women, RR 1.42, 95% CI 0.97-2.08), which did not reach statistical significance.",
"     </li>",
"     <li>",
"      An increased risk of pulmonary embolism (0.69 versus 0.32 cases per 1000 women, RR 2.15, 95% CI 1.08-4.51).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    -related thromboembolic events did not seem to be related to the presence of mutations in factor V Leiden or in the prothrombin gene, both of which promote blood coagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44246/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28218?source=see_link\">",
"     \"Activated protein C resistance and factor V Leiden\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two reports have addressed quality of life (QOL) issues in women enrolled in placebo-controlled trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    for the prevention of breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44246/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Both studies found that, compared to women receiving placebo, tamoxifen use was associated with an increased incidence of hot flashes and vaginal discharge but this did not result significant differences in depression, anxiety, major psychosocial outcomes, or overall QOL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31421397\">",
"    <span class=\"h3\">",
"     Raloxifene",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     Raloxifene",
"    </a>",
"    has estrogenic effects on bone and lipids, but estrogen antagonist effects on the breast and uterus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44246/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition to its approval as an agent for breast cancer prevention, it is approved for the treatment of postmenopausal osteoporosis.",
"   </p>",
"   <p>",
"    Like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , it reduces the risk of hormone-positive breast cancer but has no effect on overall survival. It also increases the risk of thromboembolic events, but unlike tamoxifen, it does not increase the risk of uterine bleeding or endometrial cancer. Thus, it is a good alternative to tamoxifen for women who may be at an increased risk for tamoxifen-related complications. Unlike tamoxifen, there are limited data for premenopausal women.",
"   </p>",
"   <p>",
"    The benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    was illustrated in a systematic review that included two trials of raloxifene as primary prevention in postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44246/abstract/8\">",
"     8",
"    </a>",
"    ]. Compared to placebo, a five year course of raloxifene resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduction in invasive breast cancer (nine less events per 1000 women-years; RR 0.44, 95% CI 0.27-0.71). This was due to reduction in hormone receptor-positive breast cancer, but not ER-negative or noninvasive breast cancer.",
"     </li>",
"     <li>",
"      An increased risk of thromboembolic events (seven more events per 1000 women-years; RR 1.60, 95% CI 1.15-2.23).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In terms of other side effects compared to placebo,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    was associated with a higher incidence of hot flashes and leg cramps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44246/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2423700\">",
"    <span class=\"h3\">",
"     Choice of tamoxifen versus raloxifene",
"    </span>",
"    &nbsp;&mdash;&nbsp;For premenopausal women with an increased risk of breast cancer, we suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    for five years. These patients are not candidates for an aromatase inhibitor. In addition, there are no data regarding the role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    as breast cancer prevention in this population. &nbsp;",
"   </p>",
"   <p>",
"    For postmenopausal women,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    appears to be more effective in the prevention of breast cancer, while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    is associated with fewer adverse events. This was demonstrated in the NSABP Study of Tamoxifen and Raloxifene (STAR) trial that enrolled 19,747 postmenopausal women and randomly assigned treatment with tamoxifen or raloxifene for five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44246/abstract/17\">",
"     17",
"    </a>",
"    ]. The major results at a median follow-up of 81 months were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      were effective in reducing the risk of invasive breast cancer by almost 50 percent.",
"     </li>",
"     <li>",
"      Compared to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      was associated with higher risks of invasive (310 versus 247 events; RR 1.24, 95% CI 1.05-1.47) and noninvasive breast cancer (137 versus 111 events, RR 1.22, 95% CI 0.95-1.59).",
"     </li>",
"     <li>",
"      However,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      was associated with a better safety profile including lower risks of:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Uterine cancer (1.2 versus 2.3 events per 1000 women; RR 0.55, 95% CI 0.36-0.83)",
"     </li>",
"     <li>",
"      Uterine hyperplasia (0.84 versus 4.4 events per 1000; RR 0.19, 95% CI 0.12-0.29)",
"     </li>",
"     <li>",
"      Thromboembolic disease (2.5 versus 3.3 events per 1000; RR 0.79, 95% CI 0.70-0.90)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31421434\">",
"    <span class=\"h2\">",
"     Aromatase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aromatase inhibitors decrease circulating levels of estrogen in postmenopausal women by blocking the action of the enzyme, aromatase, which converts androgens to estrogens. These agents are used in the treatment of postmenopausal patients with breast cancer in the adjuvant and metastatic setting. However, aromatase inhibitors are contraindicated in premenopausal women, since they may increase estrogen levels.",
"   </p>",
"   <p>",
"    There are no data comparing an aromatase inhibitor versus a SERM for breast cancer prevention, and it is unlikely that such a comparative trial will ever be completed, at least in the United States.",
"   </p>",
"   <p>",
"    The only available data on an aromatase inhibitor for prevention of breast cancer are from the National Cancer Institute of Canada (NCIC) MAP.3 trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44246/abstract/7\">",
"     7",
"    </a>",
"    ]. The MAP.3 trial enrolled 4560 postmenopausal women (median age, 62 years) and randomly assigned them to treatment with exemestane (25 mg daily for five years) or placebo for five years. At a median follow-up of 35 months, exemestane resulted in: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduction in the annual incidence rate of ER-positive invasive breast cancer compared to placebo (hazard ratio [HR] 0.35, 95% CI 0.18-0.70). There was no difference in the rate of ER-negative tumors.",
"     </li>",
"     <li>",
"      No difference in the incidence of ductal carcinoma in situ (HR 0.65, 95% CI 0.78-1.51), though the study was underpowered to detect this difference.",
"     </li>",
"     <li>",
"      An increased incidence of menopausal symptoms, including hot flashes, fatigue, sweating, insomnia, musculoskeletal pain, and arthralgias, but no difference in overall health-related quality of life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The main limitations of the MAP.3 trial are its short-term follow-up and the small number of breast cancer events. Furthermore, the decision to unblind the study and offer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    to women taking placebo means that future analyses of survival will be confounded by crossover. In addition, results of a substudy of MAP.3 indicate that exemestane has a detrimental effect on bone health, a well-known side effect of aromatase inhibition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44246/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second trial evaluating the aromatase inhibitor, anastrazole, as breast cancer prevention (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00078832\">",
"     IBIS II",
"    </a>",
"    ) has completed enrollment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31421174\">",
"    <span class=\"h1\">",
"     TREATMENT APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31421749\">",
"    <span class=\"h2\">",
"     Postmenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;For postmenopausal women at increased risk for breast cancer, we suggest endocrine therapy for prevention with treatment administered for a total of five years. The decision to administer endocrine therapy for breast cancer prevention, as well as the type of agent, must take into account the benefits and potential side effects of treatment, which will be strongly influenced by age, race, and hysterectomy status. (See",
"    <a class=\"local\" href=\"#H1328629\">",
"     'Treatment options'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A risk model has attempted to estimate the benefits of breast cancer prevention versus risks of life-threatening events (ie, invasive breast cancer, hip fracture, endometrial cancer, stroke, or pulmonary embolism) of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    and of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    among older women based on race and on whether or not they had an intact uterus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44246/abstract/19\">",
"     19",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    There are several limitations of this model including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       risk/benefit",
"      </span>",
"      ratios are quite sensitive to the specific weights chosen for life-threatening, severe, and other events, particularly treatment-related adverse effects. For some women who may be concerned about a particular health outcome, a decision on endocrine therapy based on individualized consideration of the risks may be more appropriate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      This model overestimates the benefit of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      since it was published before the updated STAR trial data were available, which showed that raloxifene was less effective than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      in terms of breast cancer prevention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, the risk-benefit ratio for primary prevention will be more favorable for younger women, those without a uterus, and those at highest risk of developing breast cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2105620482\">",
"    <span class=\"h2\">",
"     Premenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;For premenopausal women at high-risk for breast cancer, we suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    for five years rather than observation, which is consistent with the recommendations of the American Society of Clinical Oncology and the US Preventive Services Task Force [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44246/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Aromatase inhibitors are contraindicated in women with intact ovarian function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/31/499?source=see_link\">",
"       \"Patient information: Medications for the prevention of breast cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A major public health focus is the prevention of breast cancer. Among women at high-risk for breast cancer, endocrine therapy can reduce the risk of the development of invasive",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in situ breast cancers. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with an inherited germline mutation of BRCA1 or BRCA2 have at least a 50 percent or risk of breast cancer in their lifetime. These patients should be counselled on the role of prophylactic mastectomy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=see_link\">",
"       \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients at an increased risk for developing breast cancer and for whom hormonal therapy for prevention should be considered include: women over 60 years; women over 35 years with a history of lobular carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS), or atypical proliferative lesion of the breast (atypical ductal or lobular hyperplasia); women between 35 and 59 years of age with a",
"      <a class=\"external\" href=\"file://www.cancer.gov/bcrisktool/\">",
"       Gail model",
"      </a>",
"      risk of breast cancer &ge;1.66 percent or higher over five years; and women with BRCA1 or BRCA2 mutations who do not undergo prophylactic mastectomy. (See",
"      <a class=\"local\" href=\"#H9621357\">",
"       'Patient Selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most women at high risk for breast cancer and at low risk of adverse events, we suggest endocrine therapy rather than observation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1328629\">",
"       'Treatment options'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For postmenopausal women without a uterus who are candidates for medical therapy and at low risk of side effects, we suggest a five year course of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      for breast cancer prevention (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H31421749\">",
"       'Postmenopausal women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For postmenopausal women with a uterus, both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      (for a five year course) are options. For women who are more concerned about uterine cancer and thromboembolic risks, we suggest raloxifene (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For women who are more concerned about breast cancer prevention, we suggest tamoxifen (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H31421749\">",
"       'Postmenopausal women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For premenopausal women at high-risk of breast cancer, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      rather than observation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2105620482\">",
"       'Premenopausal women'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Until longer-term data are available, we suggest not administering",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/4/7238?source=see_link\">",
"       exemestane",
"      </a>",
"      for breast cancer prevention (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H31421434\">",
"       'Aromatase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44246/abstract/1\">",
"      Visvanathan K, Chlebowski RT, Hurley P, et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009; 27:3235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44246/abstract/2\">",
"      Kinsinger LS, Harris R, Woolf SH, et al. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44246/abstract/3\">",
"      Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44246/abstract/4\">",
"      Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002; 360:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44246/abstract/5\">",
"      Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007; 99:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44246/abstract/6\">",
"      Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 2007; 99:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44246/abstract/7\">",
"      Goss PE, Ingle JN, Al&eacute;s-Mart&iacute;nez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011; 364:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44246/abstract/8\">",
"      Nelson HD, Fu R, Griffin JC, et al. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med 2009; 151:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44246/abstract/9\">",
"      Melnikow J, Paterniti D, Azari R, et al. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer 2005; 103:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44246/abstract/10\">",
"      Bober SL, Hoke LA, Duda RB, et al. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol 2004; 22:4951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44246/abstract/11\">",
"      Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 2001; 8:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44246/abstract/12\">",
"      Abramson N, Costantino JP, Garber JE, et al. Effect of Factor V Leiden and prothrombin G20210--&gt;A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. J Natl Cancer Inst 2006; 98:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44246/abstract/13\">",
"      Fallowfield L, Fleissig A, Edwards R, et al. Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol 2001; 19:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44246/abstract/14\">",
"      Day R, Ganz PA, Costantino JP, et al. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999; 17:2659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44246/abstract/15\">",
"      Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44246/abstract/16\">",
"      Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44246/abstract/17\">",
"      Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila) 2010; 3:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44246/abstract/18\">",
"      Cheung AM, Tile L, Cardew S, et al. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol 2012; 13:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44246/abstract/19\">",
"      Freedman AN, Yu B, Gail MH, et al. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol 2011; 29:2327.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 756 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-6720EAAD2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_13_44246=[""].join("\n");
var outline_f43_13_44246=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9621357\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1328629\">",
"      TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31421519\">",
"      Selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31421388\">",
"      - Tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31421397\">",
"      - Raloxifene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2423700\">",
"      - Choice of tamoxifen versus raloxifene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31421434\">",
"      Aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31421174\">",
"      TREATMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31421749\">",
"      Postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2105620482\">",
"      Premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28218?source=related_link\">",
"      Activated protein C resistance and factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/14/44265?source=related_link\">",
"      Atypia and lobular carcinoma in situ: High risk lesions of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=related_link\">",
"      Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41576?source=related_link\">",
"      Managing the side effects of tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/2/7210?source=related_link\">",
"      Mechanisms of action of selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/31/499?source=related_link\">",
"      Patient information: Medications for the prevention of breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2872?source=related_link\">",
"      Risk prediction models for breast cancer screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_13_44247="Gnathostomiasis life cycle";
var content_f43_13_44247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Gnathostomiasis life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 485px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the natural definitive host (pigs, cats, dogs, wild animals) the adult worms reside in a tumor which they induce in the gastric wall. They deposit eggs that are unembryonated when passed in the feces",
"    <strong>",
"     (1)",
"    </strong>",
"    . Eggs become embryonated in water, and eggs release first-stage larvae",
"    <strong>",
"     (2)",
"    </strong>",
"    . If ingested by a small crustacean (",
"    <em>",
"     Cyclops",
"    </em>",
"    , first intermediate host), the first-stage larvae develop into second-stage larvae",
"    <strong>",
"     (3)",
"    </strong>",
"    . Following ingestion of the",
"    <em>",
"     Cyclops",
"    </em>",
"    by a fish, frog, or snake (second intermediate host), the second-stage larvae migrate into the flesh and develop into third-stage larvae",
"    <strong>",
"     (4)",
"    </strong>",
"    . When the second intermediate host is ingested by a definitive host, the third-stage larvae develop into adult parasites in the stomach wall",
"    <strong>",
"     (5)",
"    </strong>",
"    . Alternatively, the second intermediate host may be ingested by the paratenic host (animals such as birds, snakes, and frogs) in which the third-stage larvae do not develop further but remain infective to the next predator",
"    <strong>",
"     (6)",
"    </strong>",
"    . Humans become infected by eating undercooked fish or poultry containing third-stage larvae, or reportedly by drinking water containing infective second-stage larvae in",
"    <em>",
"     Cyclops",
"    </em>",
"    <strong>",
"     (7)",
"    </strong>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Gnathostomiasis. Available at:",
"     <a href=\"file://dpd.cdc.gov/dpdx/html/Gnathostomiasis.htm\" target=\"_blank\">",
"      file://dpd.cdc.gov/dpdx/html/Gnathostomiasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_13_44247=[""].join("\n");
var outline_f43_13_44247=null;
var title_f43_13_44248="Subcutaneous aeroallergen immunotherapy: Accelerated schedules (cluster and rush)";
var content_f43_13_44248=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Subcutaneous aeroallergen immunotherapy: Accelerated schedules (cluster and rush)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/13/44248/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/13/44248/contributors\">",
"     Marc Serota, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/13/44248/contributors\">",
"     Jay M Portnoy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/13/44248/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/13/44248/contributors\">",
"     Peter S Creticos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/13/44248/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/13/44248/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/13/44248/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H26044960\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous allergen immunotherapy (SCIT) may be administered using several different schedules. This topic review will discuss the advantages and disadvantages of accelerated immunotherapy schedules and the indications for their use, and will provide several specific examples of protocols that have been used successfully for aeroallergen immunotherapy. Traditional SCIT schedules and accelerated schedules for Hymenoptera immunotherapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1256?source=see_link\">",
"     \"SCIT: Standard schedules, administration techniques, and monitoring\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/46/9960?source=see_link\">",
"     \"Rush and ultra-rush venom immunotherapy for Hymenoptera allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11674182\">",
"    <span class=\"h2\">",
"     Terminology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous immunotherapy (SCIT) is divided into two phases: build-up and maintenance.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The build-up phase involves serial injections of increasing amounts of allergen. During this phase, tolerance to the allergen is gradually induced and the patient&rsquo;s immune response to the allergen is modified from a Th2 phenotype to a Th1 phenotype [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/1\">",
"       1",
"      </a>",
"      ]. In conventional SCIT schedules, the build-up phase involves one or two injections per week and lasts three to six months. Conservative and moderate examples of conventional SCIT schedules are shown (",
"      <a class=\"graphic graphic_table graphicRef60803 \" href=\"mobipreview.htm?34/4/34892\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef72555 \" href=\"mobipreview.htm?41/8/42123\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The maintenance phase of allergen immunotherapy involves ongoing injections of an immunizing dose of allergen, usually at intervals of three to six weeks. During the maintenance phase, the immune transformation becomes complete. This phase is usually extended for a period of three to five years because shorter durations of treatment are associated with an increased likelihood of symptomatic relapse once therapy is discontinued [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accelerated schedules of immunotherapy involve shortening the length of the build-up phase, while the maintenance phase remains the same. The length of the build-up phase depends upon the frequency of the injections and the incremental dose increase between consecutive injections. Thus, accelerated schedules either involve administering more injections per visit, increasing the dose more between consecutive injections, or both.",
"   </p>",
"   <p>",
"    Accelerated schedules generally fall into one of two categories:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11675165\">",
"    <span class=\"h3\">",
"     Cluster schedules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cluster schedules involve the administration of several injections (two to three) of increasing dose in one day (",
"    <a class=\"graphic graphic_table graphicRef69088 \" href=\"mobipreview.htm?35/40/36492\">",
"     table 3",
"    </a>",
"    ). The patient returns on one or more",
"    <strong>",
"     non-consecutive",
"    </strong>",
"    days, several days per week. Two days per week is a common approach, although up to four days per week (ie, every other day) is also possible. Maintenance is achieved in four to eight weeks, depending upon the spacing of the visits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11675181\">",
"    <span class=\"h3\">",
"     Rush schedules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rush schedules involve administering injections of increasing dose at 15 to 60 minute intervals over one to three consecutive days until a target dose (usually slightly less than the maintenance dose) is achieved. The remainder of the build-up phase proceeds using a traditional schedule until maintenance is achieved, usually in less than eight weeks.",
"   </p>",
"   <p>",
"    Ultrarush immunotherapy is an even more rapid dosing schedule for immunotherapy, in which an effective maintenance dose is reached within one day. Ultrarush is usually applied to Hymenoptera venom immunotherapy. Accelerated forms of venom immunotherapy are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/46/9960?source=see_link\">",
"     \"Rush and ultra-rush venom immunotherapy for Hymenoptera allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26044968\">",
"    <span class=\"h1\">",
"     ADVANTAGES AND RISKS OF ACCELERATED IMMUNOTHERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26044976\">",
"    <span class=\"h2\">",
"     Advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advantages of accelerated schedules include increased patient convenience and more rapid induction of clinical benefit:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Greater convenience",
"      </strong>",
"      &mdash; Inconvenience is the most common reason patients discontinue conventional immunotherapy. Accelerated schedules involve fewer office visits and usually result in improved compliance with therapy.",
"     </li>",
"     <li>",
"      <strong>",
"       More rapid onset of clinical benefit",
"      </strong>",
"      &mdash; Accelerated schedules induce the immunologic changes that occur during the build-up phase more rapidly than conventional schedules. Thus, patients experience clinical benefit sooner.",
"     </li>",
"     <li>",
"      <strong>",
"       Reduced risk of dosing errors",
"      </strong>",
"      &mdash; Dosing errors are one of the leading causes of systemic allergic reactions during SCIT. Accelerated schedules involve fewer doses overall during the build-up phase, and these doses are administered over a more concentrated time period, so dosing errors are reduced.",
"     </li>",
"     <li>",
"      <strong>",
"       Reduced cost",
"      </strong>",
"      &mdash; Rush schedules (although not cluster) involve fewer total injections and so can be less costly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26044984\">",
"    <span class=\"h2\">",
"     Risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary disadvantage of accelerated immunotherapy schedules with aeroallergens is the increased risk of systemic allergic reactions (SRs) during the condensed build-up phase. With both accelerated and conventional schedules of SCIT, the risk of systemic allergic reactions is greatest during the build-up phase. The vulnerability seen during this initial phase has been attributed to the fact that the patient is exposed to even more of the allergen than at baseline, because he or she is receiving it through the immunotherapy, in addition to natural exposure, and yet immunologic protection is not yet established. Therefore, shortening the build-up phase would be desirable in theory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/3\">",
"     3",
"    </a>",
"    ]. However, giving the same amount of allergen in a shorter period of time necessitates a more intense exposure, and patients are variable in their ability to tolerate this.",
"   </p>",
"   <p>",
"    With conventional SCIT using a traditional weekly build-up schedule, systemic allergic reactions (SRs) occur in 0.86 percent of injections or 28.6 percent of patients total during a multi-year course of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/4\">",
"     4",
"    </a>",
"    ]. Severe life-threatening reactions occur in less than 1 percent of all injections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/5\">",
"     5",
"    </a>",
"    ]. Fatalities occur at a rate of one per every two million injections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Systemic reactions induced by SCIT using conventional schedules, and risk factors for these reactions, are reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17656?source=see_link\">",
"     \"Anaphylaxis induced by subcutaneous allergen immunotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1500589\">",
"    <span class=\"h3\">",
"     Systemic allergic reactions during accelerated SCIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accelerated schedules for aeroallergen SCIT are associated with higher rates of SRs compared to conventional schedules, even though low-risk patients are usually selected for accelerated treatment. (See",
"    <a class=\"local\" href=\"#H26631167\">",
"     'Contraindications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Reactions tend to occur in the final doses of the 1:10",
"    <span class=\"nowrap\">",
"     v/v",
"    </span>",
"    strength, or in the 1:1",
"    <span class=\"nowrap\">",
"     v/v",
"    </span>",
"    strength (if the protocol extends into this strength). SRs are uncommon following the first few injections. The use of premedications can significantly reduce the incidence of SRs, but even with this precaution, SR rates are higher than those of conventional schedules. In general, the most accelerated protocols having the highest rates of SRs.",
"   </p>",
"   <p>",
"    A large prospective study of 1152 patients (age 3 to 63 years) compared the rates of SRs with a three-day rush schedule to those of a cluster schedule (ie, nine injections administered in six visits over two weeks), using a lyophilized dust mite extract. In addition, the impact of premedication, exclusion of patients with reduced FEV1, and adjustment for large local reactions were examined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/8\">",
"     8",
"    </a>",
"    ]. Subjects were premedicated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , long-acting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33024?source=see_link\">",
"     ketotifen",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    . Among patients receiving dust mite: 36 percent had a SR using a three-day rush schedule without premedication, compared with 16 percent in the premedicated group. SRs decreased to 7.3 percent when patients with FEV",
"    <sub>",
"     1",
"    </sub>",
"    &lt;70 percent of predicted were excluded and when the protocol was modified for large local reactions (&gt;10 cm). SRs occurred in 5.4 percent of those receiving the cluster schedule. Children under five years of age experienced greater rates of SRs than older patients, leading the authors to conclude that accelerated immunotherapy is not appropriate in this age group.",
"   </p>",
"   <p>",
"    Specific studies are reviewed below within the discussion of each type of accelerated schedule. (See",
"    <a class=\"local\" href=\"#H26045151\">",
"     'Specific protocols (including premedications and safety)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When comparing different studies, it is important to realize that each protocol has several variables: the allergen, the type of accelerated protocol, the target dose (how close to maintenance the schedule aims to achieve), the premedication regimen, and the way in which systemic reactions were measured. These details are reviewed with each study below. (See",
"    <a class=\"local\" href=\"#H26045151\">",
"     'Specific protocols (including premedications and safety)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19997142\">",
"    <span class=\"h3\">",
"     Need for hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accelerated SCIT schedules were designed to be performed in the outpatient setting under the supervision of an experienced allergist and nursing staff. There are no data to suggest that patients should be routinely hospitalized to undergo accelerated immunotherapy safely. However, patients should be screened appropriately to exclude patients who are at increased risk (See",
"    <a class=\"local\" href=\"#H26631167\">",
"     'Contraindications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17982574\">",
"    <span class=\"h2\">",
"     Strategies to reduce risks during accelerated SCIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to careful selection of patients, other strategies to reduce the risk of systemic allergic reactions (SRs) during accelerated immunotherapy include the use of premedications and avoidance of initiation during peak pollen seasons in patients being treated with pollen allergens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17982582\">",
"    <span class=\"h3\">",
"     Premedication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premedication is recommended to reduce the risk of systemic reactions. The following approaches are recommended by most authors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients undergoing cluster immunotherapy should receive an H1 antihistamine prior to each injection visit. Many studies have used",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      , administered anywhere from 15 minutes to 2 hours prior to injections (peak serum concentrations of loratadine are achieved 60 to 90 minutes after dosing). (See",
"      <a class=\"local\" href=\"#H16818310\">",
"       'Cluster schedules'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Prior to starting a patient on rush immunotherapy, it is widespread practice to administer a corticosteroid, in addition to an H1 and H2 antihistamine. Some protocols additionally call for H2 antihistamines and antileukotriene agents. Different regimens have not been compared head to head. Premedications are usually administered for three days prior to the start of the protocol. Specific regimens that have been used successfully with certain protocols are discussed below. (See",
"      <a class=\"local\" href=\"#H26045159\">",
"       'Rush schedules'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10034566\">",
"    <span class=\"h4\">",
"     Efficacy of H1 antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a randomized trial designed specifically to study the impact of premedication with an H1 antihistamine on the safety of cluster SCIT, 45 adults were treated with either birch or timothy grass",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/16/27910?source=see_link\">",
"     aluminum hydroxide",
"    </a>",
"    (slow release) extracts (Alutard SQ, ALK), using a seven-week cluster protocol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/9\">",
"     9",
"    </a>",
"    ]. All patients had seasonal allergic rhinitis and about 10 percent also had asthma. Subjects received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"     loratadine",
"    </a>",
"    (10 mg orally) or placebo two hours before each visit. Findings included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were significantly more SRs in the placebo group (79 versus 33 percent of patients).",
"     </li>",
"     <li>",
"      The SRs in the placebo group were more severe (28 versus 6 percent of reactions were grade 3, which consisted of urticaria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      asthma), although there were no life-threatening SRs in any of the patients.",
"     </li>",
"     <li>",
"      There were significantly more dose reductions due to SRs in the placebo group compared with the premedication group (25 versus 9 reductions).",
"     </li>",
"     <li>",
"      There were no differences between the two groups in the time to onset of SRs, suggesting that premedication did not delay the appearance of symptoms.",
"     </li>",
"     <li>",
"      More patients in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      group reached the maintenance dose (95 versus 71 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is some evidence that H1 antihistamines may enhance the efficacy of immunotherapy as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/10\">",
"     10",
"    </a>",
"    ]. A proposed mechanism is that reduction of systemic histamine levels secondarily decreases levels of other immune modulators and shifts the immune response away from an allergic response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10034600\">",
"    <span class=\"h4\">",
"     Efficacy of combination regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small randomized trial evaluated the impact of premedication with a combination of agents or with placebo alone on 22 children undergoing a two-day rush protocol with different aeroallergens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients in both groups received an average of 26 to 28 allergens in their immunotherapy solutions. Premedications were administered for three days, beginning one day prior to the two treatment days. Premedication consisted of astemizole (an H1 antihistamine that is no longer available),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . Children &ge;12 years of age received 15 mg astemizole twice daily for one day, followed by 10 mg twice daily the next day, and 5 mg twice daily on the third day. They also received prednisone (30 mg twice daily) and ranitidine (150 mg twice daily) on all three days. Younger children received age-adjusted doses. Seventy-three percent of children in the placebo group experienced systemic allergic reactions (SRs), compared to 22 percent in the premedication group, and the reactions were more severe, although all responded to treatment. The SRs began between 30 and 120 minutes after the injections, and the most common eliciting dose was 0.3 mL of 1:10",
"    <span class=\"nowrap\">",
"     v/v.",
"    </span>",
"    The incidence of local reactions was also reduced by premedication.",
"   </p>",
"   <p>",
"    Following this study, most subsequent studies of rush protocols have used combinations of H1 antihistamines and glucocorticoids for premedication. Some also include H2 antihistamines and antileukotriene agents. The authors use a combination of H1, H2 antihistamines and oral glucocorticoids. Different combination regimens have not been formally compared.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10034607\">",
"    <span class=\"h4\">",
"     Omalizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38629?source=see_link\">",
"     Omalizumab",
"    </a>",
"    has also been studied as a premedication for rush immunotherapy, although this clinical application is not currently approved by the United States Food and Drug Administration and the agent is costly. A randomized trial of 159 patients examined the impact of omalizumab treatment (for 9 weeks before and 12 weeks after) on a one-day rush protocol with ragweed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/12\">",
"     12",
"    </a>",
"    ]. All patients also received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/33/35350?source=see_link\">",
"     fexofenadine",
"    </a>",
"    . On the day of rush immunotherapy, epinephrine was required to treat SRs in 14 percent of patients receiving omalizumab and immunotherapy, compared to 21 percent in the group receiving immunotherapy alone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/46/17130?source=see_link\">",
"     \"Anti-IgE therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26631145\">",
"    <span class=\"h3\">",
"     Avoidance of peak pollen season",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with conventional immunotherapy, we do not recommend initiating accelerated SCIT during a pollen season if the patient is to receive injections for that specific pollen, because during this season, the patient is exposed to pollen in the air in addition to the doses of immunotherapy, resulting in an increased total cumulative dose of pollen exposure and an increased risk for SR. Given that immunotherapy is a non-urgent procedure, all steps should be taken to perform accelerated SCIT during a time that is most convenient and safe for both the patient and the clinician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17982610\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for SCIT (of any type) are reviewed in detail separately (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39049?source=see_link&amp;anchor=H2#H2\">",
"     \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The indications for",
"    <strong>",
"     accelerated",
"    </strong>",
"    aeroallergen immunotherapy are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A desire by the patient to increase convenience of the immunotherapy process,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"     </li>",
"     <li>",
"      A desire by the patient to experience clinical benefit sooner than would be possible with a conventional schedule",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple studies have demonstrated that clinically significant reduction in allergic symptoms is apparent shortly after reaching maintenance in patients receiving accelerated immunotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/13-16\">",
"     13-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26631167\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accelerated forms of immunotherapy should not be recommended to patients who are at increased risk for developing systemic allergic reactions (SRs) in response to the injections or who have comorbid medical conditions that would reduce their chances of surviving anaphylaxis. Accelerated protocols are not appropriate for patients with any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poorly controlled asthma &mdash; Poorly controlled asthma is one of the leading risk factors for developing an SR during immunotherapy. Patients whose FEV",
"      <sub>",
"       1",
"      </sub>",
"      &le;70 percent of predicted should not undergo accelerated immunotherapy and studies have demonstrated that exclusion of these patients reduces the rate of systemic reactions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/8\">",
"       8",
"      </a>",
"      ]. Clinical discretion is required in deciding to treat patients with FEV",
"      <sub>",
"       1",
"      </sub>",
"      values of 70 to 80 percent of predicted, as data are limited about this group, whereas those with an FEV",
"      <sub>",
"       1",
"      </sub>",
"      &ge;80 percent may safely be included.",
"     </li>",
"     <li>",
"      Increased sensitivity to the allergens to be administered &mdash; A careful clinical history is probably the best way to detect patients with extreme sensitivity. Most studies have not found a correlation between the size of reaction on skin testing and likelihood of SR.",
"     </li>",
"     <li>",
"      Medical conditions, other than asthma, which would impair the patient&rsquo;s ability to survive anaphylaxis or treatment for anaphylaxis &mdash; These conditions include cardiovascular disease and other pulmonary diseases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accelerated immunotherapy is also avoided in young children (under the age of five years) because higher rates of systemic reactions were reported in this age group in at least one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/8\">",
"     8",
"    </a>",
"    ] (See",
"    <a class=\"local\" href=\"#H1500589\">",
"     'Systemic allergic reactions during accelerated SCIT'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26045086\">",
"    <span class=\"h1\">",
"     STAFFING, EQUIPMENT AND CONSENT",
"    </span>",
"   </p>",
"   <p>",
"    <strong>",
"     FOR RUSH IMMUNOTHERAPY",
"    </strong>",
"    &mdash; The following recommendations about staffing, equipment, and consent are based upon the authors&rsquo; clinical experience with administering rush protocols over a period of 15 to 20 years. Practice parameters have not been developed specifically for accelerated forms of immunotherapy. No special procedures are needed for cluster immunotherapy, beyond those required for conventional immunotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19998236\">",
"    <span class=\"h2\">",
"     Staffing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinic staff should be trained in administering accelerated SCIT, be able to provide close monitoring, and be comfortable with the treatment of anaphylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19998243\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following supplies and equipment should be available when administering RIT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient&rsquo;s allergy extract, with the required dilutions",
"     </li>",
"     <li>",
"      Injection supplies (syringe, alcohol wipes)",
"     </li>",
"     <li>",
"      Peak flow meter and spirometry equipment",
"     </li>",
"     <li>",
"      Equipment for monitoring vital signs: blood pressure cuff, stethoscope and thermometer",
"     </li>",
"     <li>",
"      Supplies to obtain intravenous access and administer medications and fluids",
"     </li>",
"     <li>",
"      Rush immunotherapy administration forms",
"     </li>",
"     <li>",
"      Emergency medications (including weight-appropriate epinephrine autoinjectors and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      with nebulizer)",
"     </li>",
"     <li>",
"      We also recommend having a dosing guide at the patient&rsquo;s bedside with pre-calculated doses of all anticipated emergency medications based on the patient&rsquo;s weight (particularly important for children), which have been reviewed by at least two health care professionals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26045103\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;We obtain informed consent from all adult patients. For children and adolescents 18 years of age and younger, we obtain consent from a parent or legal guardian.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19998280\">",
"    <span class=\"h2\">",
"     Overview of rush protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our approach is to perform rush SCIT over two non-consecutive days. A pretreatment counseling session is devoted to educating the patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    guardian, obtaining consent, and equipping the patient with appropriate premedications and an epinephrine autoinjector to take home after the injections are completed. The patient then begins the premedications and returns three days later for the injections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21211347\">",
"    <span class=\"h3\">",
"     Pretreatment counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients present to clinic three days before the day that injections are to be administered. During this pretreatment counseling session, the following issues are addressed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinician and family discuss the purpose of rush SCIT, review the protocol to be used, and review benefits and risks of the procedure",
"     </li>",
"     <li>",
"      Informed consent is signed",
"     </li>",
"     <li>",
"      The nurse and family discuss the epinephrine autoinjector and how and when it should be used",
"     </li>",
"     <li>",
"      The teaching record is signed by the patient and clinician",
"     </li>",
"     <li>",
"      The family receives prescriptions for premedication (glucocorticoid, H1 and H2 blockers) and for an epinephrine autoinjector",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26045127\">",
"    <span class=\"h3\">",
"     Treatment day",
"    </span>",
"    &nbsp;&mdash;&nbsp;On the day of the procedure, the patient and one adult guardian must be present. The patient and family must have signed the consent form. The patient must have taken the premedication as prescribed. The authors suggest that adult patients arrange for a companion to drive them home, in case sedating antihistamines are administered during the treatment day.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The nurse obtains a height, weight, and baseline pulmonary function test.",
"     </li>",
"     <li>",
"      The nurse takes baseline vital signs.",
"     </li>",
"     <li>",
"      The nurse starts a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      lock (this is controversial and is not always done).",
"     </li>",
"     <li>",
"      The clinician examines the patient.",
"     </li>",
"     <li>",
"      Some practitioners advocate skin prick testing with a histamine control prior to beginning the injection series. Response to histamine suggests failure to comply with the pretreatment medications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The clinician begins the immunotherapy as scheduled on the immunotherapy forms.",
"     </li>",
"     <li>",
"      The patient is carefully monitored for signs of local and systemic reactions.",
"     </li>",
"     <li>",
"      Peak flow readings are obtained before and thirty minutes after each injection.",
"     </li>",
"     <li>",
"      Follow-up vital signs and pulmonary function tests are done as needed throughout the procedure.",
"     </li>",
"     <li>",
"      The patient is observed for at least two hours after the final injection. If stable, the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      lock is removed and the patient is discharged with follow-up instructions to return in one week to continue build-up towards full maintenance immunotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1500782\">",
"    <span class=\"h1\">",
"     ALLERGEN EXTRACT PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The composition of the immunotherapy prescription and preparation of the extracts are not different from what would be used for conventional immunotherapy, although it is desirable to limit the number of injections required to deliver the relevant allergens. It is the authors&rsquo; practice to use solutions mixed for each patient individually, combining compatible allergens, usually into one or two solutions. If this results in two solutions, we administer one solution per arm.",
"   </p>",
"   <p>",
"    Preparation of allergen extracts for use in SCIT is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/24/40327?source=see_link\">",
"     \"SCIT: Preparation of allergen extracts for therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/49/15127?source=see_link\">",
"     \"An overview of allergen extracts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26045151\">",
"    <span class=\"h1\">",
"     SPECIFIC PROTOCOLS (INCLUDING PREMEDICATIONS AND SAFETY)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following protocols have been used successfully in clinical practice and reported in the literature. In these protocols, concentrations have been expressed for the purposes of comparison using the currently accepted nomenclature system, which calls for a volume per volume",
"    <span class=\"nowrap\">",
"     (v/v)",
"    </span>",
"    representation (with 1:1 representing the undiluted maintenance concentrate &ldquo;red vial&rdquo;) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/5\">",
"     5",
"    </a>",
"    ]. Some practitioners and older studies express concentrations using a weight per volume nomenclature - in these studies, the maintenance concentration is expressed as 1:100",
"    <span class=\"nowrap\">",
"     w/v.",
"    </span>",
"    However, all the tables in this review have been translated into the current",
"    <span class=\"nowrap\">",
"     v/v",
"    </span>",
"    system.",
"   </p>",
"   <p>",
"    Ideally, concentrations are assigned a standard color vial used to represent that",
"    <span class=\"nowrap\">",
"     v/v",
"    </span>",
"    concentration: Silver 1:10,000, Green 1:1000, Blue 1:100, Yellow 1:10, Red 1:1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/5\">",
"     5",
"    </a>",
"    ]. This convention is used by most, although probably not all, allergy practices.",
"   </p>",
"   <p>",
"    There are no convincing data that one type of allergen is better tolerated than another (eg, perennial allergens versus pollens) in accelerated protocols.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16818310\">",
"    <span class=\"h2\">",
"     Cluster schedules",
"    </span>",
"    &nbsp;&mdash;&nbsp;A representative cluster schedule for aeroallergen SCIT is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef69088 \" href=\"mobipreview.htm?35/40/36492\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/17\">",
"     17",
"    </a>",
"    ]. As mentioned previously, visits occur on one or more",
"    <strong>",
"     non-consecutive",
"    </strong>",
"    days, several days per week. Two days per week is a common approach, although up to four days per week (ie, every other day) is also possible.",
"   </p>",
"   <p>",
"    Most cluster protocols use an H1 antihistamine alone for premedication, as discussed previously. (See",
"    <a class=\"local\" href=\"#H17982582\">",
"     'Premedication'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following studies of cluster protocols all included premedications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 44 patients randomized to either aluminum absorbed (slow release) (Alutard SQ, ALK) timothy grass pollen or placebo administered the treatment using a cluster protocol of 11 injections given over four weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/18\">",
"       18",
"      </a>",
"      ]. All patients had severe allergic rhinitis during grass season, and 81 percent also had chest symptoms. All patients received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      , 10 mg orally, at least 15 minutes before each visit. There were no immediate systemic reactions during the three-year study, which could be explained by the use of a slow-release allergen preparation, but there were delayed SR, all of which were mild. During build-up, SRs occurred in 18 percent of the active therapy and 23 percent of the placebo injection group, and during maintenance, 15 and 0 percent of the active and placebo injection groups, respectively.",
"     </li>",
"     <li>",
"      A randomized trial to determine the most effective maintenance dose of standardized cat allergen immunotherapy (based on short-term immunologic changes and nasal challenges) used the protocol shown in the table (",
"      <a class=\"graphic graphic_table graphicRef69088 \" href=\"mobipreview.htm?35/40/36492\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/17\">",
"       17",
"      </a>",
"      ]. Active injections were administered to 21 patients, with another 7 patients receiving placebo injections. This study did not involve a prolonged maintenance phase. All subjects received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      two hours before each visit. There were no systemic reactions.",
"     </li>",
"     <li>",
"      A study designed to evaluate three different maintenance doses of cat allergen used a four-week cluster protocol administered to 28 patients, followed by one year of maintenance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/19\">",
"       19",
"      </a>",
"      ]. The schedule was the same as that used in the birch and timothy grass trial mentioned previously [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/9\">",
"       9",
"      </a>",
"      ]. Patients were premedicated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      (10 mg) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=see_link\">",
"       zafirlukast",
"      </a>",
"      (20 mg) two hours before each visit. Only one patient experienced a mild systemic reaction (4 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A review analyzed 29 studies (of both aeroallergen and venom SCIT) and concluded that reduced rates of systemic reactions were associated with the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Premedication given 15 to 60 minutes before the first injection of each visit (most studies used H1 antihistamine)",
"     </li>",
"     <li>",
"      Use of a depot preparation",
"     </li>",
"     <li>",
"      Four or fewer injections per visit",
"     </li>",
"     <li>",
"      A total of four to six visits",
"     </li>",
"     <li>",
"      One or two visits per week (with some evidence that two were safer than one)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most studies of cluster immunotherapy have been performed with single allergens, and the published literature regarding the use of multiple allergens in cluster protocols is limited. However, the authors perform cluster immunotherapy with aqueous extracts and multiple allergens in their clinic, using an H1 antihistamine for premedication, and have had rates of systemic reactions that are in keeping with the literature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26045159\">",
"    <span class=\"h2\">",
"     Rush schedules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rush protocols involve building the patient up to a tolerated dose that is somewhat lower than the effective maintenance dose. Once this lower dose is tolerated, the remaining injections are given according to a traditional schedule of build-up until maintenance is reached.",
"   </p>",
"   <p>",
"    Several different premedication regimens have been studied for rush SCIT, all using an H1 antihistamine and oral corticosteroid. Some protocols additionally use H2 antihistamines and antileukotriene agents. As discussed previously, different regimens have not been formally compared. (See",
"    <a class=\"local\" href=\"#H10034600\">",
"     'Efficacy of combination regimens'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Various rush schedules have been described. It is difficult to compare them because of differences in extracts, final goal concentration, pretreatment regimens, and classification systems for systemic reactions. However, we present examples of schedules which have been used successfully in practice and reported in the literature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1501159\">",
"    <span class=\"h3\">",
"     One day protocol with multiple aeroallergens",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study described a one-day rush protocol using multiple aeroallergens (including tree, grass, weed, mold, cat, dog, dust mite, and cockroach) administered to 22 patients (",
"      <a class=\"graphic graphic_table graphicRef81687 \" href=\"mobipreview.htm?38/44/39627\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/21\">",
"       21",
"      </a>",
"      ]. Reactions were seen in eight patients, of which five (23 percent) were SRs, four received epinephrine and all responded quickly to treatment. All were discharged after two-hour observation in clinic and none had biphasic reactions. The five patients who experienced SRs were switched to a conventional SCIT schedule for the remainder of their treatment.",
"     </li>",
"     <li>",
"      A retrospective review of 65 patients evaluated the safety of rush SCIT using multiple aeroallergens and mixes of standardized and non-standardized allergens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/3\">",
"       3",
"      </a>",
"      ]. This study used a protocol similar to the one described above [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/21\">",
"       21",
"      </a>",
"      ] and premedicated patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"       ranitidine",
"      </a>",
"      , and either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=see_link\">",
"       zafirlukast",
"      </a>",
"      . SRs occurred in 25 patients (38 percent), of which 4 were moderate in severity and required epinephrine, and 1 was severe (hypotension, facial angioedema, urticaria) and required epinephrine and IV fluids.",
"     </li>",
"     <li>",
"      A subsequent study modified the protocol used in the first study in an attempt to reduce the rates of SRs (",
"      <a class=\"graphic graphic_table graphicRef55823 \" href=\"mobipreview.htm?42/39/43643\">",
"       table 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/22\">",
"       22",
"      </a>",
"      ]. The modified protocol lowered the highest concentration of allergen reached on the first day by tenfold (1:10",
"      <span class=\"nowrap\">",
"       v/v",
"      </span>",
"      instead of 1:1). In addition, patients were treated with a three-day pretreatment regimen of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (20 mg twice daily for ages 1 to 12 years, or 30 mg for ages &gt;12 years, for three days), and a choice of antihistamine (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/33/35350?source=see_link\">",
"       fexofenadine",
"      </a>",
"      , based upon",
"      <span class=\"nowrap\">",
"       patient/insurance",
"      </span>",
"      preferences). The time between doses was lowered from 30 to 15 minutes. After the rush component was completed, build-up continued with a conventional weekly schedule until maintenance was reached, as in other rush protocols. In a report of 893 patients treated with this approach, two percent",
"      <span class=\"nowrap\">",
"       (18/893",
"      </span>",
"      patients) experienced SRs (which were not graded), although half of these reactions occurred during the conventional build-up phase after the rush portion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/13/44248/abstract/22\">",
"       22",
"      </a>",
"      ]. One patient had anaphylactic shock and required epinephrine and hospitalization. However, the severity of this patient&rsquo;s reaction may have been increased by treatment of bronchospasm with bronchodilators alone, rather than epinephrine and bronchodilators.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, there are several approaches to rush immunotherapy, most of which result in SRs in up to a third of patients, even with premedication and careful patient selection. However, the modified protocol (",
"    <a class=\"graphic graphic_table graphicRef55823 \" href=\"mobipreview.htm?42/39/43643\">",
"     table 5",
"    </a>",
"    ) induced SRs at a significantly lower rate. The authors currently use a similar protocol in their own clinic (",
"    <a class=\"graphic graphic_table graphicRef64328 \" href=\"mobipreview.htm?24/34/25131\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10034933\">",
"    <span class=\"h1\">",
"     ADJUSTING THE PROTOCOL FOR LOCAL AND SYSTEMIC REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is common practice to terminate cluster or rush immunotherapy in a patient who develops a systemic reaction (SR) and convert to a conventional schedule. Other approaches have not been reported.",
"   </p>",
"   <p>",
"    As with conventional immunotherapy, patients who develop SRs should be treated for anaphylaxis and observed for a period of time once symptoms have resolved. Patients with mild to moderate SRs that respond promptly and completely to treatment can usually be observed in the clinic for two hours and discharged to home. However, it may be more appropriate to hospitalize a patient with a more severe reaction or with symptoms that do not respond promptly to treatment. Likewise, patients who live far from medical care or have little home support may be better served by hospitalization. There is a risk of biphasic reactions with anaphylaxis from any cause and the risk factors for recurrent symptoms are unclear, although these have rarely been reported in the rush immunotherapy literature. Deciding on the best immediate aftercare for a patient with a SR obviously required clinical judgement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19847?source=see_link&amp;anchor=H12#H12\">",
"     \"Biphasic and protracted anaphylaxis\", section on 'Possible risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patient should then return in one week to resume injections. We (the authors) believe it important not to extend this time period by even a few days, as it is our observation that patients who wait longer than a week tend to experience more systemic reactions in the remaining build-up. We resume treatment with the dose that caused the reaction. Patients should premedicate with an H1 antihistamine prior to that visit and all future visits.",
"   </p>",
"   <p>",
"    Large local reactions are treated symptomatically (eg, with ice and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ), as with conventional immunotherapy. We do not terminate cluster or rush therapy for large local reactions, unless the patient is too uncomfortable to continue. In most cases, we wait a few minutes longer between injections to allow treatment to start taking effect, and then continue the protocol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11673954\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Accelerated schedules use a condensed build-up phase of immunotherapy to reach the maintenance dose more rapidly. The maintenance phase is unchanged compared to traditional schedules. (See",
"      <a class=\"local\" href=\"#H11674182\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cluster schedules involve the administration of several injections of increasing dose in one day. The patient returns on one or more non-consecutive days, two to four days per week, and maintenance dose is achieved in four to eight weeks (",
"      <a class=\"graphic graphic_table graphicRef69088 \" href=\"mobipreview.htm?35/40/36492\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Rush schedules involve administering injections of increasing dose at 15 to 60 minute intervals over one to three days consecutive days until a target dose (usually slightly less than the maintenance dose) is achieved. The remainder of the build-up phase proceeds using a traditional schedule until maintenance is achieved, usually in less than eight weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Accelerated schedules for aeroallergen subcutaneous immunotherapy (SCIT) offer increased patient convenience and more rapid onset of clinical benefit compared to traditional SCIT schedules. (See",
"      <a class=\"local\" href=\"#H26044976\">",
"       'Advantages'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compared to traditional aeroallergen immunotherapy schedules, accelerated schedules carry an increased risk of systemic allergic reactions. (See",
"      <a class=\"local\" href=\"#H26044984\">",
"       'Risks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Accelerated aeroallergen SCIT should not be offered to patients who are at increased risk for developing systemic allergic reactions (SRs) in response to the injections or who have comorbid medical conditions that would reduce their chances of surviving anaphylaxis. (See",
"      <a class=\"local\" href=\"#H26631167\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To reduce the incidence of SRs, we recommend premedication for all patients undergoing accelerated forms of immunotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients undergoing cluster immunotherapy, we suggest an H1 antihistamine (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This is usually given 15 minutes to 2 hours before each visit. (See",
"      <a class=\"local\" href=\"#H17982582\">",
"       'Premedication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients undergoing rush immunotherapy, we suggest a more extensive regimen of premedication that includes an H1 antihistamine and a glucocorticoid, starting at least one day before the day of injections (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Most protocols administer a combination of an oral glucocorticoid and H1 and H2 antihistamines, with or without an antileukotriene agent. (See",
"      <a class=\"local\" href=\"#H17982582\">",
"       'Premedication'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergen extracts for use in accelerated immunotherapy are mixed similarly to those used in conventional immunotherapy, although the number of different solutions needed should be minimized. (See",
"      <a class=\"local\" href=\"#H1500782\">",
"       'Allergen extract preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Different protocols for cluster immunotherapy have been published, and a representative schedule is shown (",
"      <a class=\"graphic graphic_table graphicRef69088 \" href=\"mobipreview.htm?35/40/36492\">",
"       table 3",
"      </a>",
"      ). Studies evaluating the tolerability of cluster immunotherapy with multiple aeroallergens are lacking. (See",
"      <a class=\"local\" href=\"#H16818310\">",
"       'Cluster schedules'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various protocols for rush immunotherapy have been published. One protocol has been studied for use with multiple aeroallergens and is relatively well characterized (",
"      <a class=\"graphic graphic_table graphicRef55823 \" href=\"mobipreview.htm?42/39/43643\">",
"       table 5",
"      </a>",
"      ). The authors use a similar approach in their clinic (",
"      <a class=\"graphic graphic_table graphicRef64328 \" href=\"mobipreview.htm?24/34/25131\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26045159\">",
"       'Rush schedules'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients who develop systemic allergic reactions during accelerated immunotherapy be converted to a conventional schedule (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10034933\">",
"       'Adjusting the protocol for local and systemic reactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44248/abstract/1\">",
"      Durham SR, Kay AB, Hamid Q. Changes in allergic inflammation associated with successful immunotherapy. Int Arch Allergy Immunol 1995; 107:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44248/abstract/2\">",
"      Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44248/abstract/3\">",
"      Harvey SM, Laurie S, Hilton K, Khan DA. Safety of rush immunotherapy to multiple aeroallergens in an adult population. Ann Allergy Asthma Immunol 2004; 92:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44248/abstract/4\">",
"      Stewart GE 2nd, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992; 90:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44248/abstract/5\">",
"      Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44248/abstract/6\">",
"      Bernstein DI, Wanner M, Borish L, et al. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2004; 113:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44248/abstract/7\">",
"      Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA. Survey of fatalities from skin testing and immunotherapy 1985-1989. J Allergy Clin Immunol 1993; 92:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44248/abstract/8\">",
"      Hejjaoui A, Dhivert H, Michel FB, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol 1990; 85:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44248/abstract/9\">",
"      Nielsen L, Johnsen CR, Mosbech H, et al. Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol 1996; 97:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44248/abstract/10\">",
"      M&uuml;ller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol 2001; 107:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44248/abstract/11\">",
"      Portnoy J, Bagstad K, Kanarek H, et al. Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts. Ann Allergy 1994; 73:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44248/abstract/12\">",
"      Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 117:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44248/abstract/13\">",
"      Tabar AI, Echechip&iacute;a S, Garc&iacute;a BE, et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol 2005; 116:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44248/abstract/14\">",
"      Zhang L, Wang C, Han D, et al. Comparative study of cluster and conventional immunotherapy schedules with dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis. Int Arch Allergy Immunol 2009; 148:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44248/abstract/15\">",
"      Horst M, Hejjaoui A, Horst V, et al. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 1990; 85:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44248/abstract/16\">",
"      Kohno Y, Minoguchi K, Oda N, et al. Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma. J Allergy Clin Immunol 1998; 102:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44248/abstract/17\">",
"      Ewbank PA, Murray J, Sanders K, et al. A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract. J Allergy Clin Immunol 2003; 111:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44248/abstract/18\">",
"      Walker SM, Pajno GB, Lima MT, et al. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 2001; 107:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44248/abstract/19\">",
"      Nanda A, O'connor M, Anand M, et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol 2004; 114:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44248/abstract/20\">",
"      Parmiani S, Fern&aacute;ndez T&aacute;vora L, Moreno C, et al. Clustered schedules in allergen-specific immunotherapy. Allergol Immunopathol (Madr) 2002; 30:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44248/abstract/21\">",
"      Sharkey P, Portnoy J. Rush immunotherapy: experience with a one-day schedule. Ann Allergy Asthma Immunol 1996; 76:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44248/abstract/22\">",
"      Smits WL, Giese JK, Letz KL, et al. Safety of rush immunotherapy using a modified schedule: a cumulative experience of 893 patients receiving multiple aeroallergens. Allergy Asthma Proc 2007; 28:305.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13526 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-2EE9D05621-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_13_44248=[""].join("\n");
var outline_f43_13_44248=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11673954\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26044960\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11674182\">",
"      Terminology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11675165\">",
"      - Cluster schedules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11675181\">",
"      - Rush schedules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26044968\">",
"      ADVANTAGES AND RISKS OF ACCELERATED IMMUNOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26044976\">",
"      Advantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26044984\">",
"      Risks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1500589\">",
"      - Systemic allergic reactions during accelerated SCIT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19997142\">",
"      - Need for hospitalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17982574\">",
"      Strategies to reduce risks during accelerated SCIT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17982582\">",
"      - Premedication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10034566\">",
"      Efficacy of H1 antihistamines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10034600\">",
"      Efficacy of combination regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10034607\">",
"      Omalizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26631145\">",
"      - Avoidance of peak pollen season",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17982610\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26631167\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26045086\">",
"      STAFFING, EQUIPMENT AND CONSENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19998236\">",
"      Staffing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19998243\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26045103\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19998280\">",
"      Overview of rush protocols",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21211347\">",
"      - Pretreatment counseling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26045127\">",
"      - Treatment day",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1500782\">",
"      ALLERGEN EXTRACT PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26045151\">",
"      SPECIFIC PROTOCOLS (INCLUDING PREMEDICATIONS AND SAFETY)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16818310\">",
"      Cluster schedules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26045159\">",
"      Rush schedules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1501159\">",
"      - One day protocol with multiple aeroallergens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10034933\">",
"      ADJUSTING THE PROTOCOL FOR LOCAL AND SYSTEMIC REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11673954\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/13526\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/13526|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/4/34892\" title=\"table 1\">",
"      Conservative schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/8/42123\" title=\"table 2\">",
"      Moderate schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/40/36492\" title=\"table 3\">",
"      Cluster for aeroallergen SCIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/44/39627\" title=\"table 4\">",
"      One-day schedule for aeroallergen SCIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/39/43643\" title=\"table 5\">",
"      Aeroallergen SCIT - One day - modified - A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/34/25131\" title=\"table 6\">",
"      Aeroallergen SCIT - One day - modified - B",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/49/15127?source=related_link\">",
"      An overview of allergen extracts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17656?source=related_link\">",
"      Anaphylaxis induced by subcutaneous allergen immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/46/17130?source=related_link\">",
"      Anti-IgE therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19847?source=related_link\">",
"      Biphasic and protracted anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/46/9960?source=related_link\">",
"      Rush and ultra-rush venom immunotherapy for Hymenoptera allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/24/40327?source=related_link\">",
"      SCIT: Preparation of allergen extracts for therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1256?source=related_link\">",
"      SCIT: Standard schedules, administration techniques, and monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39049?source=related_link\">",
"      Subcutaneous immunotherapy for allergic disease: Indications and efficacy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_13_44249="Prevention of seasonal influenza in adults";
var content_f43_13_44249=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of seasonal influenza in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/13/44249/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/13/44249/contributors\">",
"     Kimon C Zachary, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/13/44249/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/13/44249/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/13/44249/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/13/44249/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/13/44249/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza is a communicable but preventable viral illness. Annual immunization is the most important preventive measure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/1\">",
"     1",
"    </a>",
"    ], and is recommended for all individuals over six months of age in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/2\">",
"     2",
"    </a>",
"    ]. However, antiviral drugs are available and play an important adjunctive role for patients who have not been immunized or who may not develop immunity from the vaccine.",
"   </p>",
"   <p>",
"    Two classes of antiviral drugs are available for the prevention and treatment of influenza [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The neuraminidase inhibitors,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      , which are active against both influenza A and B.",
"     </li>",
"     <li>",
"      The adamantanes,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"       rimantadine",
"      </a>",
"      , which are only active against influenza A. Due to a marked increase in resistant isolates, these agents should generally",
"      <strong>",
"       not",
"      </strong>",
"      be used in the United States for preventive therapy except in selected circumstances, which are discussed below. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Choice of antiviral drug'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of these drugs in the prevention of seasonal influenza will be reviewed here. The role of antiviral drugs for the treatment of seasonal influenza, the prevention and treatment of pandemic H1N1 influenza and avian influenza, the prevention and treatment of influenza in children, and the pharmacologic characteristics of the these agents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38234?source=see_link\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39032?source=see_link\">",
"     \"Treatment and prevention of avian influenza\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26746?source=see_link\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19640?source=see_link\">",
"     \"Pharmacology of antiviral drugs for influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEURAMINIDASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     Oseltamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    are the recommended agents for prevention of influenza. Oseltamivir is a neuraminidase inhibitor that is available as a capsule or powder for liquid suspension. It is generally well tolerated. Zanamivir is a neuraminidase inhibitor that is taken by inhalation. Inhaled zanamivir is relatively contraindicated in patients with underlying asthma or other chronic respiratory conditions. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     Oseltamivir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    is recommended for the prevention of influenza based on their demonstrated efficacy and lower rates of resistance compared with the adamantanes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. However, it is important to assess the risk of oseltamivir-resistant influenza before choosing an antiviral drug for influenza chemoprophylaxis. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Neuraminidase inhibitor resistance'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H24\">",
"     'Influenza activity'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Choice of antiviral drug'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neuraminidase inhibitors are effective for the prevention of influenza in healthy individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/6-13\">",
"     6-13",
"    </a>",
"    ], in community-dwelling persons at high risk for influenza complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/14\">",
"     14",
"    </a>",
"    ], and in residents of long term care facilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/6,15-18\">",
"     6,15-18",
"    </a>",
"    ]. The efficacies of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    have not been directly compared.",
"   </p>",
"   <p>",
"    In a meta-analysis of seven prevention trials, prophylactic therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    was associated with substantially reduced rates of influenza [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/6\">",
"     6",
"    </a>",
"    ]. The incidence of laboratory-confirmed influenza was significantly reduced when oseltamivir was used as seasonal prophylaxis in a healthy population (OR 0.26, 95% CI 0.08-0.84), as post-exposure prophylaxis in the household setting (OR 0.10, 95% CI 0.04-0.29), or as seasonal prophylaxis in a long term care facility that housed elderly individuals (OR 0.08, 95% CI 0.01-0.61). The incidence of laboratory-confirmed influenza was also significantly reduced when zanamivir was used as seasonal prophylaxis in a healthy population (OR 0.31, 95% CI 0.14-0.64) or as post-exposure prophylaxis in the household setting (OR 0.19, 95% CI 0.09-0.38).",
"   </p>",
"   <p>",
"    A subsequent meta-analysis that included only trials of healthy adults showed similar reductions in the incidence of influenza with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    prophylaxis (RR 0.39, 95% CI 0.18-0.85 and 0.38, 95% CI 0.17-0.85, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     High risk contacts",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multicenter, randomized trial evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    in community-dwelling individuals &ge;12 years of age (mean age 60 years) who were at high risk for developing complications of influenza and who were able to take the first dose within five days of laboratory-confirmed local influenza activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/14\">",
"     14",
"    </a>",
"    ]. Subjects took the study drug (inhaled zanamivir 10 mg or placebo once daily) for 28 days. Those who received zanamivir were less likely to develop symptomatic, laboratory-confirmed influenza (RR 0.17, 95% CI 0.07-0.44) and complications of influenza (RR 0.12, 95% CI, 0.02-0.73).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Long term care facilities",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     Oseltamivir",
"    </a>",
"    is effective for preventing influenza virus spread during outbreaks in long term care facilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. A randomized trial of oseltamivir prophylaxis in residents of long term care facilities assessed its efficacy in 548 patients &ge;65 years of age in 31 long term care facilities in the US and Europe during the 1998 to 1999 influenza season [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/15\">",
"     15",
"    </a>",
"    ]. Individuals were randomly assigned to receive oseltamivir (75 mg once daily for six weeks) or placebo within seven days of the detection of local influenza activity (defined as laboratory-confirmed influenza in one individual in the residential home or two individuals in the immediate geographic community). Oseltamivir prophylaxis was associated with a significant reduction in the incidence of laboratory-confirmed clinical influenza (0.4 versus 4.4 percent in the placebo group).",
"   </p>",
"   <p>",
"    In patients who had received the influenza vaccine, there was also a significant reduction in the incidence of laboratory-confirmed clinical influenza (0.5 versus 5.0 percent). Twelve of 13 patients who developed influenza had been vaccinated, despite the fact that there was good antigenic match between the influenza vaccine and circulating strains of influenza [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/19\">",
"     19",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     Oseltamivir",
"    </a>",
"    use was also associated with a significant reduction in the incidence of secondary complications, including bronchitis, pneumonia, and sinusitis (0.4 versus 2.6 percent).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     Zanamivir",
"    </a>",
"    has been studied less extensively than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    among residents of long term care facilities, but small studies have suggested efficacy in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The route of administration (inhalation) might present more difficulty in this population than an oral drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hematopoietic cell transplant recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the use of antivirals for the prevention of influenza has not been studied extensively among severely immunocompromised patients,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    was safe and effective in controlling an outbreak of influenza among hematopoietic cell transplant candidates and recipients in an outpatient residential facility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neuraminidase inhibitor resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with the adamantanes, neuraminidase inhibitors have been less likely to promote the onset of viral resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/22\">",
"     22",
"    </a>",
"    ]. However, the emergence of influenza H1N1 isolates resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    during the 2007 to 2008 season, and the high rates of oseltamivir resistance during the 2008 to 2009 season worldwide, is concerning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Most isolates that were resistant to oseltamivir remained susceptible to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    . Since September 2009, 99 percent of influenza virus isolates tested in the US have been susceptible to neuraminidase inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/4,26,27\">",
"     4,26,27",
"    </a>",
"    ]. Information regarding antiviral resistance that emerges during the influenza season is available through the United States Centers for Disease Control and Prevention",
"    <span class=\"nowrap\">",
"     (www.cdc.gov/flu/professionals).",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Adamantane resistance'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/60/39880?source=see_link\">",
"     \"Antiviral drug resistance among seasonal influenza viruses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of neuraminidase inhibitors are typically mild, although serious side effects have also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/28\">",
"     28",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     Zanamivir",
"    </a>",
"    can cause bronchospasm and a decline in respiratory function in patients with asthma and other chronic respiratory disorders. As a result, the manufacturer has issued a warning advising particular caution in patients with asthma or chronic obstructive pulmonary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     Oseltamivir",
"    </a>",
"    can also cause nausea and vomiting but these side effects have not generally resulted in discontinuation of therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19640?source=see_link&amp;anchor=H9#H9\">",
"     \"Pharmacology of antiviral drugs for influenza\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ADAMANTANES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The US Centers for Disease Control and Prevention (CDC) issued a health alert in January 2006 recommending that adamantanes (M2 inhibitors) NOT be used for the treatment or prevention of influenza in the United States due to high rates of resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/5\">",
"     5",
"    </a>",
"    ]. Resistance to the adamantanes remains high in the US, and this recommendation remains in effect indefinitely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     Amantadine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    are only effective against influenza A [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/30\">",
"     30",
"    </a>",
"    ]. A systematic review that included trials of healthy adults from 1969 to 1990, prior to the emergence of substantial rates of resistance, showed that amantadine was effective at preventing influenza A infection (efficacy 61 percent, 95% CI 35-76) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/7\">",
"     7",
"    </a>",
"    ]. Rimantadine showed a non-significant trend towards being effective (RR 0.28, 95% CI 0.08-1.08).",
"   </p>",
"   <p>",
"    However, later studies that evaluated the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    for the concurrent treatment of index cases and close contacts showed no protection against influenza in contacts and a substantial rate of development of drug resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. As a result of the emergence of high rates of adamantane resistance worldwide, the adamantanes are no longer effective against currently circulating influenza A.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Adamantane resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance can develop as early as two to three days after adamantane initiation and is mediated by single nucleotide changes involving the transmembrane portion of the viral M2 protein that is the target of these drugs. Isolates resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    are also resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    and vice versa. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19640?source=see_link\">",
"     \"Pharmacology of antiviral drugs for influenza\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/60/39880?source=see_link\">",
"     \"Antiviral drug resistance among seasonal influenza viruses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rate of adamantane resistance has risen since the mid-1990s. The US Advisory Committee on Immunization Practices (ACIP) therefore recommends",
"    <strong>",
"     against",
"    </strong>",
"    the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    for the prevention or treatment of influenza in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Choice of antiviral drug'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/60/39880?source=see_link&amp;anchor=H527125#H527125\">",
"     \"Antiviral drug resistance among seasonal influenza viruses\", section on 'Adamantane resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in young adults have reported a discontinuation rate of 13 to 17 percent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    , largely attributable to central nervous system (CNS) toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. CNS side effects of amantadine include anxiety, insomnia, impaired thinking, confusion, lightheadedness, and hallucinations, and are more common in elderly patients.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"     Rimantadine",
"    </a>",
"    causes fewer CNS side effects than amantadine (13 versus 6 percent in a randomized comparative trial) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/33\">",
"     33",
"    </a>",
"    ] and has a discontinuation rate due to adverse effects that is similar to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19640?source=see_link&amp;anchor=H13#H13\">",
"     \"Pharmacology of antiviral drugs for influenza\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ANTIVIRAL PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral drugs should",
"    <strong>",
"     not",
"    </strong>",
"    be used as a substitute for influenza vaccination. Their adjunctive use is appropriate in certain targeted populations, particularly during outbreaks in nursing homes, hospitals, and other long term care facilities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Target populations for prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral prophylaxis should be considered in specified populations at high risk for complications of influenza in identified situations of exposure, as discussed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/4,35\">",
"     4,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Definition of high risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adults at increased risk for influenza complications include (",
"    <a class=\"graphic graphic_table graphicRef72029 \" href=\"mobipreview.htm?32/50/33579\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/4,35,36\">",
"     4,35,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Residents of nursing homes and chronic care facilities",
"     </li>",
"     <li>",
"      Adults &ge;65 years of age",
"     </li>",
"     <li>",
"      Pregnant women and women up to two weeks postpartum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/37\">",
"       37",
"      </a>",
"      ]. The risk of complicated influenza during pregnancy increases by trimester and with associated comorbidities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Pregnancy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Individuals with chronic medical conditions including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pulmonary disease, including asthma (particularly if systemic glucocorticoids have been required during the past year)",
"     </li>",
"     <li>",
"      Cardiovascular disease, except isolated hypertension",
"     </li>",
"     <li>",
"      Active malignancy",
"     </li>",
"     <li>",
"      Chronic renal insufficiency",
"     </li>",
"     <li>",
"      Chronic liver disease",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Hemoglobinopathies such as sickle cell disease",
"     </li>",
"     <li>",
"      Immunosuppression, including HIV infection (particularly if CD4 &lt;200",
"      <span class=\"nowrap\">",
"       cells/microL),",
"      </span>",
"      organ or hematopoietic cell transplantation, inflammatory disorders treated with immunosuppressants",
"     </li>",
"     <li>",
"      Any neurologic condition that can compromise handling of respiratory secretions (eg, cognitive dysfunction, spinal cord injuries, seizure disorders, neuromuscular disorders)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Native Americans and Alaska Natives",
"     </li>",
"     <li>",
"      Individuals who are morbidly obese (body-mass index [BMI] &ge;40)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a large cohort study, obese individuals (including those who were not morbidly obese) were more likely than non-obese individuals to be hospitalized for a respiratory illness during influenza season (BMI 30 to 34.9: 1.45 [95% 1.03-2.05]; BMI &ge;35: 2.12 [95% 1.45-3.10]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/40\">",
"     40",
"    </a>",
"    ]. Among individuals with a BMI &ge;35, the association was present both for those without previously identified risk factors for severe influenza (OR 5.10, 95% 2.53-10.24) and for those with one previously identified risk factor (OR 2.11, 95% 1.10-4.06). Obesity was first identified as a risk factor for severe influenza during the 2009-2010 H1N1 influenza pandemic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/2/31786?source=see_link&amp;anchor=H26#H26\">",
"     \"Epidemiology of pandemic H1N1 influenza ('swine influenza')\", section on 'Obesity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of the groups described above, patients at highest risk for influenza complications may be those with underlying lung disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe immunosuppression (eg, lung transplant recipients, individuals with advanced HIV infection [CD4&lt;200",
"    <span class=\"nowrap\">",
"     cells/microL],",
"    </span>",
"    hematopoietic stem cell transplant recipients).",
"   </p>",
"   <p>",
"    Although there are no data regarding the risk for severe or complicated influenza among asplenic individuals, influenza is a risk factor for secondary bacterial infections that can cause severe disease among such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H837889\">",
"    <span class=\"h3\">",
"     Definition of close contact",
"    </span>",
"    &nbsp;&mdash;&nbsp;A close contact is an individual who has cared for or lived with a person who has confirmed, probable, or suspected influenza infection, or who has been in a setting where there was a high likelihood of contact with respiratory droplets",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    body fluids of such a person, including having talked face to face with a person with suspected or confirmed influenza infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Indications for chemoprophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The US Advisory Committee on Immunization Practices (ACIP) states that the decision of whom to offer chemoprophylaxis to should be made on a case-by-case basis and should be based on the patient's individual risk for influenza complications, the risk of influenza acquisition from the specific exposure, recommendations from local or public health authorities, and clinical judgment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/4\">",
"     4",
"    </a>",
"    ]. If supplies of antivirals are limited, preference should be given to those at highest risk for influenza complications (eg, lung transplant recipients, individuals with advanced HIV infection [CD4&lt;200",
"    <span class=\"nowrap\">",
"     cells/microL],",
"    </span>",
"    hematopoietic stem cell transplant recipients) who have been exposed to someone with influenza.",
"   </p>",
"   <p>",
"    With the exception of residents of long term care facilities, individuals who have been vaccinated against influenza during a season in which there is a good match between the vaccine antigens and circulating viruses do",
"    <strong>",
"     not",
"    </strong>",
"    require prophylaxis. Conversely, during seasons in which there is not a good match between the vaccine antigens and circulating viruses, vaccinated individuals should be managed as if they are unvaccinated and prophylaxis should be offered to those with indications.",
"   </p>",
"   <p>",
"    Individuals receiving prophylaxis should be counseled that chemoprophylaxis reduces, but does not eliminate the risk of influenza, that susceptibility to influenza infection returns once the antiviral medication is stopped, and that adjunctive influenza vaccination should be administered if available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H155239410\">",
"    <span class=\"h3\">",
"     Post-exposure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACIP states that individuals in whom post-exposure prophylaxis can be considered are those who have had close contact with a confirmed or suspected case of influenza during that person's infectious period (one day before the onset of symptoms until 24 hours after the fever ends)",
"    <strong>",
"     and",
"    </strong>",
"    who are at high risk for complications of influenza (eg, individuals with certain chronic medical conditions, &lt;5 years of age, &ge;65 years of age, pregnant women) (",
"    <a class=\"graphic graphic_table graphicRef72029 \" href=\"mobipreview.htm?32/50/33579\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/4\">",
"     4",
"    </a>",
"    ]. An alternative approach for such individuals involves early treatment. (See",
"    <a class=\"local\" href=\"#H837889\">",
"     'Definition of close contact'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'Definition of high risk'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Balancing the evidence for efficacy of influenza chemoprophylaxis, and the importance of both preventing complications in patients at high risk and reducing the risk of promoting antiviral drug resistance, we favor the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend influenza prophylaxis during influenza outbreaks in long term care facilities in elderly and chronically ill residents regardless of prior influenza vaccination. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Outbreaks in long term care facilities'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In unvaccinated individuals at high risk for influenza complications who have been exposed to an individual with influenza within the previous 48 hours, we recommend influenza prophylaxis (",
"      <a class=\"graphic graphic_table graphicRef72029 \" href=\"mobipreview.htm?32/50/33579\">",
"       table 1",
"      </a>",
"      ). Such individuals should also be vaccinated against influenza and prophylaxis should be continued during the two weeks following influenza vaccination. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Definition of high risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend influenza prophylaxis for vaccinated individuals at high risk for influenza complications who have been exposed to an individual with influenza within the previous 48 hours when there is a poor match between the vaccine and circulating viruses.",
"     </li>",
"     <li>",
"      The use of chemoprophylaxis in pregnant women is discussed below. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Pregnancy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Regarding the other groups for whom antiviral prophylaxis should be considered, we suggest that the decision of whether to offer prophylaxis be made based upon both the individual's risk for complicated influenza",
"      <strong>",
"       and",
"      </strong>",
"      the degree of exposure (",
"      <a class=\"graphic graphic_table graphicRef72029 \" href=\"mobipreview.htm?32/50/33579\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Post-exposure prophylaxis should be used",
"    <strong>",
"     only",
"    </strong>",
"    when antivirals can be started within 48 hours of the most recent exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The US Advisory Committee on Immunization Practices recommends post-exposure prophylaxis only for individuals at increased risk for influenza complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/4\">",
"     4",
"    </a>",
"    ], whereas the Infectious Diseases Society of America states that prophylaxis may be considered for otherwise healthy unvaccinated adults, including healthcare workers, and children &ge;1 year of age who are in close contact with individuals at high risk for influenza complications during periods of influenza activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/36\">",
"     36",
"    </a>",
"    ]. We agree that it is reasonable to offer prophylaxis to such individuals following close contact with an individual with confirmed or suspected influenza. The use of prophylaxis in staff members of healthcare facilities is discussed in greater detail below. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Outbreaks in long term care facilities'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H68413650\">",
"     'Hospital staff'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Individuals who do not have risk factors for influenza complications and who are not close contacts of individuals at high risk for influenza complications do",
"    <strong>",
"     not",
"    </strong>",
"    require post-exposure prophylaxis.",
"   </p>",
"   <p>",
"    Given the concerning trends of increasing resistance with both the adamantanes and the neuraminidase inhibitors, the risk of promoting antiviral drug resistance should be considered when deciding which patients to offer prophylaxis. Overuse of the neuraminidase inhibitors, which are the agents of choice for the prevention and treatment of influenza, will promote further development of resistance that could lead to these agents becoming ineffective. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Neuraminidase inhibitor resistance'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H155239417\">",
"    <span class=\"h3\">",
"     Pre-exposure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;During widespread outbreaks when no vaccine is available (as occurred during much of the 2009 H1N1 influenza A pandemic), pre-exposure prophylaxis has a very limited role because of concerns about the supply of antivirals, need for long-term use, and the potential for adverse effects and promotion of antiviral resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/4\">",
"     4",
"    </a>",
"    ]. Under such circumstances, pre-exposure prophylaxis should be used",
"    <strong>",
"     only",
"    </strong>",
"    in individuals at very high risk for influenza complications (eg, severely immunocompromised hosts) who cannot be protected by other means and have a high risk of exposure. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Duration'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Certain individuals who have ongoing occupational risk for exposure (eg, healthcare workers, first responders) who are also at increased risk of influenza complications should follow guidelines for personal protective equipment stringently or consider temporary reassignment in order to reduce the need for post-exposure prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2599?source=see_link\">",
"     \"Infection control measures to prevent seasonal influenza in healthcare settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Outbreaks in long term care facilities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza vaccination does not provide complete protection to all individuals, particularly among elderly residents of long term care facilities. As a result, outbreaks can occur in long term care facilities even when 80 to 98 percent of residents are vaccinated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Influenza testing should occur when two or more residents demonstrate signs of an influenza-like illness within 72 hours of each other during influenza season [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/36\">",
"     36",
"    </a>",
"    ]. Rapid recognition of the outbreak (defined as at least two cases, or one laboratory-confirmed case with other compatible illnesses on the same unit when influenza is circulating in the community) and early initiation of prophylaxis is an important determinant of efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/36,42,43\">",
"     36,42,43",
"    </a>",
"    ]. In a study of outbreaks of influenza A in long term care facilities in New York during 2001 to 2004, facilities that initiated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    &gt;5 days after outbreak onset had significantly longer duration of outbreaks, higher incidence rates, and higher case fatality rates than facilities that initiated earlier chemoprophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree with the US Advisory Committee on Immunization Practices and Infectious Diseases Society of America recommendations that the administration of antiviral drugs for both treatment and prevention should be a central component of influenza outbreak control in nursing homes and other long term care facilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/4,36\">",
"     4,36",
"    </a>",
"    ]. Chemoprophylaxis is recommended for",
"    <strong>",
"     all",
"    </strong>",
"    residents of an institution during an outbreak, even if they were vaccinated during the same influenza season.",
"   </p>",
"   <p>",
"    Employees of long term care facilities who have not been vaccinated can also receive chemoprophylaxis; they can also receive chemoprophylaxis when the vaccine is expected to be ineffective.",
"   </p>",
"   <p>",
"    Chemoprophylaxis for residents and staff of institutions should be continued for at least two weeks or ten days after the onset of illness in the last affected patient, whichever is longer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other components of outbreak control include initiation of droplet and contact precautions, offering influenza vaccination to unvaccinated staff and residents, restricting contact between residents and ill staff or visitors, and restricting staff movement between sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/34/26152?source=see_link\">",
"     \"Important sites and pathogens causing infections in long-term care facilities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2599?source=see_link\">",
"     \"Infection control measures to prevent seasonal influenza in healthcare settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although it may not be feasible to perform influenza testing in all residents who develop influenza-like symptoms following identification of an outbreak, individuals who develop symptoms more than 72 hours after implementation of prophylaxis and those residing in previously unaffected units should be tested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of influenza is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68413650\">",
"    <span class=\"h3\">",
"     Hospital staff",
"    </span>",
"    &nbsp;&mdash;&nbsp;In acute care settings such as hospitals, unvaccinated staff members who provide care for patients at high risk for influenza complications can be offered prophylaxis during an outbreak within the institution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/4\">",
"     4",
"    </a>",
"    ]. Such individuals can also be offered prophylaxis when the vaccine is expected to be ineffective. Infection control policies vary by institution, so staff should consult with the infection control department at their institution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;All pregnant women are at increased risk of complicated influenza, but the risk increases by trimester and with associated comorbidities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Conversely, the risk of antiviral complications is probably greatest in the first trimester. All four drugs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    ) are classified as FDA Pregnancy Category C, indicating that their effects in pregnant women and their fetuses have not been well defined. No adverse events have been shown to be caused by oseltamivir or zanamivir among women who received these agents during pregnancy or among infants who were exposed while in utero, although there are limited data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19640?source=see_link&amp;anchor=H14#H14\">",
"     \"Pharmacology of antiviral drugs for influenza\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The US Advisory Committee on Immunization Practices states that antiviral chemoprophylaxis can be considered in pregnant women and women who are up to two weeks postpartum (including following pregnancy loss) who are close contacts of individuals with suspected or confirmed influenza A infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/37\">",
"     37",
"    </a>",
"    ]. Early treatment is an alternative to prophylaxis for some pregnant and postpartum women who have been exposed to an individual with possible influenza infection.",
"   </p>",
"   <p>",
"    We recommend prophylaxis for all unvaccinated women exposed to a patient with influenza during the third trimester of pregnancy, as well as all unvaccinated women with comorbidities who are exposed to an individual with influenza during the second trimester of pregnancy. Comorbidities that increase the risk of influenza complications in pregnant women include chronic cardiac or pulmonary disease, diabetes mellitus, chronic renal disease, malignancy, and immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Definition of high risk'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     Zanamivir",
"    </a>",
"    is probably the drug of choice for prophylaxis given its limited systemic absorption (",
"    <a class=\"graphic graphic_table graphicRef50350 \" href=\"mobipreview.htm?14/32/14860\">",
"     table 2",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     Oseltamivir",
"    </a>",
"    is an alternative agent for women with a relative contraindication to zanamivir, such as asthma or chronic obstructive pulmonary disease.",
"   </p>",
"   <p>",
"    Antiviral prophylaxis in pregnant women is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35224?source=see_link&amp;anchor=H5795668#H5795668\">",
"     \"Influenza and pregnancy\", section on 'Antiviral prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H245746564\">",
"    <span class=\"h3\">",
"     H3N2 variant influenza",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since July 2011, the United States Centers for Diseases Control and Prevention (CDC) has reported cases of H3N2 variant (H3N2v) influenza A infection caused by reassortment of swine-origin H3N2 influenza A viruses and pandemic H1N1 influenza A viruses, most of which have occurred since July 2012 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. Almost all patients reported direct or indirect contact with swine, and the majority attended fairs where swine were present. H3N2v influenza viruses are susceptible to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    , but resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/50\">",
"     50",
"    </a>",
"    ]. Although the CDC does not recommend antiviral prophylaxis (pre- or post-exposure) for H3N2v influenza [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/48\">",
"     48",
"    </a>",
"    ], we suggest antiviral prophylaxis for high-risk individuals who have had a likely exposure (eg, an immunocompromised individual who has visited a swine exhibition at an agricultural fair within the previous 48 hours in a state in which H3N2v influenza is known to be circulating). The epidemiology of H3N2v influenza infection is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/58/15272?source=see_link&amp;anchor=H104949276#H104949276\">",
"     \"Epidemiology of influenza\", section on 'H3N2 variant influenza'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Choice of antiviral drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our recommendations regarding the choice of antiviral drug are in accordance with the US Advisory Committee on Immunization Practices (ACIP) and the Infectious Diseases Society of America (IDSA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/4,36\">",
"     4,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to assess the risk of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    -resistant influenza before choosing an antiviral drug for influenza prophylaxis. Clinicians should review local or state influenza surveillance data weekly to determine which types of influenza (A or B) and subtypes (pandemic or seasonal H1N1; H3N2) of influenza A are circulating, as well as resistance patterns. This information, which is updated weekly, is available via the CDC through its website (",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/weekly\">",
"     www.cdc.gov/flu/weekly",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    We recommend either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    (75 mg once daily) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    (10 mg [2 inhalations] once daily) for targeted populations with likely exposure to patients with pandemic H1N1 influenza A, H3N2 influenza A, or influenza B (",
"    <a class=\"graphic graphic_table graphicRef50350 \" href=\"mobipreview.htm?14/32/14860\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/4\">",
"     4",
"    </a>",
"    ]. Zanamivir should be used when oseltamivir-resistant influenza is suspected. Since oseltamivir is primarily excreted by the kidneys, dosing must be modified in the setting of renal insufficiency. Zanamivir is the drug of choice during outbreaks that are suspected to be caused by oseltamivir-resistant influenza [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/4\">",
"     4",
"    </a>",
"    ]. Zanamivir inhalation powder should",
"    <strong>",
"     not",
"    </strong>",
"    be reconstituted in any liquid formulation and is not recommended for use in nebulizers or mechanical ventilators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Target populations for prevention'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19640?source=see_link&amp;anchor=H9#H9\">",
"     \"Pharmacology of antiviral drugs for influenza\", section on 'Adverse effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of seasonal influenza in adults\", section on 'Oseltamivir resistance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/60/39880?source=see_link&amp;anchor=H528441#H528441\">",
"     \"Antiviral drug resistance among seasonal influenza viruses\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of high rates of adamantane drug resistance in viral isolates, we recommend",
"    <strong>",
"     against",
"    </strong>",
"    using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    for the prevention or treatment of influenza, except during outbreaks of suspected",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    -resistant H1N1 influenza in patients who have a contraindication to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    (eg, asthma or chronic obstructive pulmonary disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    -resistant H1N1 viruses may be susceptible to adamantanes,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    ) can be used in combination with oseltamivir when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    is contraindicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/4,52\">",
"     4,52",
"    </a>",
"    ]. The recommended dose of rimantadine for the prevention of influenza in adults is 100 mg twice daily in the absence of renal insufficiency. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Adamantanes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The necessary duration of antiviral prophylaxis following exposure is unclear. The usual duration of antiviral prophylaxis for seasonal influenza varies with the indication:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During outbreaks in long term care facilities, prophylaxis should be continued for at least two weeks, or 10 days after the onset of illness in the last affected patient, whichever is longer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Outbreaks in long term care facilities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For unvaccinated persons who have an indication for post-exposure prophylaxis, the influenza vaccine should be administered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/36\">",
"       36",
"      </a>",
"      ] and antiviral prophylaxis should be given for 10 days when administered after a household exposure and for one week after the most recent known exposure in other situations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"       \"Seasonal influenza vaccination in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      During community outbreaks, pre-exposure prophylaxis in unvaccinated individuals who have an indication for prophylaxis, including those who are unable to mount an immune response to the vaccine, may be given throughout the period of peak influenza activity (usually six to eight weeks) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/13/44249/abstract/8,33,34,36\">",
"       8,33,34,36",
"      </a>",
"      ]. During widespread outbreaks when no vaccine is available (as occurred during much of the 2009 H1N1 influenza A pandemic), pre-exposure prophylaxis has a very limited role. (See",
"      <a class=\"local\" href=\"#H155239417\">",
"       'Pre-exposure prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     VACCINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Annual vaccination against seasonal influenza is an essential component of influenza prevention. Seasonal influenza vaccination is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     INFECTION CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection control measures for patients with influenza are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2599?source=see_link\">",
"     \"Infection control measures to prevent seasonal influenza in healthcare settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=see_link&amp;anchor=H26#H26\">",
"     \"Treatment of seasonal influenza in adults\", section on 'Infection control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     INFLUENZA ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The US Centers for Disease Control and Prevention (CDC), in collaboration with the World Health Organization and its reporting network, tracks influenza virus isolates throughout the world to monitor disease activity and antiviral resistance patterns, and to predict the appropriate components for the annual influenza vaccine. This information, which is updated weekly during influenza season, is available via the CDC through its website (",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/weekly\">",
"     www.cdc.gov/flu/weekly",
"    </a>",
"    ). The typical trends of influenza activity in the United States are shown in the following figure (",
"    <a class=\"graphic graphic_figure graphicRef60877 \" href=\"mobipreview.htm?12/3/12349\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/12/39105?source=see_link\">",
"       \"Patient information: Influenza prevention (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral drugs should",
"    <strong>",
"     not",
"    </strong>",
"    be used as a substitute for influenza vaccination. Their adjunctive use is appropriate in certain targeted populations, particularly during outbreaks in long term care facilities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Target groups",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The decision of whom to offer chemoprophylaxis to should be made on a case-by-case basis and should be based on the patient's individual risk for influenza complications, the risk of influenza acquisition from the specific exposure, recommendations from local or public health authorities, and clinical judgment. If supplies of antivirals are limited, preference should be given to those at highest risk for influenza complications (eg, lung transplant recipients, individuals with advanced HIV infection [CD4&lt;200",
"      <span class=\"nowrap\">",
"       cells/microL],",
"      </span>",
"      hematopoietic stem cell transplant recipients). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Indications for chemoprophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the concerning trends of increasing resistance with both the adamantanes and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      , the risk of promoting antiviral drug resistance should be considered when deciding whether to recommend prophylaxis to a patient. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Indications for chemoprophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend influenza prophylaxis for",
"      <strong>",
"       all",
"      </strong>",
"      residents during outbreaks in long term care facilities regardless of prior influenza vaccination (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H155239410\">",
"       'Post-exposure prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Outbreaks in long term care facilities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With the exception of residents of long term care facilities, individuals who have been vaccinated against influenza during a season in which there is a good match between the vaccine antigens and circulating viruses do not require prophylaxis. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Indications for chemoprophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In unvaccinated individuals at high risk for influenza complications who have been exposed to an individual with influenza within the previous 48 hours, we recommend influenza prophylaxis (",
"      <a class=\"graphic graphic_table graphicRef72029 \" href=\"mobipreview.htm?32/50/33579\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Such individuals should also be vaccinated against influenza and prophylaxis should be continued during the two weeks following influenza vaccination. (See",
"      <a class=\"local\" href=\"#H155239410\">",
"       'Post-exposure prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend influenza prophylaxis for vaccinated individuals at high risk for complications who have been exposed to an individual with influenza within the previous 48 hours when there is a poor match between the vaccine and circulating viruses (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Prophylactic antiviral therapy should be given for approximately 14 days. (See",
"      <a class=\"local\" href=\"#H155239410\">",
"       'Post-exposure prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest prophylaxis for unimmunized pregnant women exposed to a patient with influenza during the third trimester, as well as all unimmunized pregnant women with comorbidities who are exposed to an individual with influenza during the second trimester, provided that prophylaxis can be started within 48 hours of exposure (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Pregnancy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35224?source=see_link&amp;anchor=H5795668#H5795668\">",
"       \"Influenza and pregnancy\", section on 'Antiviral prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest prophylaxis for otherwise healthy unvaccinated adults, including healthcare workers, and children &ge;1 year of age who have had close contact with an individual with confirmed or suspected influenza",
"      <strong>",
"       and",
"      </strong>",
"      who are in close contact with an individual or individuals at high risk for influenza complications (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H155239410\">",
"       'Post-exposure prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regarding the other groups for whom antiviral prophylaxis should be considered, the decision of whether to offer prophylaxis should be made based upon both the individual's risk for complicated influenza",
"      <strong>",
"       and",
"      </strong>",
"      the degree of exposure (",
"      <a class=\"graphic graphic_table graphicRef72029 \" href=\"mobipreview.htm?32/50/33579\">",
"       table 1",
"      </a>",
"      ). Post-exposure prophylaxis should be used only when antivirals can be started within 48 hours of the most recent exposure. (See",
"      <a class=\"local\" href=\"#H155239410\">",
"       'Post-exposure prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals who do not have risk factors for influenza complications and who are not close contacts of individuals at high risk for influenza complications do",
"      <strong>",
"       not",
"      </strong>",
"      require post-exposure prophylaxis. (See",
"      <a class=\"local\" href=\"#H155239410\">",
"       'Post-exposure prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During widespread outbreaks when no vaccine is available (as occurred during much of the 2009 H1N1 influenza A pandemic), pre-exposure prophylaxis has a very limited role. Under such circumstances, pre-exposure prophylaxis should be used",
"      <strong>",
"       only",
"      </strong>",
"      in individuals at very high risk for influenza complications (eg, severely immunocompromised hosts) who cannot be protected by other means and have a high risk of exposure. (See",
"      <a class=\"local\" href=\"#H155239417\">",
"       'Pre-exposure prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Choice of antiviral agent",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend use of a neuraminidase inhibitor (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      ) as the first-line agent for the prevention of influenza, when indicated (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Zanamivir is the drug of choice during outbreaks that are suspected to be caused by oseltamivir-resistant influenza. Zanamivir is relatively contraindicated in patients with asthma and chronic obstructive pulmonary disease. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Neuraminidase inhibitor resistance'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Choice of antiviral drug'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The recommended prophylactic dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      is 75 mg daily and of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      is 10 mg (two inhalations) daily (",
"      <a class=\"graphic graphic_table graphicRef50350 \" href=\"mobipreview.htm?14/32/14860\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Choice of antiviral drug'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Due to high levels of adamantane resistance,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"       rimantadine",
"      </a>",
"      are generally no longer useful for the prevention of influenza. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Choice of antiviral drug'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68413846\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of prophylaxis varies depending upon the clinical indication:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During outbreaks in long term care facilities, prophylaxis should be continued for at least two weeks or 10 days after the onset of illness in the last affected patient, whichever is longer.",
"     </li>",
"     <li>",
"      For unvaccinated persons who have an indication for post-exposure prophylaxis, the influenza vaccine should be administered and prophylactic antiviral therapy should be given for approximately 10 days when administered after a household exposure and for one week after the most recent known exposure in other situations. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/1\">",
"      Glezen WP. Clinical practice. Prevention and treatment of seasonal influenza. N Engl J Med 2008; 359:2579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 2012; 61:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/3\">",
"      Ong AK, Hayden FG. John F. Enders lecture 2006: antivirals for influenza. J Infect Dis 2007; 196:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/4\">",
"      Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     CDC health alert. CDC recommends against the use of amantadine and rimantadine for the treatment or prophylaxis of influenza in the United States during the 2005&ndash;06 influenza season. www.cdc.gov/flu/han011406.htm (Accessed on January 17, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/6\">",
"      Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003; 326:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/7\">",
"      Jefferson T, Demicheli V, Rivetti D, et al. Antivirals for influenza in healthy adults: systematic review. Lancet 2006; 367:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/8\">",
"      Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/9\">",
"      Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001; 285:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/10\">",
"      Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004; 189:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/11\">",
"      Monto AS, Robinson DP, Herlocher ML, et al. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999; 282:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/12\">",
"      Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med 2000; 343:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/13\">",
"      Monto AS, Pichichero ME, Blanckenberg SJ, et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis 2002; 186:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/14\">",
"      LaForce C, Man CY, Henderson FW, et al. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2007; 29:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/15\">",
"      Peters PH Jr, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001; 49:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/16\">",
"      Bowles SK, Lee W, Simor AE, et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. J Am Geriatr Soc 2002; 50:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/17\">",
"      Parker R, Loewen N, Skowronski D. Experience with oseltamivir in the control of a nursing home influenza B outbreak. Can Commun Dis Rep 2001; 27:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/18\">",
"      Vu D, Peck AJ, Nichols WG, et al. Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. Clin Infect Dis 2007; 45:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/19\">",
"      Centers for Disease Control and Prevention (CDC). Update: influenza activity--United States, 1998-99 season. MMWR Morb Mortal Wkly Rep 1999; 48:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/20\">",
"      Schilling M, Povinelli L, Krause P, et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine 1998; 16:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/21\">",
"      Lee C, Loeb M, Phillips A, et al. Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. Infect Control Hosp Epidemiol 2000; 21:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/22\">",
"      Dolin R. Resistance to neuraminidase inhibitors. Clin Infect Dis 2011; 52:438.",
"     </a>",
"    </li>",
"    <li>",
"     www.cdc.gov/flu/weekly/index.htm (Accessed on September 22, 2008).",
"    </li>",
"    <li>",
"     World Health Organization. WHO/ECDC frequently asked questions for Oseltamivir Resistance. file://www.who.int/csr/disease/influenza/oseltamivir_faqs/en/ (Accessed on February 04, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/25\">",
"      Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats. J Infect Dis 2011; 203:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/26\">",
"      Centers for Disease Control and Prevention (CDC). Update: influenza activity --- United States, October 3-December 11, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/27\">",
"      Centers for Disease Control and Prevention (CDC). Update: influenza activity - United States, 2009-10 season. MMWR Morb Mortal Wkly Rep 2010; 59:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/28\">",
"      Drugs for non-HIV viral infections. Treat Guidel Med Lett 2007; 5:59.",
"     </a>",
"    </li>",
"    <li>",
"     Relenza dear doctor letter in EU follow U.S. advisory. In: \"The Pink Sheet\" F-D-C Reports, Chevy Chase, MD, January 31, 2000, p. 20.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/30\">",
"      Antiviral drugs for prophylaxis and treatment of influenza. Med Lett Drugs Ther 2005; 47:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/31\">",
"      Hayden FG, Belshe RB, Clover RD, et al. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989; 321:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/32\">",
"      Degelau J, Somani SK, Cooper SL, et al. Amantadine-resistant influenza A in a nursing facility. Arch Intern Med 1992; 152:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/33\">",
"      Dolin R, Reichman RC, Madore HP, et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982; 307:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/34\">",
"      Monto AS, Ohmit SE, Hornbuckle K, Pearce CL. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrob Agents Chemother 1995; 39:2224.",
"     </a>",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. 2011-2012 Influenza antiviral medications: Summary for clinicians. file://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm (Accessed on September 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/36\">",
"      Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1003.",
"     </a>",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. Updated recommendations for obstetric health care providers related to use of antiviral medications in the treatment and prevention of influenza for the 2010-2011 season. file://www.cdc.gov/flu/professionals/antivirals/avrec_ob2011.htm (Accessed on January 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/38\">",
"      Rasmussen SA, Jamieson DJ, Bresee JS. Pandemic influenza and pregnant women. Emerg Infect Dis 2008; 14:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/39\">",
"      Mak TK, Mangtani P, Leese J, et al. Influenza vaccination in pregnancy: current evidence and selected national policies. Lancet Infect Dis 2008; 8:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/40\">",
"      Kwong JC, Campitelli MA, Rosella LC. Obesity and respiratory hospitalizations during influenza seasons in Ontario, Canada: a cohort study. Clin Infect Dis 2011; 53:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/41\">",
"      Centers for Disease Control and Prevention (CDC). Recommended adult immunization schedules--United States, 2008. MMWR Morb Mortal Wkly Rep 2007; 56:Q1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/42\">",
"      Monto AS, Rotthoff J, Teich E, et al. Detection and control of influenza outbreaks in well-vaccinated nursing home populations. Clin Infect Dis 2004; 39:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/43\">",
"      Rubin MS, Nivin B, Ackelsberg J. Effect of timing of amantadine chemoprophylaxis on severity of outbreaks of influenza a in adult long-term care facilities. Clin Infect Dis 2008; 47:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/44\">",
"      Tanaka T, Nakajima K, Murashima A, et al. Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women. CMAJ 2009; 181:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/45\">",
"      Cox S, Posner SF, McPheeters M, et al. Hospitalizations with respiratory illness among pregnant women during influenza season. Obstet Gynecol 2006; 107:1315.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. CDC reports cases 18-29 of H3N2v virus infection; continues to recommend interim precautions when interacting with pigs. file://www.cdc.gov/flu/spotlights/h3n2v_us_cases.htm (Accessed on August 03, 2012).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Information on influenza A (H3N2) variant viruses (&ldquo;H3N2v&rdquo;). file://www.cdc.gov/flu/swineflu/influenza-variant-viruses-h3n2v.htm#table (Accessed on August 20, 2012).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Interim information for clinicians about human infections with H3N2v virus. file://www.cdc.gov/flu/swineflu/h3n2v-clinician.htm (Accessed on August 20, 2012).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Case count: detected U.S. human infections with H3N2v by state since August 2011 file://www.cdc.gov/flu/swineflu/h3n2v-case-count.htm (Accessed on September 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/13/44249/abstract/50\">",
"      Centers for Disease Control and Prevention (CDC). Update: Influenza A (H3N2)v transmission and guidelines - five states, 2011. MMWR Morb Mortal Wkly Rep 2012; 60:1741.",
"     </a>",
"    </li>",
"    <li>",
"     United States Food and Drug Administration. MedWatch Safety Alert. Relenza (zanamivir) inhalation powder. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm186081.htm (Accessed on October 09, 2009).",
"    </li>",
"    <li>",
"     CDC issues interim recommendations for the use of influenza antiviral medications in the setting of oseltamivir resistance among circulating influenza A (H1N1) viruses, 2008-09 influenza season. file://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum=00279 (Accessed on December 22, 2008).",
"    </li>",
"    <li>",
"     file://www.fda.gov/cder/news/relenza/default.htm (Accessed on October 06, 2008).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7017 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.75.47.146-274201436B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_13_44249=[""].join("\n");
var outline_f43_13_44249=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEURAMINIDASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - General",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - High risk contacts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Long term care facilities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neuraminidase inhibitor resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ADAMANTANES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Adamantane resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ANTIVIRAL PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Target populations for prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Definition of high risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H837889\">",
"      - Definition of close contact",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Indications for chemoprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H155239410\">",
"      - Post-exposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H155239417\">",
"      - Pre-exposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Outbreaks in long term care facilities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H68413650\">",
"      - Hospital staff",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H245746564\">",
"      - H3N2 variant influenza",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Choice of antiviral drug",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      VACCINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      INFECTION CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      INFLUENZA ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Target groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Choice of antiviral agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68413846\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7017\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7017|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/3/12349\" title=\"figure 1\">",
"      Peak influenza activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7017|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/50/33579\" title=\"table 1\">",
"      Groups at high risk for influenza complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/32/14860\" title=\"table 2\">",
"      Antivirals for influenza",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/60/39880?source=related_link\">",
"      Antiviral drug resistance among seasonal influenza viruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26746?source=related_link\">",
"      Antiviral drugs for the prevention and treatment of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/58/15272?source=related_link\">",
"      Epidemiology of influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/2/31786?source=related_link\">",
"      Epidemiology of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/34/26152?source=related_link\">",
"      Important sites and pathogens causing infections in long-term care facilities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2599?source=related_link\">",
"      Infection control measures to prevent seasonal influenza in healthcare settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35224?source=related_link\">",
"      Influenza and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/12/39105?source=related_link\">",
"      Patient information: Influenza prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19640?source=related_link\">",
"      Pharmacology of antiviral drugs for influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39032?source=related_link\">",
"      Treatment and prevention of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38234?source=related_link\">",
"      Treatment and prevention of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=related_link\">",
"      Treatment of seasonal influenza in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_13_44250="Molluscum on face";
var content_f43_13_44250=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55247%7EDERM%2F68001%7EDERM%2F56699%7EDERM%2F81042%7EDERM%2F59150%7EDERM%2F57836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55247%7EDERM%2F68001%7EDERM%2F56699%7EDERM%2F81042%7EDERM%2F59150%7EDERM%2F57836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Molluscum contagiosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple dome-shaped papules with a central core are present on the face of this child with molluscum contagiosum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed., Lippincott Williams &amp; Wilkins 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Molluscum contagiosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple dome-shaped papules with a central core are present on the face of this child with molluscum contagiosum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed. Lippincott Williams &amp; Wilkins 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Molluscum contagiosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the linear configuration of lesions resulting from autoinoculation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Molluscum contagiosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 267px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAELAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5s1C0f7e0ksapHMq3G5D8m1lDcH8SMdjxVzULlbqddWjSKGeMJmKBSil1QASgdiSMkevPQ8MuLW7bEUKbkVJFDSqE2qhJyCTgErjoefeoGCNpDPI0oe3KRRpGo24YszOx/DA459eADZmZjM0iF2OWB5PXOa07KNgs02xtkMcU7YwzBchSR7ZYcH1FNhDQwR3aossBBjMeePMGcDH5N+lbKvFYWmmrtEiXunTI/lII2WQvIuHPVsFUIGcdOlJIbZn29u13b6haRosjwR/bYXxg+Wo+cD2KncfdPrVT7LNNdQeXIcvjySU2BvoOwHqansRFK/kzOkkxAMUgPDBhyhPY88Z75B65EscMkk8xuZW+zhXMjqDlioJEXqMkAYz784osFyWHUBDeuphS8tmyZIJfuNuGNwI5BAIw3Y+oyDaspLSPSTawiSO+NztSZ3CrsyDg+v8AKs+ORnVREnl5VldYlzkDBAyenH8VTWzxxwbxEHlIxtD+hwM9/ukj8OOlDY0db9sFiRNduqyMxEkizBvNO09D7ehxjdjmtqJBcXrwysbeO5WJsG3YsAGViwABCgo5I4OfQZrmoYvtsyx30zRKsIEzysT8zjgg4OVwFOPcGumsZjf65bWstuNlzJBHbpkqjYISOJ9uNxEa5BP0zkVLOmDdzqJbS/1IJaaCNZhhAAeSYrEI+4LHaMk5zgAYGMtWZYaJb2ekRLb6pdy2lzcJDd2sNyu5l8zaNvT5mUEBDjOc5ruJ9O0+xtpFtrKwcxNmeZy0szsD/q1LkgO3ALEHbkd+mBqTJpWl6a8KObkX0JgiWPl5AScZPck+mOnNS9NzrULizCDUL+SCGw1i0hjBkmitJ9jySk7Q0ykKhx8xwMkgkbjzjUhtdU1i2ns4JJISXBuhPcTwzxIOWLpuZRuO0A4IwTjpUnh2ze2huLu6lurm8kdJ2FumfNJXPBPX0Gegye5NdF/Zcksj3V22bo4bKTbVhHVUVlwc9+TyecdKXMaqnGJzEvhoWySXtrZzJcSHc11NqRKqw6uTtDfxexP61i+FLW5trSaC3nmlhW8mhlD3Bji3O4KyfLzg7wCgJ+8D6mvRItAt3n8ye1LuCrEzzNJj1JVyf6YzWBr48i21+KU20UF08M0I8xQ7SMEicBFG7oiE9vepu+hdo9TRj0yfeUDxRx7drxwIobA6q2TuA6AkZJqrqFzbWFk8sdxHbzQL8iKcnKn+PoQh+4dwIOSBk4Fa8k1zcXE8ah9Mt5PmaRoFkkIPI2qOE6tycnpxVSWw0mzdbh2a4vA/mC4uZB5qvkYZSeQ2B16+mKGy4q+iIdKtpdWYajPbFbZ8bLZ22uWRsESAfdCEH93nJPLdlGyQhQIINztn5mAQdffkn36VlwxXLzvdI3m2jnZODnczAYDMAMFsKBuXqAMg4zWjZzWlz+7gI2sQoEhwGGM5Q5w3XHBPTtUXNVHuWfJBiZmVBhAo2p1x346df1qC9gtY4xLIg2KA5JOcnp1POTwBWhK0dpbl3uFijVMuyAD5fX378c+1VWFxqLGbY8NunzQQyAFnPTfIMccche3U80XFymSbBIBKJEcq8heTaoyPcKewH0rO1iwVbu1uLOESrPLGs0O4AShckEr/AHhjr7DPFdDfb2thIRIfL5OxcDqM/jx06msvUFWGa1khbzYlVpQ2cKcsi5B74DMccVSkS6asZ1zaROLdJJZHtvLKQz4CsOrbCO4+8Pwx6VjT6JDdWZtdSiSUtykzcg/jjr6Z612klikr3VtcRBo3K3MYjPCknDkH1DANx/epWtXkdrW7t1ZsFRKR8sg656/Ken07cVcZmFSjFo8F8V+BrywLzafCLuxKlmiVvnXHJOO/0HpXn1xaISwjBJHQY5+lfV2owCJA25yzkq527dp9uw5yPyrzvxx4K0+XGrWZ8l1ytx5SkZX++V9R1OO3Nac19zzquHcdYngMic/Kc+1XtCaF9XsYr+c29sZBFLNt3GONvlLYyM4Bziruv6TNp98be6QLIV8yOReVlQ9GX1rOCRvCudizpnr/AB+lFrM5i5pbxWk9xbX8DeXPEUkXJBjPVJE9QOPXIJxUCJBatf290kglABhMfzAHP6qQev0qtcSO0gZwWO3auTyB2q9ebbjyGV0R/JDJ23joyH0IYNj1yKaYiqkroxiMSSRk4CMDjn+If3T05FJOyRo3lJIsTsGUyHLDHbI6/Xitu2sw/hNrrcnmx3i25BPzYZMj+X6VT12N5LGxkEGzzAEAXoxHf8arlaQrq5mJIFuRKpGSc49Pet5NYgtYbUWciyiORLi4srqPdbTup6EA9COCDg+9YVuEBXziwCt8w7Ad60k0C9k03Ub6ziWa10/Y9y4YZVHbCHHUjPFEXJLQGl1Ox8Oa/pAbxPcaLoP2VtQ0G4tbm3kkEsEEruuHhJ+ZV6YDFiD3NedzEMyxlcBRg+ualt7gwrN5QwJYij84yM/44/KrOmGKS7hZ42eUYUR8kuxwBj/Cj4rINtSKyiEEqXAIXY3RxkVoM8cguHlSNfObcpjOAD/kVJqdo39uS2aqMWp8t19H/iz7g8fhVT5FulVlURxrycYBpbKwy5bEiBDtJ+YhSOORyKsi+uW2lNqFcqcd6WB0MbRx9HxtYg5HqPrU2o6RHBZtPLKkP7resedzdcD8TSaKUuhRRbi4he6VMWcMy72J/iPOP5fpXTWVzasNzhUMRzwfzNYOpm6h0mxs1bbZb/OWP+9JjqfWoikhWMvGWVuSQeg96HboCueg2s6vOqWarJLNz7LXb+E/CCW8TT6i0c0i87FYHbXA+GrBmto7jT1cRx/elYdT7Gu703VJRP5q2Z+z2qbHZT95j/nrQ7I0jzM63Sru3huHht1G4gD5jyfxrpbexcyefHwx4PvXjs+pSDURdwBkjDAOp6/jXqll4lhbShLnkIMALyx9BWb12OiMeXRluTUntLidZcHjgd8gUaRdpey+aH6sCFI7+9ZlgPtbGa9lG6Yh2jK9B6frS3yDSb6KWFxsdgdoHHNT5FeZ6CsiJbBhnOOfes6+Zri3cIQTVK11FHiIduRwatQXUTZ2OCPahjXczoLVWidZIwW9TUEGmeTIzxgdjW25RBkdBwOtIk0TN94Y6AUi7ux8FXIaG1tbW7LASIWRi2TERI6hT7ZHP50xFWCISvKPPcsWDNwU4AOD94kkn8K0rmxQ6y8V8ZGnFqsqorZ/fEZ2MexLk8dQTj1NVLYRxxGNxMHAwxAX5FdM52kdDn1GOO+K6NjytyO2tJJbO8hgiWSRZCP3bbjwpOVx1BCvUKSSvbRgtnyW81Btzv3Y64+nQ+prW0m9m0+aG6spSs8ASRJIh9x0cMu8Efd688cGquuWsdnqAuLWMizvB51uN+8rE+cIW4+deQfdaQynPbeXdrFGw/ehXhcnCshGQDnj2PuK67RBbXdq9zqO4RzNb27zTSZAjwwkTYFJONqneMlMocHORgJGklgVGXkt8tg9Gh4LEdsAndgDIy2egrW0GZJ9T07TdQikNvdSJDlWAMeWXEsROApZOOcg89MDDWgmU4tNuI9TNtAxCOS0UyuAZFxkcqSM464PrVrULdLCzYbYg5dSihThyOTkH0OM1U0W8ETK5QTbWeYIsxjcEKSSzcbeCOec9BWzrEV9cxRQSYutTMxtniRC8i4LfKSeFHONo+9gE8ipa7GkXoW9D+yP4dvJ7wfvAcJODtIdkBy2eMEq3HrgDFX9Nt530uIOZLW9lC3Nvw4MYU8MOMbSxB4PB4IFYGjsqW97btbLcuAWUK2GTOPmRcHd0656Z9665HM1raLJeCy+xK6iGaQLLMxVthKkjaHBjBwScZbjApPubU3bRno9pqGhT2tpPJcWttHDapcvDcNsKSOAQDuwckEt7gqR1rJ8Taxp11f2bR6hELexmtbgCOYH5mlVeQuQPl8xiAf4k7ism31d7xrS08P21wLyOFfKbygRdkEfJIHIXylJwGYEj+HGcGa6vomluJr9dUl1RtQTy5IpMW0coZVZIdrAZCAfMRuG3+Hms3udsW2rHWxa3u+TTtK1C9nkcmMizkiAUAAZBGSAox2HUZ4p5HijUpC7/ZdPiBG1TKFwM8ZEQZsnrxIPSpNDfS7rzZNKnnZQVSTbdzK5Ykk7/myvJI+brjvVy9fM72/nxmeRwywLPLNIOOTsVv54HPapkbxRCvhuwsYmuNdvLvUHc7T5krxLIeoGxTluccMzHpUISK71a1t9PghjsYGE0qwR4DugIG5uM4BJx2yM8jAuyaPbQSRgpJNKSWyVCh84GXI5C98fgcgc7tnarHAjAxmUrtKxoAAQOgUYAX/PNS2WlbUruly6qm57aMnG7aS5x157D6ZpFtIvN8ySJXlVQC058xox+H061fEKGRPMKxkcqxG7Cnvj86heaN5JLe0jW5MbKGYEbEI6gnpkegGealstabELxQ2dpLKEIjRQBsOQzHGFAIySTgD04qlDaTWtkZmMVxMXJu7b5WR3ZtzGMZwJBk4/vAY64NakemB5Vurrc82TtLcpGpHRFHfjBb7xz1xxVs7RG8bpsEbbWJBwVbtjv9KQ+boVdPtLZ4oJgxnRx5iSGTdt9Su4DYcgfTp7VawI4vM3LnOVVjuDHAJyO1VFV9OuGRZAsF0zFQD92XqVHYBhk9+VPc0+Z2AYg7SWyW2ZGfTgnB4PNFw3ZFMqhhvUxoynBI5OOv4dqwNZsZ4F1Oe2j3bITujY/wAWGbemeh+7kfdJ54PNdKIyrbCoeNz0VD65Jzxnp3+lV9iuVHlssb8AN97byCAfxpofMUYLy2mitb+B1lt5ZMZHBBfgqR1BDbcj2qwwDhcSZ3thip+bGBx7iudg02aXRra50/dFdvaqkq7Mo5j+Xa6dDgjG4EEHo3Y60+oRwT2nmSR27zHCJISqs+B8oY8Fgc4GQcHp2qkRJ2JLmMNvhCKVORlhlcnjsOc1jzQS2c5dCJLZMgBm+ZB0xnuOeM+mM10RCuhacFH3YMbDlPfNVhKsIX7QTsckFwuQPmHfvjP0q4toykkzyLxH4fhcXEN2AukTzmSN0Tc9lIOpTPIXk7o+OOQOCK8c8QaVc6NqdxZXJjdomO14m3JIvZ1PcEYNfWV5b2kto9tKgO9chkYhs5ypBHQ8cH3rxvxz4bWACCeVmt14t7l0AMBJ/wBXJjgr/tDGO4Fap30PNr0bPmR5MvkmFVmB+ZPlcclXHUH2poXzNNUqCXgn2nPdXHQ/ip/OrlzYvaz3ljMrK4OYw2OTjjH1B/HirV5a2lpoCTR3W+6volc26pgRbWwST69fzq+U5L2K9m8YsbxXZg+BtJ5Bbpg++M1Jrk0moXltaWIdshSqKOjbcHA/CstJG2SQZOw4fjqSo/wzUltdPa3SSwSsk6pjd6E9waalpYVupFcR/Z7iSNmzjhh61b07VJY7u6KExRXcJt5Y0HDKQOD+IBrLYnzHDNkk4JJ6/WtfSY4YYZbieCR1jQg4GVLHp83Qd6UW76A1pqVbDyobhvtm4xj92yqOWHcfXFbfhHUtP0aS81aYTPqdsv8AxKo9itH5pP35c9lXJGP4sVnaJdrZ3VtLJAkytK2VKbsgqV6e2c/hUs1gsqq5uERhiMEJgEDjcR9OapLS6E97FaK6kCeYkhMzkl3PJZieSffNOhYmUeb++IOSPU/4Ulw1tbSNGYvMK5BdWyjD+8P/ANVSaM+PMl8vegzlGbGfap12KNJgyASlx52MoF/g/wDr4qO7C3UqLApWIAZJJJPqSTStKv2PzhgAcbcYA9qLS4aFVcR7ifmO4cUmykkWbaFmjEkrZeMlUV/8K1rOCK3sjIzAyyMVG4+vtVbS/sZnS41Zm+zkF9q9WY9BUMmoo84fyiqbuN/8PpStZXZafRHqngyOK20Ew3EgIlUiMDn14/xrV04fYHjt2cRW4b594+Yse+K4Pw1rkiOsnkBhGMRA9mPeuk+yCWB7nU73ZK2W4foR0HFJs2hGyudpq1hBeKHtl23BG0gDAb/GqXh7Q5oLwvdZZlOAGOQPal8La80tp5dx2U7Z+fm/MUybXLpL3zYwHtUJy+0lT+VTazNFO6sztLW2gilzMqgDkBW5xT1mtNQ1CGNZVIBwBuz061xB1u91mV4bGN18rlnLhfwrf8L2a6fCVvFb7Q5BDtxk0uWwcyeiPR59NgNkAq8YzWFHai3lI+YBj2PUVqQ3m2BERt4x/ninyxJKmT1HNRY0T7kcQjmTaQ4z2zTZbLyo2ZMkjnGcU6AhM44PPB70xrveTE/ftQO58GC6eRULhnleN3lYAsSMkgn3Byc+9LBeG4kilkAluCDFIvRpVxjGehOMeh4qK1mMWpSTxRiRI0do1c7RtAx+OBxjvUEnkQ3uwhmtG54PO08jnuR/Sum55djYsLW8h1JYtKlMF2yHA8zCuhU/LnjhgSu09enXit3UZZdX06Fo4oLX7MfJn0+XeUTe+R5eSTtOWcDdkN5uOozxsc0G2RLgNJ5hylwxIIIJ7dweMj8vfqdM1DddBpIYWhjQxCWQlWZZAAA3UHYW3AgY6nvQJkZuLWO7iitESGCMBbUyoMq4GD5h6OHyd6nBXPAIXBiuVe1fc9tPEEwsaj79pcIxwhyDkBieCclHXutaItodLt7O4v7aQx6hExiDMhFxEZWjO4c7SCrr2dTtPSl05LXyfJuxcrBdEwWN6XJnhcDDIwACuqgruQ4YBkZTjKliKugWllcwyzalc2dvGg+YSsWklI42rGmX5DH+6uTyQBVaQKBBGtuH8x1USbisihAMHCnbuYY5OSCvXuYY4zbF5kzJPse3kXIKucqEKHHdSOvPB9aitpzDJEFV4Sj7CoPCk4JH5/1qXsUtzqx9k1TVZkvAzXKMsFxcRkgNtXlkA4Uklt3YnnuQbdreJo99fWtzI728LBneMGNygQAIR0bqV2+/oDin4NuYbHQ7m9uLh9+H2xKAQ7YwI/X5sjv09ar6bJ9sNzHJHmeV423Sk+XIQ/zAnOBuDPg9eMcZ5k2TsrI7XSbVJdHt5DqkgHlA3Vz5pcpglVDjoBnOF6gDI+Zlrq/C2kpelXu7TyksFzBZqWVjuGDNtP8AAcMADyPm3c15vZ6FLZCS6QD7TbGKRZ4WKzJnlVODxnBG7nnOfb1Lwxrz3luF1IhNQ0vLRyt8plg25lhb/aCDzFz97Z6q5Ob0O6m20r7F+70S2k1OI2+nWzTrESrz2cZjdlGV3jAyCpZSfcMOUFb+mzSXWjWr6HZW1hZTokvzAKZRjOPLQDjJ6nGeMDvUd9qNw2txWFqULQhgsfJy5KhnY84jjAOeOWIHUYrQlSy00wW91KA2xdsTHdIwHC/IvJBPPSspM7YryLEUH2cfKyMnzHgfMxHVmLE5HB474FRT30cQJaTmTkRxgs02ORtQcsMZ6cfhRbrcSeXI26zhGQfNG+WQk5O1PuqOnXPTkCpEsoUllmVHkuJlAaWSQtIQBgBmPOBjIA49BUXKSV7MjgW4uIjJdJHaRv8AMQH+ZgRk5I4B6DHOCeCDWhaqkKRSeTtjKkKoOcYP3cH37+tOEChHLR4CgDgcNwRznv371OFEbKrcowJZgAVUnGePw/Ohkt3K/lpdWckVx5bqxBdJUDj1AwRgEcYHbHqKFRclNwyAMl8Haf8Aazzn6+9TblKsN4TgMWHHOeAPUHP4c03KSLuYr907F65HbrjHr/8ArouCWpTYAA7mWRi4BYEcEHspH5EVYRYzvZW4246ZHPIHvn8x3qSUHyAVVvLGCUOR9ScY544OO3aqsqs0ISJyDIDuyc5xkY479f8APNItLmHna8W5VGwjOAeMBsE/oR/nFNeE+bnO5Q2DGeAQOvPuP60AYmZW3nA/5aL+GRjt2x25qYss+4Ow2pgMFc4BPTORk/5+lNMTVtjKsoHTUrq1kjfG43kJUj5kf/WKM9dr5OPRlNQ22mRXujguFaKSPy2PEiSpngMr5Vx04NX7pkmtX37RIpzb/PtIfBAZW7DjJ9entUNpmO3SEL5sUarGHY7WwOMkdCe/GO/FO5STMF7W/wBGj/0Ex3FjHwbOeQ7FAHHlycunT7pEg7AKKgGv6YzwpqDz6PLIMRi+IETHnhZQShI7ZKn1FdNOECkuwUl8DC5KnPX2+tV5Fe4iJSNjgt5ithjz1BHRvbNWpGcqatdaGRKqrGsp2yW7fMkiv8nPTDDj6djXL69LYS20sGozRxzOQBsYFm4yMIOeM/UZroLrwxoaRSznR9OZlG5hJCoV+MEkDAHOBj24rLvLWxs7ZjpenJCWAAZUWOLvw0uB7cEZ6VqmclSLPGfE+gzzJBNDbyRXCYUrtwGXJ2sFGeDg9O4OBXKXsSmAbVCq7MQvXyywwyk/3c4II9cHmvb9Y0O4u5W8wteXyAeYYwNiHqAMnA+nOR9Qa82vtPk0rVybqxS50+6ZmNmspjLMB83lvglJB1HBGRhgw4OiPOqRs7nAwpukGdykrlT6kUydwzgE9OCfpXQyWNlEbeWO5ZrFpxsnZCrIO6SKMlWxzxkHqM4OKt+JNM1KY6fPb7NzGNiq79uTjJI6/SixmZUFs8/MZGc8KeC309avvqF0NKXTI2KQM25wepYYH4DgVC7y7YpZ5JWmckl2bOAemP8APepNPb/SVllO7ygZFL85x61S7CYsrfZbiQTfeC4QA9DikgdpQ+zAHMrZPGBgYqpdyNcyh3xuI7Dr3q5pEltbXDSXiGSGIKWhDFfN55U+xoTu7BsiGSVy5VlBUrjaasWbRxg74/nUbSBx+dV/tYmud5iVQWLYHQZ7D6VdjysZuSigD5XJPJH0pDLhuGSPIZfKkAWSPaMcHtTGuGAVgg2gMcD3pFgkuVVLcZ3At6AAd6fJbx/aLaK2y7bSXZmzk0dNQW+hoaRJBEsfn+bJk84QcfTNS3kf2mYrDHtckbEYgnHqSKfY2LNF5ifKRxiug0uzjhAc5Mp6MBUOR0Rptk/hq0+2ToLdkWJJArK33uO+K9et/DdgjQvcSPPFwwTov415lp9kLVDdWVz5dyhBaNhlXUfyNdjouvKiCG8OJN4aPP8AEp9M+lPSw1GSep6TbQafDaosVorsEHYECqf2C0izImAzDGzAGPWqVx4hUWm2KMDgdBmsa31ieR1BUOzvglV4qE9bmrjdWQaZoty2tyT2kUaQvkEdyQf5V0U9jMzoGKhc5KgfyrPtLy6XU2YRusfYetbcMVxcXCuT8gxkelJyNI0rIliSRZ4wpfjpnrWldtOFDKpLdzTghW4UMCAD39K0JJo9uxiCfShaiasZEGqDaUcZkHXnH0q4lr57GQDnFVNWsEePzU4I5BzyaTRtRlVTHJg445NAao+KNImOr6HJpk5ja6tpHubV5HVC6ld00e5iOu0Mo5+bIAJeqqiDULC2gsI/LuFlETKwVnk3jgL3OCG/76FZ12zWl95QDRm3IjYA85HDfrmrFhOLM3N5bH5nElvCZcE/OpBb6hSeexIIre55liF4xBvEY3jCnDjhgRkHGP8APFTJeuNPlto5Z/JJX92XGwHoT9e30zTrUhLcx7SLgnYGJwVH933B61avbi5v54TM6GNAyxxxxhEiTJPygdBk/rSGb1ks8mpQq1uLrTZhJLLBOxMfmPGoZlKtkMSoyR3C5zisyEtbfarKa9jO/a/zk5jmwQu0DqdpKt/veoFUQ9vKI4Z41cvbmNZXBBSQSsVY+xBCn/ez2qvqEklw6XTgG5nYiZec71PJP1GD65Bp30FYs6rdbYw0XmKJ3D/M2CjAAnjv94c1cW3W6upPtDbQLtUcKRuKBWJP4haZdot3bJ5QjzYzAuV/55MThj9MbT/wD3ptncOYkTy2klLPckMOGwBtx34KtkfhUspGzJ5lvqBWGB4XLfLDtBw/lkjPOMgDP1zV/wAN2zQXUMc8SkAqwjKjLEAqBznjPUdDmkv7a0uNSjSxzOYoIRv37wZEjMtw/XBG9ig9cVqpO516e5kuZmtYbUt50dshYgMM4VuvzNgHI9alrWxvTfU65Liytry4hunlbS28q1juHwxtpTGJWBOM+WSARjJXDeuQzxBpf9m6bFfaYLsLBsL+a5iDAgHCk/N1+ZTgbTzypYVhPb39vp9xfzbjcxyx3cu+EKBlghXcrjAwSpwoyBXocOmfb7my0OQss1opuL2VkG/ygypBEFGQnJk+UE5CcknNRLXU7qPu+69mWPh2IbzTLZZbho7yZFy0Mm03AXG5XIO4SJyXQnq5YZU5ruLZILOKZIYYohMFeURxYJHqzdcfN39etedajpdxa3z6naSxC2nXfKkyMItybVUv5fzIwHKyL8w2/wAQJFb9v4sisvJtvEizWolIRLi4Csr8jP7xRskHT5l2t6oME1jJHXG6ST2OsugJZEAKOqZKgdOw/E88/UVPbRL9liZAdkgIYgZyBtA7cY4/SsaXVdNsUW8fULNInJCMsqusgxnEe0neMY6D+I0w6vcXMZGn6RdSwOw/f38v2OAKQMMFIMh6jogHvgVI30sdLJCwLrEpklSMbtq569SB2+vtVC41fT7WUQG58y4Vj/o9v+/kjO7phM47cms+PT559767qb3AkXa1pbMbe3AwM5w2+XjgB2x32jNaVxNptrJDBpUCWlmifJbWsfyEkc8Dj6/SglRu7bk3nv8AaGHk7FYZYuoUdOwHzDGB+vNV3jKW/wDqoLgqUxH5u3bxnHTnJAJI6ZNOkJmZWto7hNuG3cIOSB1znnngDj86J/PMrWkJhcKfupLlcbSeeM4wAeSOnpRcaVuo21aU2/lz2MYkYLs2XeSSByuCoGPcknAqFZtkoaS1nQYbc3yyn7v3sIxJ744/KpFlmeCT5UWPKncVYknoT1/+vyOlNnEmVLuqqshGEOCemcd/brntUtmiWo5biaJZIotqo2VMeflbpgcnnvweetI0jpu+9GQQVIOeOcA9vXqe2PSpLgosBzKTcJwUAGAPw445/wDrVWluJIoGt1IRAuSCcE85H4d+3egcVfYsXMTNaJGY5Nkg83y9oGF6+vPfjg1RijG7y22IZTySvAx14NKjPcFHLGQtgBQcnIHOD269P1p1xLLNdygoqnGWB+UA9v1xT8y0mvdFREWAqRtO3BI58zOBz7c1Snt4y+5zJvCj+MjeM8DGeemMdePwrTgilmbZGcMnzKSRx/TGT/niqSp5DzcckhyVGV3dQCR6fXiqTJ6sqwwWUbbypaQE/vpCS4x1IJ6H261U1PbDbSsHb7S5jjBwcMxYAAryWPOenINalxGqWbo7Fmx8vRj654644/X0rP1CIMbQhm2l9ysVLZUKcD/voj3HHpVxZlONzn2s0W2kt7eBbeQNuVy7IzBvUj5SCSTjHGTgiuP8UWEN6rJc2syzwsGYON4Lf7y/nnivS3XMcgcO67gDFjJB57Docfnwaw7mwLKZ1lSSQn5WU4YAA4APQ9utbRkcFaij5y1G3ksLy6a1U3EIUfaEf5gyN0P0z36gjrmqcrxeVPB5fmW1wVk+dcy27DjcG7jnB7HuMgGvT/Gmgi/sp7yxhWK+gH7xASCy4O5SpPOeD7HpXlauBON58yPAMbAbSB71oedJcrsUbvAmAyWwv4Z9BVnT8eTLGvzMykhM/e45A9Djn8MVNNar58YQF4JGwoGC6n0I65qrAFjvBhx8hDIw9exNFtSRsEbyBcAgY+92x70XMckccYZWET5dGI++M4znvWnqE4jmxaxlEmLMu0/KFPVV9t2arMFjtyhcbSAxTHy9f0NDQBY2hG6TbujiG9yKsRxxTOglmWKN2wxx0H41WtZ/JaSMktC64P8ASr7yRyyW7MoMUY+6vTNLQepEC0aO0Dl4R8nJwcVv6HphFj5hU+ZMc8j5gvpVHda3Yitre1CkPueXPLDA4x/Wu00Gbzr6FBEI4lAUbvT/ABpN62NIRvqWdL0wJZ4KHzW4Celadto9ysiQsDvbjgV3ulaIJgt4wRXUfKCKuT20sVwjJbq0zjAPYVLSZ1Qny7HnT6cYb8RXAZ3b5UUdff8ACtnWbdJrGGKONEngbAHXFXL22exu4bid/MuHY5bsPanWumzPvuJAcOwYe9JWRbfNuWrC+EmnRxyhVmVQG4wa6jwvb2ssp4XMS/rXPG1tJUXf/wAfC/IjA4Jz9Pxrd8P6NNa2nlyOpLDIOSCPSk2NReiR0dnYRTzswAOORxyKvWsaQzqhIwTxmsXTHu4neEBN6HDMc8j1FbXkskLOxO7rkDnNSW23oW7+aCLL5x25rNtAlxOWLdOMDvVWFWvrrDZKDB5Pet+LTkiVWUkd+KLia5dzP1FXVNqAY6AVgT2VwkiSIPlzk4rrI/3r7ZAAO1TS26xwNjoB6U1cXMloz87Yle4uDHGg8x3yMnpn1z2FOvXie4WKBx5MeEQ84I7sfqef0q3axOmh3N3HsabHlnD/ADJESAzEe5IUf8CrIXA5OSPyrY8ws+YI9yqo3cAPuJ6d1FW45jFbO7OTIRtjAXGMk8H+ffoPWqKSbVXYuWXPzHOBmmSEMdqfMAevr6mkBrLC2pWlzOokZLRVMxznam4APj0y2D6FhVdJPMvYwwOIwS4J7d+R7D86isL6TTr6K6tijNEeEZco4I+ZWB6gjgjuKv3cafZJr/S4NlmZAJV3b2t2bkKSeSvBwe+OeRT3EFtJI51CNWxm2IkDHB5lVgPwYr+Rqy1wwvLplIkjG2EBDyVGCSvuck/jWbasYEW3I/eXDqZMnGEByFP1PJ+gp8bzSi6a23uYo9xwpO1MgMePqM59aBnQ6PqEUOn+TIpw8n74IDvZBkbFx90fMck9c8etdHHcw3F5pl2zpbzyJIog2mMJjaVYnhc5zhRwNq9TXK+Gyk0sEUiK3lPHJIJz8qjIVn+gyuc9voa6pYbOTWphLte1jf7PcR+WFZt3JKj+IKVBx7mhpmlNrY9H10reeBdRlVWQNp0jCMDPCZGP+AncM+qmun8IX32nXtb1abYDNcpBuCjkQxqrEDPdndseprzN9QTQtP13w8z+batBKbOf+L94AfK3c5UlsjJHQ+orqfA+qpF4ZV32291LdNLEADsCyOdgX2+Vsn1Q5NTudlN6naYElvpkcgKo7zeYhJG9WikJU/qee4pLKQXEU1okuJ7dVWZJEBWVDkI5Uj5gwH4HI61ApJuLRI9twUWZmZlIJ6Yf2zvIxV2+tUucljIJ4nZlliYK0OABwehBAGVIwcdK55+Z6lNWWhWtdLksLma40w2FlM4JHkxBCeAMEYIPHfGfc4xVkXGpNKz3BikjdcsbX92Rz1O7PGcdMdanWS8jWFJlguFEu5pIz5ZO3Kg4OQB908e9BuXkY4ttuyMlSemDwRz1PVsd6zNfkSiS3EMavb3MT8BxJGXxz7EjB/pVuC6s1kkRHKkbi2OB8hBIwecjdnp3HXOarxG7uAVjQDaPMJjYOVA67SRwMH0J4og0+G5En2wPNKq4ikLhtoJxnLdhkcDB4AHpQQ7W1ZfknW6tkeFZo3CF3DKfTaWOSCB14OD37YNqO1WSJ3K7ZmZVxI7YOV+7jt9fT6is2CIW0iwxxAkvgxxlwCQCA4B4P3lI6degrQt4ZTagiMlN2UEP3nIBAx379+SfoKpMxkuXZle5RvOUONjs5JcrwWHbpjtjA46etS3E0EltB5UbIyx4fGSegODntmrkK26NvZVnkAdfl3DGCcH0xz2rLvpWd9okIUsWZ5GypIBPQDuM4PIqWOPvO3YLWWJX3XIdYS4yqncxXBJGR9evqDUcql3ZAz5Td8wwzc8dvb8etLHJtgIVRGmCQDKFAXgkjAz2/lTisvlSMsMOSwLDfynHIGcHkjP8qDS1ncicGMsUjVZSAhUYYkg4HB4P5dh0qMbFGGlD5bnfzk/h7d/X8KsKQsCoineHO3PyhV9TyRk5x+XWiUyIC+CryENkIcdcH734UikyPzxLKXZV2KMCTGPTn6YH4809nd4jJGiI5VuhHHuO2enH/wBemyg/IHR9vlj514Lc45z0GPr0pGLxtImQoGcMwBxjp0H+eOeaYrLoNjBVXkBBYjcAAMYPYgdB16Zqs8fk3L3DOTJgoeeFzjORj27+9SEByyEeWudxYDnbnqO5HT8qft82VTuCuoJU44Ix2+uOnbNNA1YpXKEbYraExuq7DLjqCeDjvz059+KoTxzTbnlnQqwGcIPnGeuecHPPtj2rVUgbQ4KhSyqeh49+9V2X5t7HbIy9RggsBnr+ma0TMJwOR13Q7fZI2ViLfN5qgBjjnPoc+leGeN9DutA1i5a4gH2GeTcjwqNhBOcA8hW4JH4jpX0vOsLQyxYPl8fIx+5kYx/Lp/8AWrz7xv4fW80e7tj+7M3zABurA5QjPfn8s1vGR5lekeN6UNP+1XdreLNdpdRtHpd1bqVlin3Axkr3B5Rl7bsjOBnm7mNra6ZXG2WNsMp65q7qNq1o4gdZo7mFtk8Ug2tHIPT/ABpn2lmiCufMYPku43NuPOcnt1zVuzOJIuqzXXhmPMQ329+w8wKAMSRg4J69Y8j6mqAnkQxqjsrd2AwPpjv+NasYjudPaOJIoG8ySdY4zkKqJwpHXqSQxz/Ss66iAYyZV03ldw6Hjt7UMEOgCsxY7ASc8Db+nT9K0TbqYhc27I8YIWVV4aPPcr6f7Q49cVXk065tra3lngkjS5G6MsMZBGRx9OfxrWtIYxHGi8FvvEHkjvUvzNIq+xbs7CMWqtkCQc5z1rtvCkNvPf2nzKEA3c9q5jT44obhbe8YJb9UbnP0966fRrOG2YzKHeOV8RlTxkckVNzeMbnscN1avaxRq2xicYParU1mV8q5U5I/8dXrXEWl9/pcX+jl4YVwxB6E/wD1q2f+EjV5xHskFu3ynccDPbmka2sUdURNS1oGL/VRD5QTw30/GttrIQ2EQdtoUcH39Kw9GsN2rmDeyh5DIc5wB2P9fwrtJrFbjZ5pLMuVwKl6GkYt6swfDunGW9lvLqP9wpxGp5z6/rXTyKkjIVcpz8uO/wCNaen2BSBRtG3HTFR3Fg5yLUhc9VbkGpbKWhNtt7doJsqGb92xz61LPKrwMFwcgjisuWGRUVblxheVAHep9Li3A7zy3rRcLdWaOlWaxRBiMFquSyHgJ2496rqvlZCDG85Pv71chTCEkduKZnJ31ZRkDkggEZ5zjFV72adYm2ZK45rWmKCFgcE9Kw9QkVVKxsWZhtxnjrTEfBM17IdQnYxqkTIYREOUCr0HvyAfrVBjEzs2woCfug5x9K2l043ZcWsVw1yI5p5FIyuxAWJGOegb8BVFLB5HCJGWcDLfKRgnjB+h71qcBSZ8qVAJB4BY9vSg/I4LBcn+HFaEulXcMrxSRHdGdrKSOD+dWV00RgkQ3BnCgkYz39McCkNRZlQ2sk0ioiEsf88Vp2E9xppeazbc2wxyllBiaM8MpzncOPoD05ANRxxyPazCMrHCrYcM2C3oDxkjrVu2spbyT7PGGZ9vmIV+UAAZ6U0w5blCVCGE9tHtibdwckqSD3P6Z/XrSadKbaFplX5ZIZbeTBPUrxn8x+Va1rB5l5EirKVA2SjIG7ngZPQ9ee1V2tWilMAKvHIokDLjnHRhjvgkY+oPIppicWifShNZah5oiDloWwrfMHVlKsv4gsK7IWdk1nbLOUubHdGqhX+YxsMgjB4YZPHZhjHUVxIuAtmis2Wg+4FIBbLZAzWwk09tNHb2zq0gj8yOUlhHs2lmABAO5WY8Dvn1zT0GnbY3NRd9VtZbV3LX7TII8DaJIog+92OfvYjX6lm+tdraMkmn6PLbqrRQwGW7AJ3hZnkfCY4OxGDY6jJ7muFsZbU+JrSS3R5FaFERHIJkfftyo6BTlwAOncnrXoXgN4W0vTxbQur2i4mywbeSAwGMdcEjPTb6YqJHXh3qd9ZwrHcxTrc/aC6IiO+RlC45IPXpjg9MHvxqmQvGqu4wdpfnuFGATngZA9ucVyfh1/MtRhvNiRhASBkjHAUA9SM9u2PWuhDFYTudSG+VmxnILAkjPtkfUVhPc9ansmy9EvmRKQAvJG3txzz6ZAcevH0qwqs8/wAiAsCpCHhfl5HBzng9c859arxyRyxTCWTZOI08tSM7nHBI9sjH064psV0RJvgYRSqm5Qo7A8Dnvxnv3rLY1abLdpI8cke2BZGJ/dq5DE4DAqTnsCOoz371HbTtHHIAuUIVwjMSeBncD0yAc/iabBIVka482MSRHeQAVcHsQe38/Y4qzG5tLcwqqpC8TKA46qQOQeRjBGfSmTt0J5HhNsEhWTKORnqgU4xz655yPStW2Y280sdrcLIjNvZ0UjoAM+3GfyrF0+SK4EjTtIsineSyhnyRwPfPXPtx0NXVkAb5ixj8wINwAOzI5PbmmrmUop6Fxo0eMR8beRt5xjPXIORjPX2qCXT3ZHFvH5kkSNIxBwR16Dp/nFaFzJDHpodWid5XPljORkED9KpT7TDIBuQuEBcNt+Toe/OeuO4qpRSMoyl0M2OMXPmIgmO5lAwB85zy3cYO1scjr1PSo/OkuXWRXiVCQolZueByAMYAzxk56UTRsYCZi0cCKFSUnDPz8uRngZB6Z/AU64YWuUgO8MTtj6rnooJx0wef/r1mdK8iaGPLIFWV5pSwaQnLNweoxweOg96axZvOlhcbCAC4cZz3bj69AP61CttAm3z/ADfNTaFdl3ZPOVOeQPu9qkkXzHXyH2xMQhAABYjvwcAc8c/xdRQkLS5DK6JEpjUfvCU3lSSRjJy3T8PSiWNYpHBk+7wJDxtHOOD6ZPTrT0M2/MixpsBj27SpBxnPcjp2+gpjAQhHnjL3DkjAwO4xjvgYPPqfSgrZ2KxdI1jkyHbYVKqCSfT2x/8AXpWEkSN5zKCDyqr6+hz1p6uDHuZNiA7GVcEnpgY9e+QO57ZpGJRfmjGSFzv+b6Y/nTKZAMLDJENjEgk7l3kr1559PywagmVIJWK5JALLhiQMHg/Ucg5H9KldFBZ45CXU4LHqPQEdv8ahkEatL5SFGG5QoBAVuNvXtz681SIaImTPV9wYkbmAwgIx+PsevX2rGuohGEkVyOh3k7w3cj2HXnHH41uh3V5VYEBtoZFAHPQMMcZ6rxx+PFZ91E8m1RcIkjMpygBAyPc+n8j61pF6nLVjdWZ4r8WdC2WlvqUFv+8t5dlxKnBMZxtJHXgn9a8vXIfMmWXcQdvUYr6U8TafG+kXcVyWmhNu5YTL8yEA5GenavnjXrCbS72WznA3gB1YfxKeQf6fWtkzyqsOVkVnchZMYRC4MZbJUlWBB9se30qKLLsEf51PBbtj+h9qbbS4niEwDpwMEZ25AOR9M1aiieJWkYEE5yQMKcEjI/LH4U2zJI2L7UrvVZ7dp23RQIIYl7Af5x+Valjaefi4K+UUGAPX6CsvSHWZUhz8jsOQMY/Gu60KACYxmPPlHOJDjI70pNvVmtOK2I9F0M6hOgmJaMqWCqOWA5OPcdfzr0PQ7UaDpUlpeCK5tbq8iktpsco4jk+Uj/aGBkdxUHhtLWG7Miui+WN+OmPcfyq348L3Gm22t6FEQLW4S4mhY/JIItzlgOx4PTrmpWm5u9tDZsNNefTMpbkSu3mSbTjBParVzpDnTkaYEKsgzxzW7oN5b3UAuLcD7LcIJBn5SARnmoZ7g3mqCzQkwRfvHOevt/KoZtFdzKtd1neSXUqkQNwNw5XH9K1dBvjfw+aFwu9iOO2addWjXEwgAGx+CRz8taOl2cdmBCgwjdB7VNzVpIvrfkoI4+fwqxDNgDKZJ4pkOmBJg45B/SrN0RFjjP4UambtsjHu45JrxeOCfSr8Nntw6DjqRnk01pSzgjkfWrUMrRjJ5B/SgG3YkMWQCRz0q9A6iIBhjjjisyS9iM6qGA9qbr+pRWOnu4YFwvGO9UjKS6GT4i1VIZGhjP7w8ACofDVhcTsbm6IYE/JjnArL0TTJtWLXd6QpY5C+grrAghsJbcTSxKyFQ0L7HXI6q3Y+9Fy2rLzPiewlGjqt40fm/bI5oPNDDaqSQyRtgdyVcfTFT6XaTaTYXF+0kcUCBVe2eby5pYpMjA9tynIHPPvVHWNPR3tJLWOCOaSMnaCGWT5Sd3H3T2xj6iuh0aHTruOyhmtDaSzR+S7iMMGyysrIwB5Yb8c+vpWpxqOupnX1imqa1GmjWb2oYJiMEYGeBxn5e/Xmpr3S7yxjiW+tmly5bZA+d2OH3nGSeAcdPet7WLlrXUVe5e2kkj8uJlM8RBCkkEhM4JHYE/rWncXt3eTQi10WddSaQKhlkRI8MpYFI2CseBxkgfWlodEYrqcRpVzqNgpng2Rm5wpyucnJxxjqcnA/pTINNmtddhjjkkSQyDDFfnVWbacgdwe1eifDoaJawxf2vBNBemPNrLeIT5ik4Kxg/Io3cE5/PtF8QPDr6PDaa9DIkzCRJbiSJwY2UsMBSOOB0x6VJfs1KN10MfWPCzabaw6lBNb36S7nMDRlZph/GQBlcr1B447VxlzmRInfa01swCFZFCmP0JxkEZU88cNXsPg+R5ZZUiidzgNEjlWVQzlwOeNuc5ri/ifaWk2szS2VtGk2wNciEDZuxlhkEjHfA9aq/UyqUrLzOGuY2trtlhcwSq+w+TKG3IxzkHuMZ6duarW2pSx2drGZvNjjnaYQS/MqFgQ23/eAUn1IFPtZo4mhDRsw8sbD3UjnGfQgEcc8+1QzQxQ3IuNsiqTujgyHZRngnpjHPBwTxxjmqTOV6G/ps5i1lWjkG8W3lggZEJfIZfwEpGR0I49a9G0O9t9OlkkEiiGUtFOI2JEOG/dvuHUDkc843dhXjNvKdxjZi0bAhiD1Y8H8K9F0/VDptnKxKma3VnEm0skuRwjj68e+SMnrSZtSlZnovh24UWl1cLMqx3d/PMi4wRlgIyOxBAU577gO9dZE6fZ5IYmEhkj2kgEANgHB5weBnn8jnjzrQrz7HbWyqDLpscaxLJt/eIoUcHjLKpOeOV6cjp3AvNzRriJoJCJtqnCOvG0gjjvgHv8ATisZI9WlO1kaloRvUs5jZgRub5gGwcYIyQMD35yKlgJAmkkK+WxUiPAO1Cecd+Dj8PYVnq9s2EaR2kDMibCAWGPlweenPX1NWlbzriAtKNkkeXPUqT95hkdPx6/U1m4nTzJmoYpkdBG5dmXaqq2RnB4J6fMvf1ANMRpCVTyhuix8rqRgDg5Uewx+HviqTLLDeSSxNHET95eArsRw2M8E5wT/ADxU481Zo0UNMiplSc8ucZQ+vH4Zx6mlYEWbuRJGM0ZeGSNQEfqhLE5HXkE5yP8ACrcMonjkXcNyPiRW7dPTqBxjvUTSuhwix7Z4eYyAflzjk9uh/D0qF4Gt7iG43HZLiBirkhdxwh7kgE4+jH0qg0sWLO3igkZZn3EgFAvzcH09OfbvVsXDTOyYIjYDIwN2V7fTPp1qjqUqxS2cX/LR98ckKSM8hOAc7RxkbSMe9WSsMMMYt7SbzVzncdoHHHQ9P55zzSYpPm1e7CSeVI1H7prhwEkMP3WJwOvUjjPAHTBxmmiHayiMxhkZd3z5LYyc88DBxxx6d6ckcKxWzTEh2RVdQ/I6nH19uvpUd4xjdtqgEqSjSJhQ2MY7YHI59hU+pK7IWd3t2CoZ45ZI1CAA5IBySB3OQeajTbFYTMm9Y2ZiDkl+mRux6jjGT+tFg5DuxlnmbzMEopBbocDjgZJyDjuRUqQDydrkFYzlQpwF9C7Z5JGTj2/CmU2o6EUtvI8ctvcSsSzKxiA6MRnqOScHHPriopZbaPcbeNBIIyNgT1+nUjrn04ps1y91kQOI4QxLzMfmI454Gefb9KkSIxxlbTDBk3HklckdCf736dMnila5SVviJ7eBMgICBsA+Uc56ZHbOD+uPamXsBh6xtnAK7hw2OQT61bspLb5hIQ8YbO/duOW5JyQDkZ5GMj8qdrd7HM8cFuh+ZgYsZ5JPOM/Wq5UkZqTcrWOeZCGk84Ki7T82Ny8deT7449sUcuSI3Luo2YAzzkcAH0GfXnniqd5qMNtJErRSTzToZvKiQsyqDjJA5AOCagVLu6cJtELF87pchmH3cduO/P8A+trsbuDtdli4WMbXmkESqp6En8Py7exPFV9RmSKN5iY8wyBDgc57Ln1Bxj36U2XT7iZzFLIZeCyhesjYJDE545/h/wAiGC0dnt3uJ90ZUoQqqEZ+SWKnqevOe3arRzVUl1MvxGl1dWSWMMEkt1fHyzNxtUnkjBPXHGOp615x8TdA+0aBbajFcNLNAzExbBvij4UqcdccHn0NelXpuZtRggC+XHBwxZSrO7ZGQRnoqjB9T6Vi6/p0cmnyfYmMly0hLlmHzjf91j3YYxn3PbFaI82tG+h877I2uAd7o685ABB4H5Vr6a8EsLQXSuWDZgkHucsp/PI96W8sJba8UXEIETfvoW7Mh7f0ohCrKd42RPzt55542+44pnGkzqNCsY1BhlZMtgo44Vu4Iz2P9a7vTNOiR7aS3CuWwrqU4B/3gQenbNcBp2oL9kjs7qCaRoHJjlbC4B5ZHPYE/MM9Du/vGvSdE0vxBawrPDNpNrbMd5AWS6cHr1yq8+2aNtzVa7GtpOjXbajKj6ZHeW6KcBZvJkwR0AYbT+JFburXlnb6JdQ3ej6naQDTJZSZLYyLu5RTviLKAfn5OOnai1tNSv47KS88U6hZ+cApTT44rXn03bWb9a4K7tLbxFqF1YWE1/fstxJA95dXckq/Z4VxjOed0jORjHUVLs9DSLa1PQ/DV1ptn4e0wS61YySfZIjIGuFTHyjoCeo/WtVrvRHy1jrGmycb223KZI79/fn9ajHhfw7ps1hK2mRNdvGE8zzHJJ24wAW6c4q7L4J8PQ3K6lY6bDp2rqCVubMtEwz/AHsHDZ75BqJWN4SaNPRZ7WaAC3ure5fjcYJA4X2yKn1W4t4LiOMvl1/hCsT+gNZVhLrEVykV8Tc2+4BZDHhvqGQYb6Mqn3Nb93M9rCdjEsePaloVrcr/ANqtJhbW3uZG9dvlrn6vj9AanijaVt180Y44jQEgfVu/5AfWq9uCyicrk+h7Vba/tngbIG9RigTVtgtXgaZgeg7HjFWZZohwpG7oOay7FReSOyAhVOCanFoGkKhyB6jtTQmjN1q2ZoTLGWVxyuB2+lYlmZp9iXpLknoeldw1iHiCuT0/GsbW9ONvArxY4P5UxKSL9lD5aL5ZwDxwKNRUDcgI3bTgnkA+p/wrLi1eRbYAJ8wHXHXNNmv1i02ae7IUBcdck+tOw9dz5YvfDpbT7W7u/Na3nUyyyiFYxncB8mBlsBlyTgZz1xTrnSoLSPToru1DW7blkYueUKYAKg8HOPmA6/lXQahqtlqNmtpb3U93KYZIDaqPLS0kG0ESNgghcH7pOcA1S0G3iu10+4ubtfOmkhgDnDMuJNvHZRj86tqzJhGMkXNFaFdQlks42hjDBIprXy4PNRVA2NEV2mUAZPA3dR1rSuZNUv8AVra6sLnTr+GVXt45Hga3fYh3BiMnGRnGQOB26Vn6bYWrXVxbapfWsdneTAhZZkjztONxZunP0PXBANT6sLPT7lElvFu7mzm8yL7KG2XCFSomR9pBAYgMoGGwPXhalxSi7X9Cx4Z1adGmSb7NZvpplvLabzlUBZDluDwy9VK8ZGPas7xTc/29N5lxoY08zPGts1gqLE4OGaQkspJJxhSCV9c1HfRxi+k0/UHuBcRupIFo8JX5Q58xAPlAzjjI74FaNnZpf6x5bQ3DPbJuidkLybiMnO7gDGST6DPvSe1rGqim782nn/X3GfpQvrk2sVnZ65LdSI+22kW3UB0+/l35VBnOSCOce9Z1yNWkXU4ruf7MLjCb7lVYzyeZgoDGNoOWJBJA4/Cujj02Ww8SeS17Gt/HIlxHJDKWVkc7WC93TLDK/eIY5zwQzxVdRSaXq1rEZEnjma8kCnPllseXEpJ5LSOMcZCoxxkEARFWKSbbOD0izS6u7KyOwXF48duswT/j33MgSXIABz84C5wd3sTVHWvD02ma3PpUUiG6hJWcEgqSvocfe5HHYnBrZuYho9leQ3Ep8toE8+OJj82fmjkX0K/KMdQTnua0GsvKthDftK/iEuski7lYIWG5XDgnIcMS3fdx/DTOJRu7M8ymjkhiRoJgyA9R8pXBPX3612EGuR3+nwtKy+edsN0FO0ypuU7hxjkY+jKT0NZt9pUkmrSQyBY5JwduFOzzB0H4kAf8CrEt2Nsy+ZwrZUr0KZ6E007ozcXCVmexeF75La/a0uroxmQmSBzwobOWQn37H2x2rorVJ3thcWDwgktHNA5xGGDYJBz+7P3W4G055HU15xpVwupRQQAu8iFF+UZOT0AI9zweuGHpiuy8OXTeeILsr5t5GrxT8eU5KgBWP8LZDDnqRSaO6lUXU6tNbiF+WvLW4siAqur5C7+QCHUEY56HGa1dKvdOiub0rextKrxMqqCQw2kH3Odoz26+1YmnS77+SMyMnlJGhSSEHkyFTuU9cbuO3zdegq6G8jUYmeKKMhPsjbcYVScgnuMELzwTkjvWdjrTS2Om3TTXfkW0LJtGDM4BKk8hShOegPP860bO1jDxQxSzgK26CSZw56gkk/Unr0z7VmQRxwOGkd42lzGxHCluN2M9CTzt9eh6V0ojXMzWISFQRtXdk9OeRk8gHPcmly2D2hVDAW6oFPlrJtkRMA98498ZqvqFpcXMLWUrXChVZQIh5ZA9SAc5Ax64xV+5AUMG81gVJVmwSwHfj8PwqrJNDbO8ty58q2lVm8x1Zc9fqflXPWpRqn1RBpXlb9Cfa/2i8n3N5ZBcSCCQsMD33ZrQuEECvEwLKmASpyCdx6HqeD+HvXKaS7FfC3MgdoLq/lCrkwxsoIOe/wDrunvXRSzxyqZbaFEaRFKLGWG3v0PfsfU0dBtNyv8A1uO1COaG43urKrIGXcQWAOTljnjgdaUsfNeSRwApaMNG+CoVsDqMleTk96p6ifKEwEhR1BLFsjDDOc57jkU+CWS43RySBcIIneRgzH6eg9MetQVbRFsmI6eDu8uOR2Yq8m4IOuNvqdvUd6qXMBu5op5o2jjyW2OxweSQzY6ck9yetWn864UpsTcyjdPsJZRj7gOeeB9ACRVqQkxxiMuwkiWQbiBt255xxn2zjpTJUuXVbla3gLSBAmd6EhI13clgA3PQk8Hp05qOc3BjTcscryA7iJSCI1J6jHHOeepBx6VejTLxosUcI3cFcruHfJ7elV5WaOXKRZZXO3d935j7cnGPrgCncSbbMiaKd45ZRIqjarMIl6gYGeeee5xx9aZcPK08zxsGVcCNmGGCd/YnoM/zqxqEEkcMZ3L5s4YB1bIX5scjGOo9+D64qnLbqVIupWmkwioXzuTrztGOOB+eKLGymTywrbXkjopOCHYY3eacDGScdu2B24onuIZJHjBKyYPMoJC4zz6DqM+496rpJFGg+eVpjkHJLMpB6nOfWm3RQRsrzuqk5Lkjjnr04Jzj8qBW11JRvV2QMZ2XcHO8fNkfeHvgjH+OTVW6IMcjP5rI5VmYtwTjGR3HBz+gqCT5naGyud8zKvlh23bsEHkD9T61n3Ut/NK8cNncRcBBJkOi9cMvTPQ9R0zVoymupFOzO2XlKzFijkg4HTB9l96oaw5OmudrbtuxV3bTk42/kdv+cU+/0XVjGZIb+KaUDbK8qtGsbdCBtBGeD6VzuopqtlE39oRTLaxMFMluvmqoBGenOTxjgY/WtEzinZlLxn4ftzaQyNIqmA+WjOwVQeFAc9h057HPauHv0QSKyKyC2cJKB1yeGxjrj2r0q3uLO/sWV5UMbqfMRkyTnjv6d/0rjtWsHsxLZxYwExFnltoG5RnqcdKp9zilFp2NnwZpMOq/bZYoxNGlvlAqfu5QOCD3Dfr3rS0jV7fQ4Rpl9NPLosjh7a7UlZLMZ5inX0B6MO36XfDQmsp7TU9M8uGSe282aNl+ScYyVx6479ev0p15FZ65qckDotrctGXiCtkSZ/gU9GHOcHp0oewLR2NXxY2mT2kNv4akj89WLSXaybo4Uwdz5zgn0HrVnww0Wn6Hb21km5TEba3VVxk55J/Dr9a5Kz8E3+nXENpLcGOKRlP2ZsbZRnnaexA6rXottp0iarJlFhith5UEQbhc9WPqajoba3sab3ksl5ukKvLCVxtOcDuK6iBheQJcRDOecHp7/Wsuw061s9jHLSkZPHLZrQ0GVVmureP7sbblz1wag022N+wyYRgYOOfeqU0Pn3gQkEL1was7HVd8fHtVVJjHe7sghj0/pQSurLd5EsUXyk4A6Zrmbu1lExmVSEzyAOgrpbmNpZV3E7c5pmqALYvGo5Ix+NDKhK2hj6NciYlIjkjjr3rZt7by3OTya57SrYWrhl4Zj09DXQrLuKsCdvtTQT3LMz7F9BWHrV4bi3eOFQx578Vo6lM0sRjhG045YjIrIaGNLOR9w3YyeaoiK6s4iPVcXDW8jASj5Qc9PSpLmJ74+TcPI0QB4bv6/Sk0u0tkur29mGWDY+bk49a0NNkt7+CadI+7AHrntQbJLqeIWtqdReC40mDN3AGTbb/uYEVl+UeYpAD4U8jcSRggipPD7393p2naZHc2waSaS4a3dWgdAilt3mqDvX5l+4V56iult5bm50nR7iyEgnkAilCoAocBlAHoNwbp6msTTrVL/wAUavZTQxOu9Y4izbSroSWWM/wnJAyOcL7VbVgjT5vIr6bC+nqWjgFtG7SN5sKefhdxQk5G/A/GtTxDrn2rSIbtNTuLm4tJM2VxHtxFKmMEcHAUHkdTwOlZLO8UhsItRms2M08Mv2sLIETliQSMg9AOeS3vWwmjXt9p1xe3MFleTJHtS4gvGtJ0XG0LtZWQjttzSvpoaNa2ktEb2gzadaae1t4pha21Iq0kN2yBob3J3FkkPIb27ZA4JAPOxaaLe4e5tE8uMygJpr8GRnwZPKJyI2VSOT8vXO3rUlxr1xpmhtovi3THfT7gRFTNGGXbFJh87C+zO9V3r9AO1P8ADEeqWM0d8sF5/pyJbRyX0flwWvmOStuZJcyGIhgN4By+0HIKkJ7BCfLJ82tvwJtY0W0vfDU+p2V6VNsd0lpOpE9menl7+CrnPZec/KdvLeYW9tbTavIl5G0L2s6i5SIbmKkkNgEFcIC2R69ODkegeNWvtWvbWK51eys7yciCEaXaOgaEMGaaWR3LmMYOwEDcw3ADrXK+IRFbWNrp1tbxQ+ROHh8rLRu2CCVJOSxyu4HnpyQM0ttSJwdT/P8Ar+vvMjxJbSJdrDvhmbznbljsAHG7qRhsjpjpxxWrb3EN3ZWpMgt9XtFxDayRELPhhlDJk7w3BDfwkdAOar6PoDzXotVaU3TpuDLuyxB6ZB9OfxFbVt4dt7bWZ4dRURqVjkE5mkQxnJG7eCNpPHXI96dyfYu7ez2/r/M1LxLLUPDkWuRSR+bplwsx084E0SqcTRup5Lbec4/hGOtcd8QdBiinFxamJ0mOS0R3LIhG5XH1XP4g11eo6Pren3N5clLq5RYDG0lwGZwhXq4TDcLkbjkAdVA6ctrE+oSqPIt7dLFpDKRbRgpGzD5kU88HO7Yem444Ip3TRjODUveOP0e+ewuowOXizgMTiRP7hx+OD9PQV2LXkclpcR2RlkgZTPbpj51fK74zg4yAzH8Se9YWraDdGCG/SzkS0lUgS/eViM7sED/OD6VV0bUDHIkLyBY/MViSOhGQGH4HB9R7gYL3MbOB61pV0sV2q2d+8yTIYwZwSyMDkAMBnkYzwe4Hatma91G90tLeW3soQzHbcMWdy/QjGFGeR34znmvOYr9oHT7SZpIGXzUMb7W+cnIDDnBOMdgSc8murtNTWa2tf9LuIyI1ZX8wSxyMA3BVlJUbWIJ3dQenGCx0wq3PS9ImhVLi+u53upizSeZLwSm7B27cKh7kKBx9K7CxdWLTyMofJYcA9ccdehy1eO2V891pEtv9rtFZl2lZbdlZCeCch+gJx0xg12ej6xq8tlaxzW9hOQNrNDc7XypIbIZcZBz/ABYNJo6YR54nU3bRQTCbaxdS2S5O3awxke/9TmuS1+4e409dJtJ3NxqTC2WBcboYgMyuePm+TgH1ZcZq/q+vWtrBB9tgulLH5YVi3l2Cliqsu4duSTgDJrnre5RvP8S3j4uBExjKKQiJGWJjzwSvXnqWOeBgDOxtBpbmtZTxtr+uXxeG3s7OGG0iYnBjVAJXOcckExjbjnbjHWt0O9rND5olikIZZFADYOegOfvfyrmLBYrDRB/wkDwK03765a7fYPtDuZZMdCSG4AHXA6g1Ytri5uLxLrTQWSRPL+03cTxoAVyZBESGc4I5baPlzyMglmVzIu61K0EEg8oO8qnyEVhzkgEn0AOMkj25OKtW1v8AZ5TbTs9zLvc8jjzMkHjuT9O3FYap51y9ta3EspDiW8vLnazSbOVUn1Bwdo4CjjrWxbOFURxqyyTkOpzuIXHXjo3UfjUNGl3Y1VzIxjkXyju2OgYHYmMYC88/j3qSFZmCNOF3Sy5BG0NlRwTjHHp64NUkJgmyphjmLD5sFthHb0yc989KtWkhMayTbBCV+Ta244BII56Hp/nNOxm9tC6XCxH5Gm5+TqAR2PP1qB4pLh5HlkYyHnKAnYCOn1OSPzpGM0s32jABUBAy47nHOcc46delPBSSeGPBjhZfMkOcnAPAOe9CV3Yle7qZt5K0ZA/doI1I2hMc4xk/5NYMlyIxCpmhTymxvOMZx0HHXgjmul8U3Gm2cTrFJGpzuVSwZtuOpNcFp17ExQywhZCg27zjaONoGDgEgY+hNU42ZpF3hz2NtbwhZJWjcxbjl0IOSAMj1z93Jxx9ary3lvvSQgOAN+7qBjGMjp0zz74qjPcx+W5tlkwzk7Y1LBnJ57Dn8s1QurpZ5G+zlEmGSyXDmMZA6HvnoM4xgZz3osLnSNyG8Se2eN26kska4GFGM/ie4+vNStcNFzvIbO0luvHHI6f56c1xV74hWCG3lRCGlbJt42xKFAwcgkDb1xyen41QtvEl5cbEtrO++zpKGkEFoXx7HcApPI75ORii1jNu53d1eFxukxGcAqoXHGc/Mc557dfaoWkCxM0Mp8yQZAf5l7Dt3PT2rk1vtMmumGqvcadcu3CXYe3eQHgjBwuOcccjOavLYyQTK9rLGYVBKea5l525wM5+X0yapeRhO2z0HatpEUjS3I/dOTl3AAB75PPPYcH8a5rXbeW3vtM1Fw0lsj/Z2AOXzk9RyCOD1rtRNMlxFBc2k4uJMbFlCkMCckg5IOTn6Zrm/GDzWGlvLZosVuz7y6MMxkcBvqeBx0rRPQ46sGmmjI8LaiLiOGAtOTDGYoigxkbjtPPTkYJrprKxEU/mznbFMPNIz8yyDHzL9ORj296xPAt7aW8VrPFAZXKSKEwMhdu8DJ68r+tbd6L+UGeaOGGO5lEiEDJDen4j+VFzNR6mjda/Nqt1Z2T+WNStpRPaTYylztHIHoxB5FdZZsnkNcNICZX8zJOfw/nXA+JNMPl6XvfE9uftJERwW2sMFfQ8V0vh3Vba9ub1nCRgzeakZ42hh0x2Oe1Q9tDam7y1Ou0yR5rwPvUAD5QwJI+vNacc0UuqFImCXca/vFU53KejD2PP61x4v5o5pHZOSSI0Xgt6fhXReHdPktbmC9vf+Pq8jkicL0AGGXj25H41KNZHRC+TywoPPTNVYRu1FdzZznH1oayeYF41KnrkVm3b3Fvtk6PFzj1pCS7HUaq4itlZfvdBiqnno6IJDiQjjnisjR9Rn1uHzCCgXoO/FWZHKAu64K5w3TFMlR0sLqLrbsQmTn09cdqr6NfPPGySEIVxx3B71l7nv9RO2YrEO386zryOSz1FNsuPNIAAo2NeW6OzuruJYtkS5c+nc+tc2lxLOJrdwVHTB7/Wt/ToTb2waaMk46msi441TzAcKei+uaZEUtjMW0CW8yEffB5xVfSY4rDTZR5gwpLEf0q9qzpbwzO7hSDgZ71glfKkQs+VuGyFHcUGu6OJg1K50zwtcgQ3FzqGn3XmQSGF2RHyxKsybl4CtIykL/Fyazx9ne8a20sBojCPmdxIWH8TMUJ+ZiN3YgnIqewivVN/P5cUdwjOxjdjhsxRiSBe7SMXUfgCOMmrmhR/2no+nNeQfaJpHW1Fx5IYbYwFRlOOAqKoI68MDzmtL9C6cfP+kc1eeXbatdTXCzzWYRY3dl3SRMp+UtgDcM9T1456Guxlf+xLU3BlimtZXWC2SCdZGuZcj92wQkAEhjgZI2nrgCsiCXTbiz1K61B0s32CSZYt6x3KNndgAgg4bG3/ABqtYwww2EL3d9cWWpQyeXbWcssirGrKqEpgkszAYkGN2QACAOZW5UlNLT/hir4hvLganHcXFvBDeQA3s73B3NPu+WKMRZG3aMsqEnouRkkm7DcR6boMUc+oXt7pLW43aLNILWW4DKSxyo3JAMrhWPPYrkK2XFNZ2tldXF1oM4kmCTy3SyfLHG+WUFm3Mo8vYoBP481Vs9ZgvoI0CXU12Z4UjRAoEm0qeZSdueOOTgdqm+o1TjJauz+ZPoEKzmKPU5RBK7ytOQgjaWQHaoJ74BPvyx7mrviS5stUOm6Xp0UN5Z2szyho/l83y0Y4Ur0Rdz7pOeQAv3TUnhTRxqSRJqbv9ileSWa2j+4kYcufMY8vgbsLwCQoIPSpdZgkeK3uNM09LRJZxFDBG21U+0tIqrjvjaOcepppFyuqaS2Wv9fcOOj3Omaba3K3JmmLkx3KtjOGIBcdlbGNw4G7BxwSkVyt1rgupnnNqhWKOJhuJAVifxAJCjGMDjmu319lsdDnsoGWd0jW3jXZhv3hCbSOmQG5rjGtBp5uNJvHWK2nVZluFbMkca5+ZT0yNojOcclW7mm/I0UVFK/Q68+JrSy0a+tYr4KltA063qJ5rSqQcCIYwQrAgyE4HAGTzXKeEfC9zqNhaQlf7OlRZInuFXdJNtcq4cHhsHn5skdiK5zUJHis3tmVDPerGJE2bML58exVHQLgn5R6V6BoWqJr+papZ2xMX2yVmdlIBigLF3wepLblAI9/ShPQxlSXNZmLa6Jew2k1va6c93bbBKfszBkuU3ELKsR+eJ/lOSu9T3ABBrym40tp5bq50qOPbAGMiSbW+ViRt2HngHr1BwRzg19L+LMaf4fuLi0mFtLbwlbSSMZCu+E8o+gbI+hAI6VwniTwdp994V+0adAI7/R4Rbyo4Cy7sDCMe7FmBVujbvyFqctSikmeLQTRo0UbTPDlCI3bosmcbX7YIyNw65Ukda3NI18WyIhQzI7blj3gqG/iAyD14PbOeelLq+n2+kTyRX2nGeGGRo3ktbqS2uA3PBZg6D8Uzx1rHvprQxzzW2oa1Fbu4jSO7QSqp4IVpEYHOMkfJzjgdcUjineDs0dm+rwyQG0jeSFxl0B2/LKeucN6YKkEfdKkc5rc0rxpdrGsb29uHkK+d58LOGYKFJBTbyVVep7DPevN7TWC0CxExTGNfLEgQhZBnGOgOcYPIzwfardnciSQvEfILrtfJkRZDjO0jbg+2fWh+RvSrOO+x6pDdX15P5ceshp3iOZpLFdwVSCIxljhc8kdPlyc1Ue+XUdQeJ77XL6OAM14LaUiGY7uBtjVQAGIJOeuAAOa5XTLtJriJVmFtMmCHWVZH2nPKkEBMY5HLZxjbmu10fULaONLCwuYUNr5jeQXCOUJVtwQsOTnpycDOeAaVjoVeMuhJp39mxXvnW6XtlcSHEdzPMZGYf7RdWbHTjPOfSti+iaSPfda4Z33kAP5ah2HTJj6d8devFUYNStrEM15OilwREGQmQE4JKgE564xjPHtUrTJfCILYbWcgtcTgIBj5QAv3ipyDggelRym/OlqjdsriOWImCFfIAI+WPeC2fmbPXrjr7nvV+Eo0aeUjLvUbHdMA8nlOMZ9uc5rmHu75tTltkl4gQlhbxhUBZgOSSccfzFbiNcQCSW8uDNuVWYZYFl2hgCASF6np6UmjSM7l9gzTIqRCEffI2kqo6nuehz9eO9WJbmKNVVGc78Z3/KGHXoOQM55HY81knVHdUC4MQz8j5Vs8kAMOpPvSwXcZA2yKxmyOMrtb+7gd849qk1u+poz3ayW58gwj5Rja3y4XIJznryf61n6rfXEY32MoZ33DaQf3mD1XHPTGR2qv5v228e3uPLKRDzXXCnzCemcdfX14+tX/NEjyR2KZ3AKfKOwAdSVyAV+7yM8kelFilLlOYu9K1bVrtDf2JIkcFll+RFHHL9/fb+dXXsp008g3kmACWjWLDBuvckcA9cdelbcMsc15tRjIxYOpDZBJIIU+vU5yabNKxCy+Q7SMrCGNkYYc8E49gO/15qtjOpUnUav0MaWza2uYLe3mWGIAmWR8yqg68dGJ/HrWeNIW4miuJbmU3R+b7SwyqknO0qOD3x16100Vt5UdwyopGUEZYZKrjJHHQksD+FUSFe4XzLnyzK4jcxDhJOx6crx+nvVGNmwh0+xjSVpUjuLiQqkz3CDAQHKhAPuDjG0fU+tbFrFeNaxmRYhKv3j5h+XGR9Dxx/+uq2mQxmMDyothYYdvvmT6jjr2HtWtFOrwSbiizFtj4+XzJO5647jjHbt3htjUUtChf2hnQzXEVu6hCB5yqwRtvOAQcZ55GPwrnbvwzBHcCS3ubmz3qCUWRtkX0B6D1+g78V1t6zPEu0pGzx8Ky4wR79++P6Uy1uI5fPQuT8yKdwxhfl/Q89PUe9CYOmraHNHQ7W8jidr2+WdE/dqtxtAk9cjruGQB0xisXW7B47V7PUik9i4Mazo20oCcfOPUEkAjjOK7KaJInkAgiXe20bRx14GO/8ATrWFr8csqyxv+8kLFMcYkU4yCffOBWid2cdWDSseU6XDNBcra20ihlDfOB97aDj8TXcTmW50RFe5ICAOpzk7hyDWF/oWn2MtwZGZpHKx3C/8syG449P6Gl/tGS8jE1uAtq+ElGeImPb2B/nVNaWOWL1vY6nwlEdTsn1K7YSSSKIVXoI8N0H0xXRaVp1rZ+IblJ4yZJ0V1PY44rlfDesAtdWsWxFhMYiUAAgHO7Przk5966rTL4yeIriS4bdPBbrwO4POQKTNIJ2O103TLZXWUrmQnPzfw/Sr986C/tQh+5FI3pjO0VFaSRvACMA4HPr9azBKbrXZ4l6RJGmfc5J5/KsjZp9TpLG6MacgYJxmuQ8fX5jZPsy5YnLAeldVdv8AZLTbgnA6gVz9zbpPp8lxN8zk/KueabCFr3IPARMTsj/cYA/Wuk1hPtEBjhABPJzWF4ehMLpKRtUjn0roLoB1Z4XA+Xpmmybe8c7phjTV1gfjHc8Z9as6tbJJ4gswi5Xnms8Wt28k0y/fUtg9M49ao6Xf3bamJLlsrF8pyc+5NC1LldHod5JHDFtOOOg61xup3ONQgjCgEnOcdq1b3XLJITcBWmkx8qZCgn6np9a4TxDqUmoX4W1coh6FOMjPc9f5U7EQLev3ca3Lqf3mz58LyAe2av6fpqz2STSht20hTkg9OoI71UtNPWG1SBT5rO2SevP+f5V2dukaaYA64KLnNI0crHzj4R8ZaVcX0S65FLbQzM73jSwmaMysrbnBHHHC7ccYXB4zSWfii10oamLXVHnglsWnjijRmxOGCEup28lDgyAjjk5PXmYbuTTLpXspJpYZXYxm2kRmMgY7XaMggNgDpz05p9mC+ofuriydXDRjz5MQbHHITeBwCD1yfmHFVf7xpS+G5t6jenxFfafJFqFjp9nJtjhgtYWmubiVBiNjErMV5J2Fjk4BKjIrKntrmXVbudNSu1yJEhvLwSbnAXJAjUBkVmAGeAOciujvPFI1XSktZZLTzERlZ2mZmdQNoRcAjcccEcn1FZytFp8UtrqMk01/DARCWilhO8rlUfKE78svAHOeSOtJnTGnC15yM+2sLxLePUJ7+11FVeFVsZpC7SkoMYiwNxCnbkEEYrXvdUs7ua1k1PTJrKKSWBme1VbkO6sisGccAED/AFbg/MmM4YgyeH9Kk2yQW+k6hcajPcEW901ntD7AwdNruoGVTdjGeG54qPU5pBFKt9o9yguF/wBJi2rtmAx+8xu+VhgZzwe5zg0tUWqcZRav/X9f0y1DcvpWpzWIeW7VgzWbPbSxNIQWX5VPRwSwwflJA7g1NeTyapdW6MpEMS+dFEr9NkE7JnHRsq429ifWsK21Laiq0c15YxoTCWgaQwOo3KmTyY8kqwPZ2K5ztq/pN+k99b3WlR3s91O73Yg+zOzOAF8ohsY3hNw3EEZVs9c076EJ3Xs36nfeIZo4tFS4QNJE8lpN5wH/ACyM6SZI+mcVT8f21rJdaZPp8zyxJdz2oBQ5G9S2PY5j6VT025l1bQbrw/aaZIlzBE0GdTuVgIG5hFhF3sWAAGMAZHXBqLVba7vINLnfU0lGot9qkgtrf7OkTLHkhjkuQCyqTuHWlub8yl7yvc5bUIlvGhi8iaaxMlmk9xCxbyV2I7IpPVgEf5eq84zjjp/D+m3uq2j3kUyRXTTNcSTIFSTbIA0ZJ7/KQo4HTHNZWpQW1sJbCO2MUkypbw2zv8sU8rbVU4/ulpCrd1YcnNd9daBqEGoNceHZo4kRVQ25TeJ0zyCOA7cH5shvr0qgpxSk/wCvuOW8R32pnT7XT9ZgSZTdQs0yyOQduXIbk9cfh60mq3Gn6rPYwXMy21xcOnmyxxypIkMWXYFh97LKmOCPnzwa0ta1Szl8Sad9tdBp9gZJHe0DEeayYJ8o4OclV2hieG4qoSuoTX9zqRuIdWWQnypbZlZIFwVRgFwWIOWIJySOuORXJcYSdtvX+v1JtW8CWms2kl/pd9Nezqih55nMrng8Mp6fTFeT3/h+50q8v7GeSLc0WyWHdxNHkMp/AjI9CBivZotEfUBLdaFJdrb26BbiW2nAJcgEKVBBAwRnjvj1rj/EFreXrXA8i3kjs2G5mgVfLz1RioH5kdxmjQ5qtDmu1ZnickbxNvSQBegUggDA6Z9eav2uotLGI5CVkHdCQw9M54YZJ9xz1roLiKM2QaaESQ3ECQTRS8sGTADxMfuuCCAPQkEEHFcfd2OJlKBhFIQULHPyk464pnmShKJ0NnctJayJMBIFUsqgqGTH8QJGGGD0ByCK6XTRYXVpGbpJJo12qwkUt164YnpnBH/6xXn13dz2urXex96pNIuPQbiOOxHsat6fq3kRloiY1YfwsQo9Rtz68/yp2QQqtM9OsoFsiDa3M0cC9I5BvRSBzlSAQOhIB4Dd8VqyeJJ7eAeZCkVwBvR2G6KQZ+Yp35xnnA+XqeK4PSdbsWb/AEh1Wc7ShlBaNTghi3tjGOp689K3ZpvtUPl3TyqrDdbhn3KeBuYZwcnAxntikl2OhVU0dxoNz/o/2hyfLclWV2PK4HzOGA5PXHWtVbuIy+Zbuvnp8oG7YD2APHJ6EA9+MCvJ7HXbq1BAk86DAUOTkx8DGPX5cYHTGOldRLq5Wd0mklkF4A0bOpk8zI4IPHQcijRmkaljsrucyNHamUiFmOQ6AFVA5GRyOcDHvUk12sVqUEsNvNPld23p2PQk/wAPfrXP6XerFbtJd+UkpBjZ42BTCkgDB65x9PmFZOt6lK93B5JO65cRJtOR7sQex5NRY2VQ6zQJljsImtI1kJd3aQHADYwS27kcA9M98VpyXCQuCEYgYJW3BKyHODg49OBnn2HblYroWrQ2toUu7gBsKZAm1SfvH68cj1xWnFJd3Mrh5EhtY9qSIh3STtjoDnGM9/8ACixrz33NfTon1CZrgxwrGsuIRI2cdy5C5wfTngDmtaEC286SKfa82SWlXC8ZJCKDnGcZycEmsKbUBaEQFGCBRGMKpwMEjp14/n7VTW+Vnjje2jS5yPLW4OwxkdCue3OeOOaLFX5jpUlt54JJCPtDoN0yROMo2evTn14wKd5SEyMlrDKYwpfbtAIPPK+lVdrwwR3DxK7xucGNMeYhA4I53ZGcg1ZE1uYXZGihndAVG8DPpuPAGBxz+lIrQsoHYyCZhJ5hO3c2Cw4A4H8Qx2Poc9cqn+k4tp3VUZhhnYZyMHBycZJ/i+nc1Wh1KI20MrNG5kABkUgjn24PB56d+PWmyzRKTKXUhWwGHDFieoB4HQc0Ejr23MssoilmRoSCxI3hgR0A49+QfSsqHzomt4JZmEjSOzSQKM8DAjBPTsc+5xV9rvZKghUSxyyeVnp13FSOcjp259vWvK0NrdJJHNCEBwd6grsJIIbd16nr6L7U1ETm4oct9DPFGhdQzo2fmB3Yx1x9B9CKxtdvRLZzP5pfzPLUYXg/MSD+GBjHrUmo6ek1ncSWF1LZzSYdQ3zIxblMr94fh03Z5zXH2Wo3Ml7Pa3ccont5GSd5MKYjnGMnhh33DI6YNWl0OapNNXMO0jLagIZ/+Pdn+Rc8DPJFdDe6emnw3rgLCNqh/wDnlMp5x9ar60hszbRpCzxzbmtiwwTt9T26g49CKrWseoarqLw3oNwVVSgAwkQ9dv8AWmzgV72INBuJ4PEFxfRWbJsTCwyHkqOd31/wrr/CF3/aM9xdsXW/mLALtwNvpWI+m3tzeaxbW3z3MccUinuMZGB+oz6V2nh+1huP7ISzfbCUDsR1zxkH8Qalm0LbnX6RIba2xdy7QEyfwFb+kWYi09ppCouZiZWI7Z6D8BgVz95CPtlnBNEzBmLvtOAFUZ5/HFdGJESLzIySpHT3qDWV9kQXV6RZPHIR5hyq5qukMcNgsbHfIecHuaydXvQ8bXAAUxtuIznOKuadNHOUmkmUkDBBppg4mkB5YjLJhScVoXcSSQRLF1PWsy9vo5NkUY34GcgVNbyyMdoGFGPm6CkFna5LcwLY28kkRySp49TXGWOm3lzJczPJ5KFuF46e1diyNId0zZA4AOazrLy3aeJjg5x6d6PQE9NSnpyW7Ruk6KxHGeOcd6wJZI7hrhIcDY/AUAcY6etbyWJ3P5Dbi2c+3NZAs4dNd2Ybbic4xngUylZamz4csxFaK0uXm68npXStAQQzkhQDlQOMH1pNDtEt7MEqN5Gf/r0+cm4XrgqSVJzgHBGffrQZN3Z8g6jbRS22LcTzog84SwW+EJwCUkA+VcdQ44I57irek3s7NbqFZpCzSAFsowIAZwvYkYBOccLxkVt3FjLYLNLpEsttbJh8ISWt8Hkd98XJxxuXpnbkVzEunXJEkUQh2sj3SxRO5EiAEukZHbGQRxwcZpvTY63GUd90dtozazLGy6RpkdrBc3SzwvJdrIqfKB8gPBI2bucgbwcc1v6rbk2pjvbecx8yJatuuI2kOd07ynmRzyckAAnhehrBsLJ55LAR29vMVVn8xWZh2wSAeMrngdQQa7CfV7m68I3Vs09nYSWySJ5MVm7yElfukkhQcEc4OQc9KrpY6IPVSWpy/h9XtUijCNdadgSPbSIR5BYbiYnByuCOM5HOflqxqk8k07QzSwCUxfKuoKYroJu4AdMqxOeWwPu4JrW1vSb6OCIvqkkTLCxKGyjCmKLG4kge2Ccjk471matLPNfDVNTutMNlJFu84WT4iQrwjxiQYIJ5xn5ic9qWyLt76a2Ryeq6X5/lwxQLIsX76cbth8nIVv3ijOC23GQcHJGOQc3TNUfTtel1HcrQTSmMuQVRZ1JXJxwu8OzYzg5J712OpaPqssEzT22nW2oXjFjDbRsXSMRkEL+8PyqOfTc3euG1SBrSS9gaVJZiohlj8ndFGq7fKMhyQD1Hr8vTnNTsRVbb9ps16fp+J6rrJ0e8sItRvr+xs5I1YQXkJMpI4+VkH30PAx1Bxgg4rndJ1v8Asa/uzqtrKmI9ggwwa2hLEsFYr8p3sSUkHAZAWO3NYOgafHJp8s8V5a2t4WNo9q4YDC4ICsgO8EhThxwQOnStyaa5026tAdCj025DY+0W00qxPhRvQISo3H5TjcOcYz0qvMIuc3dr9SnrN9FrV1pFslwkFos7Xf2iR1dodo8uMcdFyd2AxBxk120U9zdCC11zxBqkWGVDcyQwrbXCj7pQ+VxIeBl/lH3tzHg8xc6dm9hvvDukzxSvhppLm4jC3RJLMxG8jcR+hxjFaFw01xIkMmgxQNIiXFpIZo1VIj824SEsu0jr19NvWgHFXtJWffy+46ibwtDBq2lTO11NLHMY0O7dkMjcDGFVfUqo5+tQNoUY1KGKG6mVr0B4VklbAcDayrjBGVCkc9jXO3Nvr1npjE2MkUEQDJFp986ICDuyIgvzEjI6Ec56Gtvfb3dlEF123uftSrNFAL2Iuw7MpEIZW46EAgjpSRsqiivLoUPD1vfHSZY7aaY3xuJbaKQyA+SpmfbISV3FRh/l3YJB45NPv7c6ZFLaWmowiJRtjka2LspPLJJJGxy56kkc5PANUrVrxLl4riXUry3jmminhW3SPakkjMpeXcpY/vA2CnRskDNWpdUhmDW1+sukBSTLHNJNIFAH3lVdqHGDznFCfQwiov3mrfejj5dEWSBhbnToZjl5I7m4AjfnkhWVcHGD35rhb2zS3upo5bVYnM37sLMRjnkrnrkjpmvcptM0PUrXzrGC+1VIndJXgCQQbs42+YuwZxjglv61xF1GNJubma0toI7aeF7XZvWVlIwwLep6jO7nnmrRw1431R5Pq1lHcXt1NbhiPMLuqIfkySe/Pr9KwpSoYg/I3cqOvv8AX3r2TxFdRXP2bzzcOFzH5u3YSmc7SAcHDAHBz061wmq2KqjyTRxTty3mRryuehZeh96DjqUmjPWaLULZpG2Wt/Hzv5W3mGBjGB+7fOT12HPRcc2LLUp7aQWmpStHEG3PFI/zIevA55P9aw7vfdLGedkUeGcAkZyeSB93rjoOgqH7UxjWG4HmImNrA5dF9AfT2P6VRgm0dxqN/HeItyDE3XcZPkD4PBHJwe+CPXFS2moTNZAQupJDbN0oICj5mXAHA7iuROnpuf7HfLKg6iSIq6Dn7yjJ4HUruHvUdlqj2bsm7fFnICs20N2YDik13LVTsek2erTb5I5omMdwQWUSLtxjqAQM5A9fftT2vPtetWEF0rxWeWdfMkGRtX5W3enIGPf0rg7TUiflzmMk7TnAXPPbpznir93qgE1ncJNGhQ4LDkoCCOh7ZPIx0pWNHU0PW5tUs7SGeK0YKzJkIwY5GMYDZORuA65PNXTdSWFqyz3aPOwCyyNwhA44wcYx3JFee6DfzjWdmoaeXUQtJHGGYpgcF1zk4GR7gV0sUsssU87eW1rG+wW6OHkL44IA6+wOT3oaN4Vi05nmkjt7aRYnYGWRolLpGhP3iSeBk4HB5NdR4dtzawzuBJq1mwBlMuwfMMYGOOAcYIGMn2zXn2ifPql+Y/Ktp0iRQVJLmRiSC6g4YY2jGCOa62y1FrbS4Dp72zTlTGyeYELEkFlIJyDy3Y/qKLGsajlc7O/8q1jjktWNu4bLNK4bcp4Csuc7c9yQR2xXB+IPGOnQxoovkC7jHJNCAd/XoBnIwMg4781lQ+GYfGOpPcXR/s6ON/3ixSEAjPIwTgcDjA9SemK6Zfhp4bghna3tC7OG8tZXYsuATuHAwMevXHvRyMTxHL1PMYvG0UFzciS4lijnYPujDSKv95cHoTjOQOp9hXUfD/xW96ZhmRbNZHEdxduZWbCj5fwBB69OecGsXxP4FN1bebo9pb2yWsxtVAZiblhgu5JJHHYD39qz5/CmteHEW4hjM9pKv2hwELRMEO0Mw6HBJGfcijl5dWjONepJ2uesW97bvdwGI/JGDNLJ2bJ2htu71YdOQPpVXXL2VdMaTzF3zKAPMI2lQeSQCT17nGcd68/0fxR5cYMhlu9UbiOJIwix8ngH0wRyemOK0LmaWS0W2u54pplZZJvs+dqr12k+pJwAKej2LdZrc6qxuJLiIxpNLLettiJJRkgDdBx1bHPy9hxWXdXrzayrxQLM1uQ8pU5K46hWPQ59eh96v6FaRQ2zyMrnZlZPKjG2Fep+YDG5vXnA/KrfhmwnmvFjjiO+ONpJ5GG1Y/M+RQcdeASR9e5qktTOdS6Kt7B/b2rWEXmlSpLvG5+ZV4PX3HX6V3GmQ2trp09/BH5szys7J1IjPCj6AAH8a4STT47LUp44IoUt5QYvlOWj3H5jx0GFAzWlq8cc9obi8uWsrEKQsPIecY6yY/Rfz9Kh2MNebQraX5a+JNbniaR5p7CSKBklACy7hjPqApNbXhZpdP1O4YKXClFlVRzEcY349Oefrn1rgvA1vFL9tkvGdzJLGEKgpsC5yOPYiu88OWEV5qF0ixTF5RsllSQqIwc9T3OO3bNI2iej6PdG4uryWWPKJi3jbGQ2OWIPpk1engid1AcqMcjNVN0Gl2McMK+ZBEgRB3UD19afGI57QSOMKxyCDjioNUmjP1WK3SBslcZ7mm6WkJj2CMnvwe/SjVIreRFA3+WMZNR2NnKAXtm2LjoeM1KNN1qXIo/MvgsQxGvJ9TW0yuzIiDAHLE1R0S3a2DyTsGyeSK0fNS7kxG4AU84HWmkRKWo9wuWHXFYN9Fstp5o+HAx9frXRyyW8UDDdubHp1rJYB7N1I6n0oFFkXhwr9mHmkb65/wARQyXviS0RPlVSScV0dskdtCgJGT0PpWVZRSp4rkklkUptyuT0FA1o2zqVka3tcckbadbY+yqzHk5JzVe/leQrFGAGzzj0qO8ux5OxkaIKp5xx9aZmeN6zp1xaK8iMzmLcwO3DAD09cg5I9c15/qULi288xvbXgdpWkB+XJI2gr0x83PThiO1d1Hrkt7cJaXEto7u3myTMGQSc5VuScE9CBxkVn+JboC7SaJ9NZ5ojFIkM29XBBIJ+XrkdKuSPTi7r31/XUyfB+q3+mXWovHb288nCT26uhG5flYgsT0A4YZGOoI5HR6pq63trJd6bBPHKI2hZHQ/vOCFQlSSGHO1uhBI+6eOOsSpv7eW1VlnuW2rDDH/rGJz5YZs4Z+qsBw3GMGtCe3t3DXi+ckaLvM8qsZCu7DJIB/qyCTxxzSu7F0oWuv6+R0d3rum3pFzJPMIUTPky2syoj7txZwFOSPkIGcZI61Pc64+nxXGpJpV8LCOMH/iZOIIpiBzJuk5L7gpQKpI69enn1vPNaviO8n0+SPJhiR3kZhu3KoH8WCSAQMr1yMV0wtw5kvmuNO0/U7baUtpb03FwysOJVbJEmSCMoflPBGeaLhGTl7kmtWRNeyFLx5NSWSVvuW1rKY9qNyqF/vlBmQkIIwTk85FUdWXTYvDy6Vpn2u7iRX/5YMiszHnKgDJ4zznoPQVY0vTrjVZpZA7SQeXhS0pRU2ry5yMgdXxycH3rUuIBb2sE0dysF20bsFhuGabdgKm9ByDtKngc81OrRtGlBW5mcr4bhluID9iutl/InlvbSgMtywPGCxG1sE+pyPRjt6XTNJt715LQyzQ3O4RNDIAgLnjY3OF7cnj0JqqNKtXt7qbRZLq5MLIgjW3kb5fLVQysE4KgL1AJxz6nYivtP1KGJ3uIrWRFVFkEMjBWJJ8sswJXP907lweBmqSFRqOEVH+k/wDIqPbT6Mnn2l7cPpoJARwHa3H3SxOCWXp1+YZ4zya6Cze4bR7O61kre6fc4nivMtIFz3JGQFByOwGfY1Wsr+3Ry0E0U8cTGOSCKQM7Nz84GQSOSMLjjGepFN0myAvbiHQNTl0zVGQssUSFrS4PyiRXhboRk5YbWwwJzmpNJN2Tj8u68jbXRhehpbO+ZSrs0D+WqyKeg8p9u3GDzkEEZHpWRqsNl4bjeO+sFms2LvE/lqGQtg+USB84Lng4OAecAcSSrqmnQMt/pggSEEs9sgvLNh3KKMSxHnkFW9c1BZapYavHFOb5biyRGUC5lRPKPV3UDAQ8deWxwSc4oMbpu8dPwMqDT7y18yGxklYXMMZme1mZYmlJ2/wko/3lXHHCr71sXkGpotzDe266hcBiBFqacgAj54imCpzjJGT78Gsryk06B0SGeKKT94kmZIWQBScMFwG+UFlJAYHnnFbGooBpwu7i6vNUISS4ImviqBQMfKFwMZxgHk/XihIUppStbT5/15nIapeqNZCa1Hc2qzlYZZYHBnA2ZzvXHmD7vDg8Y9KytT1PTjYCznCrIhUwXaoA7gH5g8QJ2uAcgD5WAyACCK6dNCsUW0guUtxBJHM0klvCAgypZvnfOQqjgkDp61xPi17SOO0SwWaC5kjjmeEr5bbgCUYnCkZOCMAHBGOuatXRxYhqKdv+HJ7ib7UsH2qGK2YSkIW2JLcDpuWN2Ugltoxz9446Guf1yK2JgS71I3DEn9xbwOUXB6M7BFbGcZGR168Vpxyx/abiW5s7eGWW3aFFVEaOENwVy5yrHBG49M8dcmPTLae/NwktmsjxsYFdWWMYGcZB6dOtP0OJ80viehzL6XZ3rF7W2nM4XcYIbhVeTuWUbD9dvPfFZd28cUSW62sTfNv33LlzjrwQBjpzXodtpLXDWeyE22owsrq0UmDJ1KMrDlSDjkHt2rC16xikfyjE8WoRkR3BGWSc5+8QclZM8sM7W6jaeC+hhKGpxM1wLibMr+XHngoBgfgMf40+6jYJHPKn2m1ckLKp2uSOoJ9R7irdzpLQ3DoWADDCHHBPaqkBNjcN51tFcIQVeKTODkEZBB4I6g0XM+VoqKqiVTby4PYSfL+vQ06Z5oXKuCPr/jTrqHy8OrebCcYkxgj2b3qDayk7fujn2pE7GvbtPLbx3FrdeZNC53WwZhIgx95exU5/hOR3GOa7nw94lT+x7JFQ2rIfJeWOJHIAPLbup5I6/rXmHmtvDEDcpBDKNpB+oq9b6xdRXHnsRLKTkvJ95vUMw+8D0Oc0xqVj1O4S1U6ZNbX97Cl072st7NLlCXbK56EJkfMSeMg9OB0IuLh0Sz1K0+zlIhHvhlBRVAA65JyQAB2NcLqviSHyTEkUcmnyRC4s45lLEK3BG7Iy6sGQnGMqSOoq/oP2CWOO3h1OOexIEirKwtpVz1STHzOOOinHOR3Bpo3pVLHqGgyWNxCbbTrCE2yOuZVXIZ/Uk5LHAIxn16V0et+IbHS7eXd5k1wVJWJYyzHAxz6YOOTgD3zXm8F1a3TQQ6StzZK/35TFI6wjByGXO3vgY56Z99W+ttrpb6daXs0blZrk3Ug8yUcbY92BgN1x2XPc0bnQ+XqdZ4WtTNYrazTJOLSEyzToMCaaQklh+O4/l0q/e2SXmm3dgCDEFE8a4+YM2RlRnlNyjPuQas6f59tGVuLtJ7iVgzNFlCzvhs4PVR0GcdO1Zt9qFvby/ugY7NI5TI7AFVyMYyOCMjOQeCuKGx8keXQ5tfCela3NHJqVvm5mbYZYm8txtVgSNvGM7evXHauJ1jwz/wAIxftcQR3d7aCXak24yPCDnAEY6sMY39OfU16dDrVvZ+GX1JURpZoxGmxcs3PJyefvEc/XFNvHnOjzXEsUZuV8qUiOQNtTcMEnJLMT2HTFCSbIqKyuedT+L7VJlshHeWKxxlVE9uVZz0ZQpHX3POa6HSYp0ilu9WivLO0uQZI7SKZUeQDAXzH5OeGyAM1sa/qUMu25vGlvbVWUqLtAyl1YHAwMg8kH2YivO/F/iOz+1eTo6QW9zLuJWIExxA8YIbILdTkdzQ3bcmySXQ6fT9ZknOotZQiMMVj3vlcICTtQHknkDPoPxrK1y/nkiKXcDm7GERCM4z6e+KxtAnuo0ADmWSE/KHP3v8aL7UrmTXhPdFZbhVOxEP3W55NQ3chK/vFzwtqAtrQq7ZnG4RnP8TNyf0/SvWfBaix0+CEuHdyXcluWY+teLaTJGJkfymKoP4QcBu9eufD25F5MytA6QwAYkJzuJ/mOlTuarQ7iC3lnBGRs9jnFbNrHFHYOGxu6lagaNYYVMWAT68VLAoMm1+c5NQat3RBawrKreZGu0njjvVp7cJbbl+VfTGKbG/ly+WeAWwCavaht+zpHH3xTtpqS20zDFjdXK/un2p3A/lV7SbfyZHEiE/Xt7VtwQCO3TA5Aqrb4a+cYGKVhc90xzxRtgrEMk96oA7rlomjAXtW1NHhCSeay5oD/AKwMQc4zTFGVzKvEdGeLaBgZU1yrTyicSE/vSSnPc5rptZDTMnlsd47+1c/4jjMFrbM0eHDA7v8Aaz3pWNotW1Oj0K7LW7GUjzPU+lWtRu1ksthHytyTWLaDzbVY4zhs/ex1+v0ov7fyhEst1znnPHHU59KaM3ueNaBrSJc+aIzPcu2bm2VQZJFxzjsGGM56HGeh4v3GoabcabNLaQlQtpOYmKtCZWCtt2E85DDsc1yz6IQzGylCXCqC0cgAEwbAX/gYO4dfTB5xVe8ia0s7ma5toU3odxgiEiqQQCxAOUPzZyQAckelaX01O1Ll0ubtrJY3ubOa9sURIwIxcFIxJEqLtyeBvAxu4GWUsDzTWS3utRnNxql7c2SES3P2aZT5Uz5AlGW3FBtQsA3v60Jax2I2/brEpLEk9u6bSAoORgjlWByM+jehqtYQx6lay3pmhuAZ3mmQRMzqWOFViB8oYKACTjP40ndGsVGaUebbY1r/AEyw0vUd+gGS0vIUYwu5O8urBWSbnJVww568A9uY7+UXmmr5QizI6bo3H+lQP/FsZevPy8dd2MdcVraOf+1tKsriKS3i3SJGZ3NwyIw5UBCMbSo/iIOVODmmXFu3/CRXC6hcXE9m7RG4lt1DKZAoEJKr8/V2QjAwXQ88ZW5UanJ7tuuvY3NMniMqQa5LMdCDeXPcWqbQpLZ8ufaBvzgBtnygDkdSOg1C6vNPY2oM0MEPyQmOAEheRtO04GAOAewrn44bS7tikcetqyNhIvsEhA54T7oU5GTzgda0Yry+sYBvsWtNx8pLy6m4C7sFRGm5j97oSCPXtS9TeMEnzR97y6lHw7fG31nVSuo29rJ5ENy8sjcZDPHtA7EjHU9qbc6c895JFpW57HUSFlubyN0jmJGSoThmOehG0E4wcipIJf8AiroftySapN9jlhguMJhTuBTYh27BhZO5Ykdea1LkWN556XFleG2Dvufyn2MRxkbOoGDn6fU0ty4vVp6fK/mZNobueKD+05729WAE20rDhzgHOFAR+AQc5JzkjPBz9U0fSY5ZIL/T2sSY91vIFZmUqflbY57lWBwB1x066N75uiXwt7HT5mkb99axXcJwq55kTfxzgcYIPfoTXP3Uc2x42kMZkdso/wAxV8qTGkgBHm/MMoFAXIOT0LaM3yRbTXuvyf4P/g/fudLFq8cqi3066uI7qNlBjtLl3hJOCH2SiQKhGMfxdQAMGrGp6FJqHkTX3i3Rmu2ZBGyQCHGPl3kxyDeRn+IHqe1cAkTadeG9infTryMnykmYzKxJJddxzk8AbgDzjnFbSateIge3vrLyAS2GZbeRAR/EgGdwzyFU+2aVzF003Z/1+Wpp6tc6haRvZG90PUJlD7fs5ntm3Y/1jAN5ZHy9cDOMY9eYtgjmOTUJ7uwgkXz7iTzc7ZMdCDL0yN+ApY8YHNaN9eaqtkdQaKNzIqKqG5hBJ/gBQgNkEjHA4asHTLjUtNtpLhbYm+imURTsU3wzKwK+Vk99o5I6cZxTv3JlBL4Gvx/yIdWkT7KkcdlqU+wmSO4vrl4VwyklUV2xtbB24UE5xzxmvpa3FxqltALi1kt7RZZoFh2IhkcrukXIIdsswB6gLxgAVc1i61XWr+P+1jO01zdOtxEWUY8sbnQnJPAWIDOMY4qotnPqWpNMykmJI1cxHkMOd3oMDHXNHMc3snKfNf8Arcm1nRb63jeSYuTGpkyk8L5iON+Qrdvp2rX0WyvI9SuiltexXjxNIkaxq6SruB2gAZU8Eh+RkbSMHIguUheLLxeUZt2TLM+ct/ER6DP5dq0dP8NPrOjLdxyRiWL/AFgiRRsZccD8e3vnvVrR3RlKLfuysivNHctMJ20+aCWIGMxyWzw7huyAQchWHpisZcX10rKsjTTy7XhnAXc+Plw2MdiMfTinW6rsDyF0vBwkyjjCsQdwPUAflVy6ge20+Qt9yTDEkeZDPgg/Kx5Q8fjTuYuD6mFruiXUClGgMgySsWCWBxk+59x1rFn0CTCuoAEi7kOdwb1GfUf55FddJNaBo5rSGQL91C0e0xjn5T0LZ4wx6dOeMWNU0qPR5S+oSXNhaSr5scqRs8M745V0BO3OPvLyOMihq5FrbnmlxpktswwjIxOGVuhH8iKoXNnEJFVMQuc5QtlSR3B7fQ/nXoV7a3NxFFdXoe005/mha7XaJOfuLIBtY+5A+lc1fwxSXPkWUO+OV1QHrtY8Y3d6m1iZRUldHIywPEf3i7T6GmiJ9wxgrnrXQ3OlyQQZUlFB2vHnkEccg1kzRLC4MkZ2g87OMj8cihMxnTcSI3DtYLE7sGt3LxA9g2Nw/MA49zWv4S1eLTr8yy+YowMFVEnlHOS21vvDjkZB7g8VSnt7eWN5rNskL88LHDDI7D0+maoFCXCxkAoOmcGqM9j3rw/4g/tXTdiXdrFBKuwzeYEkibuCf4xxkdM9sHIqW8vF0+4QaXLqN99nczXFy91vaNugbYzAbz0KjB254PBrwzzNR0sR+Z59us6eYqkkLIpOM8diR29Pauw07xxp+nafElhpQtrraBK+fMVzgAnOQff+eaq/c1VTQ7pdeu9VvBNeQXMKBW+yW6SjEvPzO43AEZB4AI7H1rX06OLXryaTW9Rlvoo4z5FkgAQOMH5gP4QC34jpXlQ8ds/nRyJBcWLuGW1uoN5B77XH3c5PrjNQ3Hi97iP7PHFHZW8RLtbQbwje7tnLdhjpS0Roqzatex6f4jkuCvlaS0W3S4Fu7qN5siTJAjjU4PzgNuYeg554p+neI5dQuV0uS2MUnmBbl3JQInUqO5JAwCOOc5ryeXxky6abSxtnj84lp5ZJctI3r7DrVS+8W6neqM/Z4JAc+bChDgegJJx+FO4nWvoz0jxX4nj0nUpLK3lW4kRd48uTIjPUB2yfm7Z74GcGuQtZY7mZrmVV+0SsWOONuen+NcjbAzXZebMjsxZmbkknqSfWuns5YIEZJbdHZ2DLKCyunsADgg+4zx1qG7sXNKSNaKB7SIyRu6yHJPoB7VtWOhJc28bb5EuZgM88k+lULJQ/FwHZAQzEc7VHbHua6/wdqFn9uklvJUWJBlVc7Sx/Gkio6q7Niw0C202xuIULvGpDOvcnHTNdd4EUraqABuZi/AxgGmwWQullJKuJzvdVPRcdDWn4cCDVMj5FI6E0nvY3jtc3NXMnlIicEds9Kt6VN5rMX5ZOuagvTuuy0WSPaqOlyvHqIt1wxlJJ9gKz6mtrxNqd/MhZowd6dPel069+0WpaUESIcGtCG0C4UDjH65rK1aFreYPBjBPIpshWehtxXYeAbvwz60sK7ELEYLc1kpLHc7UQ7dvp/WrbtcRx5Ygx9u9BPLYma6ebciA8HH1qnqd2YbEhQS28A+1WLWQGJig2n0xWRHcpcalPFOh+X7vofSncaSNGKDfFGzDLMASfWuL8S3KxXSRsS9vFJ85B6dMV1Mt3JDkSkKinAx6VzGqCK5t54AmPMOSO9MFroai2cctks1jcDLYIweg9KxtXx9nlnvZc+WpAUZNa2gab5GnqYHIKKRg9sVgpYT3s1490shRSDH/dbr09Txz+FA4pPc4fXIkvLTzo7VlfyWjDRAE5xlWXHPBVT07Ed6ybxkuvIuLmeWGyuIYy9ykJLkSJkrt6ZAJYAkbghAIOK3RcfYbYQb+IYxEYsZaIo24FCOcYPT249KzPDF3bvp1havJEFjnaPzi3yRlJZCiyL3jZjFhj905B4IrRrU6eZxV2Uit5YXGY7xLKTYtwskDF4psDJKqeqk7WwMfxfQaEl7FFo+nXkmnSQXIjEGJXU27huq+b/A2eQGxgjIzk5XxhFb6bD9kRxbafdjzLZ7g7m0y5BJK57IzZDDoM7vXNvRr5dO1K8tpdLMc8axmWyMJuLdgVwzBxztY5OfwNJdiuZNprT9TntVk1q4S0l0+x+zmO4ja3eVxJcJKpIC7RnaSMjDZBwDg4BrWmsYo/CrNYwNcw32JnnLl5ZC2CHB4O4ksSD1K47DFi3gsIbiNrT7LazqQzFCeVbplc7QATghcHmrU8D6bfxpbyxWkeoAtFtG6KK4OS0ThuVSQbnUHJDK+ByKXKbuUW1zf12J9NlsdQ0iwvDeLGcyR3MD3B+STK5ypO7qewxhsmup0vUtJubX7NcaWY50jJzHCY9/A53cEkYzn2561xVokTeJori1ubazupoGt5IUPmRG4iIGGUYzHIgJDDkFCK1LW7tbiR1vtIaKdITKRbEMmQufNH8WMDJGDxn6Ukjde8nzN6f1/TMvWLe0j1TWpRtt2tUiFplXTMq5lKlumCXUE571swWwn05L+C8ENqAHAmuZGBXAZxhechck8+prC0xoL+yEsjbJ7l/tUrRggjzZkG3G7n5XVeR0FTTSC3tToUMMZvxqRRYIgQ80LKJSH7BFyIyeCOcZ6FpJFus4JNO7HLai9vryC3UC+uDFHDsYYs7ZVDM7Hu5aTGOPnB6hTVGXTYLOe4tbbzp1tQvlBFIJuOCS5zysat94YYtIOuDT9P1N4rfUtRvJ7ZdQM0t7czyQhTIqMVXyt3ZVA425HXqc1d01ZLLQ082JBqdwVnnkvFbf5rks3lp97q3JbaDtHOMUtHqNXfuy1v03f/AAChqi3Nrftc6vqc2rQSo0zTKI2kHGD5ilWCj5vvdO2B1rndtxC0dtZvDtkTcsqvvEik/wCrLL1AyT688Guyt9HWRR5OrTR3GMsQ23zSMnkR4649T2HtXM6x4dVYdSu0uEjvYZ9z2kcYCldufMjbOAQNxx0JU9DzSd+hnUg4rW2nyKG+WMyvJJBHFC2fKljEiSdt6HHzDI4zg/LzVa2Mr3KymRZYEHneb5ROxuAQTnt8mT68diauppsstq9zZrtNq4he4tXXzIXbgxGEkM33cZG5cAkH0dDqo03XUK4tJoGMp+x5geIEYcjPTAGcEEgg8HNI55VNLmXqF0sHijdezQt9nj/fNHGTiTylDkfMQRkhCVyDtB6Crfhm5eH7QJzJBNqfL/J/EzcoeCfugdMd/Ss+RLa58T2IWVBayRFYoriPeqkMFRWxsOPutn5cdcYGK3LyTVNLSLTZ1hlniH2+KfLRuREGLAq4PzJxnnDD15pre5yqejU+/wCLNbVfKvXaZIcvtU3A/wBZubBGRwMAnBxirdnIi2CW2n2ssTSACeTftVx2b2Pv3FJczXNxbfak0K4hZXKgQ3cThXU4PzFhwDkY5xjmqt34htILF2l0zUbO8ZPL+TyzFMp6ghZMgkdxWjQnUjy2sY89jPa6bb3JiDyrLl1LYwN3IIx05qvdT3Nnp8sEbN9kuRvWFjnAPDL+BzV3U/EFtBZyQx2+oQziHyRDNaspRhjac8/KRx+ArnJb6I3OyORi0MbtiZGQ5C5kGCOuAx5pehjKa3Z0ts1jc6NHYTtHI7qGglJG5UA5DZPBBwAe/wCFVLWTFxpkzztJBMz77Eys0OxOFbn+Mtkg9sDFVrT+z47dJhqNnI5j3SLC6sQMcYGcnAPNOs9OE0caxhUZSVVVyMoQCD/31u59qLtGigpbu5s+ILy0vBLb20cSwmUSF7hd0gY/xliOcdM1lXWn2vlHKO833h5fJEinOfoCAfyrRjtprSCVvMFyCvzK3zKfb2NV7UzaNqY+0wNCl0gwoIID9lznpii/U1cFHTozEuLO41a41fWLwRCVruWe5iJCmPe/LKO6hmwQORkHp0xL/Q4BaiS4ikSGYlFCYLKQOOP1P1rttVeGS/vDKiSRXKLdx7l+XzFAV+cA9QpwPXvVDQ9LfVtQhlu5XtxKxS1kkfbub0Pvxx69OtPRnLKFlboecTaEY8F/uLyWHpWZcwlLlJLiEyJIu8fMVJ7fe9j65r1HxRpbwXQt1G6CIZ+9vLMAAWPA4znAHT361xt/bB22K7MkSkgY4XJ5HtzU7GM6V0cuLeGQJ5brE+1iwcnt/U+3H0pskMcIHmTBlb0RuPx6U+4j+dsqVpWaS0ePyJW+6GPHQntg9aaZyuNiCG4WCZJYkLMnQsfbr/Wm52W+P4pDk884HT8z/KtRLi1urbyL6yhjkjDObqDckh6cMmdhA9gp96zp49r/AD8hwCrJ0Ye3+FNkjEB3oM8+lADsoYhjj0FPSPDfKVPBzzz0prIVj5ypFAGpo+marfySf2bp15cmNfMk8qItsX1PoK0LdmJC7TvBwc9jWHaz3GCqTzorDDhZGGR74re0iJmMcUEZdnYIqqMliTgYpSt0NaV7m3ppdsoztvPXPf0rpNNtGN1FHLHJJI5wsezggc5yag0HRriHUpIriMrNCfmVh936/nXqWkeHWubyGS6zmJN+1SflJ6D8qm3c6I2eiLWh+HWXTzPa2tr8/wA0isgZ1H+zj0o0LR7K11uW5RXknQA+cxPHqAM4Fb1rbSaNE0sLOY+jK3UCqGoo8enzX8OPMuCFwOnJzuov1NFG2h3GkES2j3GRhlyBWbpEZXULmV+GYgIfaofNlsraGCAgu4G5eyrjnNQapqsUZj8klPKHUdDU2K5uh1Ul0VjUuSDnGB1NSQxC7kHnLlRzg81zui6vDfocxnevAB9fWtq3v/Ll2nIfHFANWV0Utos9XZo1zE3BHp9a6XckkO5SuT2JrL8l5JUfHLVNewyRoWTgAUkKXvMmvo1ht96KFbGcelYV5dJb7ZGAJJyeOlMNxPdSKGkMaqck4qtf2cck27ezJjA5/rQVGPRlHVbyPz/OmZo424C/1rJS4ZdWjuYwZojHtbA4zmti4jVY8SrwvCqwrjdTv5tMvA8IXJbGw9MZ71SYpRaWh28OrNFpcrIoPm8Lntk960bYGKxXzSFZuQo7mvNtX1NWubZ7YtHHkSYPQn39Oa7Twxf/ANoKZpT5vl4Cfp1/GnYR5Ppuux25xeppkcvyPazRSMwd1bowOSMq55IOdoFYNtb3VwjX8MdraKxnX52yJw8rsQeMMQCF7cYqe++xIZpNPZmmjywVUZYzjoWY4x245rZ0PTra1EdtNb3OI7aF1MkbNG6umQeCSA+C2fftiq30Z1xXLJMw7k3c1o9rd3BNkEC5AjbAz0lG7JUDo2cgcE4qM29xY3scT20izxRLIbj7Q9zBJAD8u4x5dVwQMpgEY4yM12EegQXXyx3zRHJKuo3DGPQcj61gPozWepwwSvc28UkjK8Krx8wALDGMArk4UjJXpUu+5vKnFrR/15Ezatb3mneTZOby+XKR2TuLktuJX5WKEsuSh6A4yCAeaTT9ZhTT/sV9aXM6z/LPE5O6Vt2C2ThkcMoIzgrgEHGKwdYtWt75U1KSO6ghJEVxGvmJK38Tj+JcDC5453DqKfLfBZpoLOWVre9xI8H23cFkABxvkI4wBw2RwKOYlQstXdf10Lep+IbyCSN0uZ53hmF1azvatHOrBsHzPkwwbBUspweSV611N3rthrthDY21xYFdQYR5ZgHtoyAZS+4cMASmD/EwI6VzEPii5NtHstd7x/K85Qb0Vhj5miwCMg4yc89TWPaxodT8+5jmvnnYi7FiDbkDaSGjZsFmIBJBJ35PAIFFxudtY/PT+n+Z3evSr5TWlvEZbiFWCqjCRBs+YZJyVQY6DqRgCsm1nePxXI1lcmd7mHyGnkUpvbHmfKCCUUKRhRycd+tZqWkVrAlxp98QseGEDW8ZmA2liSq52EBedzBs54GM1T+2TafDpwH9ly3cu/Y00Z2gsrgs+84JDEYyMZHPANJlqvF++7/1/Xc6dIP7UsbXTcnfdag0bNvG5ow7SyYdumFjAxx94euD1mmXjT3Ekcboboj94LgqCQw6hSRnJzxnhhj0rlvDOg6rbLFJZ3mnwpBbtaxR3Ebu8iMQZJMNgqzlR17dhnjSudjyvJd3t/eXqBo3TeILc4AzEfLIZ8gAY3HBAyO1NG8G0n7pvarqMFkUtbtoLu+wMW8EYmmUdckDO38SB71yHi7fqetQK6C1tZWjjNp9p8xgjOq4kcZC5AY7OffIrZuNWitbS3S3u9M0/wCY/u7GxUBRtyHIBOTjpnnJ9q5++N3cG8vIlVY7WJJUV0ZFVIx5xZsE/M/PHf2FJhUTcfeEt/sUjWk1/NO9y1qIYXs59rAnbnaewGWyrfJ8x4FZfji1vYrBPtxtZo/LPlfZGjCrg5LbVOHPABK4HP3RmtH7WIbDRZvKX5LQSuzfPNcMojGwLngAggDAHXrgmq/ii3QaXe3ccUSXM4CqFk+VVcjEfqfr3oe1jmlZpuxxM0zSSyiafzwFMqGXCOxUksrBupOG4zz0710DeJF8oQTSRzLbQXCW7TqWcF8bUJPRh8wDcEgnOeQVsbCayuNQtjMAtlNHNI8inYqKqswK5+bl8Y9/Tms24BttOnnndVgvVFzGUclo0EhIyOi5I3AdQHFJaHLU7f1p/X5HX+HPErzaTZ6arW0MMES2shdSdzAbmYHpk53df4qrTT2V5ZvqLQbU+aNS+5IkkDsqqvHXapOOT1rC0e8tlih3wvcQvbqtzApK7ynGVzjLAbWX1Bx1PGiZLVWubRZJL2zEqy2tyPljAlQMQUzhSSD8wxk9cHitUzLm2iinqUsV6JoJblrqaNo0tmiU7clwM+oGAcVnXMrOkbIYxNJcE/ImxWGF3LgejcY6c+9T3dkoIZ91vJJcwxQ4fJAG4yMO+BlOvc1X1VZI7aQo4kgE7tAyLtdVwFLfQgfmRmpbEo+8aGmmG9heyuo4I7RGLwLJEpMmPvojEZAU54z3/Gtbw3p0F7Iv2a8lgkeFxGT86PIhBwVPqpPTGMZ7VQWF7nTFkSACOFlb93x/DgEfVf8APFGmXraRfPFHC90gkint5Eb5irfIVI9SCV9jRfubKLidxZWaTQRGRPKIXZMxG1S4b7uDzkdfcVneJNMa5haaKX90DtR24Vm9h1xVNNZthrcbWNvePC6O/luOdw4yQemBx+FSXUl48yST2rRISTD84Ib1FDaOiKund3OfW3d54rq48w6fFKImdznbuGGBP90HHPqOa7PTbS1n0c6fJarPFyoOcjAbII9PrWHrBnsdBvpYJYXa7CxSWZUkuxONyejY69jik0LUb7T9KUm3lnsEG0ugyYvXpyR7HkURaRDjZtMgvLaSLWX0+5nlMhX/AER5PmLoCcqx/vL+o5rA1zSHSQTuFMR+XfypOOf5V1kpgvZom85HhY7JJgw3RscFGT0IYDmq+vpcQpFa6lCj3EYV0mH3JR1PH8LY6qfwps55LeKPONX08RymOJFkQjI/vH/GqKaQWxKjIcL93J3L+Fd/rWmLFZSyhvLkiIcKyY+TGRj+VVLPSru60C4vGjjeCIp5rbeU3dDntQkcsonD2Wl+Vo2v3k1zGk0EcUUcbLlpS7YO30wBWSiEjymAZAMgnqh9RXbXtrGNFntfs9wZnullNwJMqFUEbMdzk5zXNXVrcvcCRYX2j+ILgAVUtkjlcbNmZc2clsxEoUqwBVk6MD3FRENgFS2Md62IY/NjaKU/Io+Rv7v4elZrh1lZMoqqMHmkKxJZKHJGACw5IrqvCzGz1O2nL7Gt3EiNjuOn61z2kCJGO4nHr610docyxzxpkRdR6j0qdnc0itD0jwhK+oa7c3N4+S5+0Tv3PfH+favWdDMkNm13dBR5rbsdcDsK8U0C4IlTJGZmEkpU/cj9Pf8A/VXtUOpaQNJSV7hcBQCN1HQ0jZMfquo26WVxMT8oQlgTXMaTrkF/pDXUqZtrdisKg5809uOuKzvFWrafremDS9LEgupW+dhkBV7n6YrS0PSIdPt7W0tclPvZODhvr/SklY1u5bG5pVjf3WnxveOYlkI3E/eA7A1sto1pNHEtun3eNx7/AOIpEvTZQrFdfM3ADjvWno3lpGZEz5ajAXGcfSk3ctLl1MBoH0nVIyABG3Xjt61vyRtcSI5B244981HrqLcwNIAfQHFGgXyXEKwSD94gGR6CpXYqT6mjppkleTL7iOmar393cFXgSItjjOaad1rK8iNyeuRiq88sziT94CW5GByKGJLUja4KmO3SDfnqccH8ajlY2Tj7RHlWI2r3zmoDfyxMscC4m6FiMHHpWNqtzcyX1skr5dpM5PQfWqRTi7G/rNnLdxxzMQjDkKDjNeb+INNnvdYaHztuFJLZ9+OPavUTZz3BVpn+RcBQRx9cVQ13QAwSaD5Zx95+9ARlY810PTCmtrFdFmgxwG5wfrXXeGfJXWb1bIELw23+AH6/0qhqsT6bcOsKGR5FJYY5BxT/AAwktraiOCctdTks7Y4XP+FNClrotjz9Li4vrSEFPtts3Cu+FYfUngGo9MuzZeJYUM8yQW0IRVkxIm3duEWQemCx46ZpPBsY/ta3XdIFlRHdd7YYkEnIzitrxJDCb1SIYk2bWUIgUA7j2FXvqdMZXun6lia6Z7hmgiRZjjypfNIULkYDnuPQHB468VU1oT3lhC0ktzcTibyoY42EcbM4ITbtAJw3zHJOAD6Vn6OBLcSrL84ltmnfdzlwwG7nvV25QJf6eELKosjdbVYgeb5yJux67XYfiaLXVzbmS9SnoM8mnwG3ee4srtCwmzGJI5v+mq+5JO7rnOfaqPjW309lt2s3jlnkba+XUK8uNwVD12KBlj1GQvU11viP9xo8F7CAl1FZvNHKowyOp+Uj0rzmeR49fuCjFfItVWPH8IZSWH49/Woeisxu7fuaFu204hZZ5LzMaMR5j/Myt/ECo5HPpxUV3DA94A12kkUqiJ54EKbjksrZIyW5PPXj2rWiY2jW9zbExzzxfvHXqflH5fhUus2lubu1UxLjYX9yw6Envjt6UcmlzX2klGz2/plDUUhvk0+xv03Si6RZHS3Cu0ADlpEZvm27V+7nAJI9KxtDkifUYL8xbi7PLFbSoZNsRACsFbIIO9sDsdx70njTUbxNav7cXEhit4ZUiDncVDIQQCeeQB+Qp3hhfP1uASM/y4hG1yuEAC7Rjtjj3pddDldSLfNbb+v8zuILoJaRw2UhsHn4eYyYZVH3swnODyAGBHLdeKsSzXiQyQLNDd2CL5aNaW6ZQDgAI3PbqCelYlrcSz3WpPK5LwbIon6Mi5bgEc9hUmjXdwdUtoWld4nkLsrncC2cZ57470N7I9CnCVnNEti8jXRhjneCayjIK+Su9cscblCgjAIHP51S1iS5k0PVmimmWKZ5MRysu0s5ERbhRk7snjoAB71JHK41p3BAdLu4KsFAIwvGD+Aq1JIx0HwbdEgzz6jK8jEcMVaRhx04IHHtTTJrJpJPqiibq8W13hLd45La3iDshiYq5ZlC+g+UEnrgZ5rD1XVXubdI2mieGGVQfn2BmJwACc5KqCcnu1Ubm9uU0WPE8nztbWrZbP7oxYK+wwoH046E1fv7aGLQrWdI18/7QVEh5YKEbAyece1K9zhnUuvkVHvby7k1OyhMgsZX3yPGdp2bEA3Aj7p2gdt2ew4Lr9Et8rNHI83lhn3jLdwVUDhRg46Vl2h22N4o6SziJ/8AaURqQPz5p4ke4nsJJ5Hd5mAkLMfm/dk8/jzRc55JWd/61ImkXTr2eC3ZnjuEC243KTE2VIyDnIOCo98YJAxW/wCFIIrjWpUkuJI4XQPiVgFZldg4APGMMGKnjrWVaWlvfXLrdxJIrWiggjGcu3p34HNZFvf3UVpKUnYGa1jEh67syAn88Dn2qttzG7WiOm16/me4+320RNntKwROAWijViyjI/vHJ55xgZwK1vDkEd6stxbPHJALeGPc3P3gSw/M4/CsXxWzW2jRywHZIyHLDryKveE2a31fVYoWKR+bE2wHjLA54o6lp8rVjS8PWt2Z00uylidbjekSmRV3mNmwELcFiwGB334qjriRW1xez2zSrNHIVa3nHkuAR3U9GV1HHv261SuxjQ7W5H+uF63zfVmzTtTZtRsJzfO07QwSlHkYlsqCBlupxgdc9KadypNwT7C294TfteXcs5jZmaQgckY+8M9cd/Wtg3QjvI2tozcROwEb3EmyMH+91zj6DmovBSq0cTkZPmH6HJUHjp3NSXztYtfW9ofJghv5Io0UYCrxwPbk1Nram8NdEWJxFJeNc+b9pMWczgEInrtAyAOw7mremXFumlpLEzrOrliQPlbP8Ljv9evNZmpTSQeH8RMVEs2x8dwFBA/Op7FQkDRqMIQMiqWjOjk9o3F9BZDLp9vfTXGmw/2RcqUZWAcQMf41/iH0HTrWPbXm2NrO4vBNG42CWaTcuR/C27ocdK19Vupm0e8maQmSO18xT6MEyD+dQaLDEZrOyMSG1kaWF4yoIZVQMufUhiTnryae7scc48jbMC91KWOBLd7jzrSHjYy7sKeMbvT60y0vWj8xQtzHBcJ5bIkgCvjkZHcVdsxu065Dc7ZmUZ9AeBTbu2hbwzLKY18wMVDe3pST6nNKF3buYV1cXMlltikfywzHLMCdx68CsS6h/fuGZ9qrudsciujuAINKhWIBQ2S2B16Vh6mzC7vUBO0qoI/Gg55KxV0ySG3lSS6DeQT8xA59h+eKzL2SNru4AGY1c+Wx647Zq5OcwID044/Gm2UavcSb1B+c0+hj1J9IVInWSdSU7ADrXY2Qt5GUIwy/AUGqug20LaNJI0YLg4BPYc1oRW8VvYIYY1Qk8kdaTRpFm14aS2srmUXrYbO5RjP/AAE1q3UbwXIvbWMvbtn91n3rkcfv4253YznPfivSdKAms/3qq2AMZFJGsSpb7LXT5riWNRdzHAI6Ae1dB4Zvo5tkVzN8x4JI/WuR1KV/tyR7jsDnAr0fw/p1oVgYwJu2bs+9SdSTsbz2Di3LLIsijkZ5q/osamMxr8pyc4GRRIixwsEGBjpUfhd2+3XC5+UN0pWJb0LGqs9tFtbaUPHI6+9Y/hoTDWZpNpaNgANo71ta4BJNEjjK7ulU9B+TUJFXhQBxS6jv7po6jA7Mpb5UbqMVHYWib3XadwGTmrevOywLtOOKi0wnyg2fmIPP407akpuxUvtPijTewAfJ5FQX2n26LbPx5jPkHHetHUTu8sHkHkis25Ytc2qscgFsD8aew02zYMgUxxsM/wBKuzxoQGbGQKpW6grk5yGHOfcUupOyMdpxwKLkNanl/iqaWHxeVjOQ8TDbn0//AF1Vv9Vg+xRQaY+Lgn5yvH+RSeKPm8USOfvLBwfTJ5rO8Kov26Q7RnrTfY1h3P/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Characteristic dome-shaped, shiny, waxy papules are present on the penis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Molluscum contagiosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient has a \"giant\" molluscum lesion on the shaft of his penis as well as other scattered smaller lesions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Molluscum contagiosum in a patient with atopic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lesions are present on a background of atopic dermatitis of the flexural creases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_13_44250=[""].join("\n");
var outline_f43_13_44250=null;
var title_f43_13_44251="Carbapenemase subgroups";
var content_f43_13_44251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Carbapenemase subgroups of the OXA family of beta-lactamases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cluster",
"       </td>",
"       <td class=\"subtitle1\">",
"        Enzyme subfamily",
"       </td>",
"       <td class=\"subtitle1\">",
"        Additional OXA member(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        OXA-23 (ARI-1)",
"       </td>",
"       <td>",
"        <p>",
"         OXA-27",
"        </p>",
"        <p>",
"         OXA-49",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        OXA-24/OXA-40",
"       </td>",
"       <td>",
"        <p>",
"         OXA-25",
"        </p>",
"        <p>",
"         OXA-26",
"        </p>",
"        <p>",
"         OXA-72",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        OXA-51",
"       </td>",
"       <td>",
"        <p>",
"         OXA-64 through OXA-71",
"        </p>",
"        <p>",
"         OXA-75 through OXA-78",
"        </p>",
"        <p>",
"         OXA-83",
"        </p>",
"        <p>",
"         OXA-84",
"        </p>",
"        <p>",
"         OXA-86 through OXA-89",
"        </p>",
"        <p>",
"         OXA-91",
"        </p>",
"        <p>",
"         OXA-92",
"        </p>",
"        <p>",
"         OXA-94",
"        </p>",
"        <p>",
"         OXA-95",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        OXA-58",
"       </td>",
"       <td>",
"        <p>",
"         OXA-96",
"        </p>",
"        <p>",
"         OXA-97",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        OXA-48&nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         OXA-162",
"        </p>",
"        <p>",
"         OXA-163",
"        </p>",
"        <p>",
"         OXA-181",
"        </p>",
"        <p>",
"         OXA-204",
"        </p>",
"        <p>",
"         OXA-232&nbsp;",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007; 20:440. Copyright &copy;2007 American Society for Microbiology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_13_44251=[""].join("\n");
var outline_f43_13_44251=null;
var title_f43_13_44252="GISSI risk index mortality";
var content_f43_13_44252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    GISSI predictive model for risk of death after acute myocardial infarction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Men",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Points",
"       </td>",
"       <td class=\"subtitle2\">",
"        Absolute risk of death, number",
"       </td>",
"       <td class=\"subtitle2\">",
"        Points",
"       </td>",
"       <td class=\"subtitle2\">",
"        Absolute risk of death, number",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &le;-11",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"       <td>",
"        &le;-8",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -10 to -6",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        -7 to -3",
"       </td>",
"       <td>",
"        1.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -5 to 0",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"       <td>",
"        -2 to 0",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 to 3",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        1 to 3",
"       </td>",
"       <td>",
"        2.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 to 6",
"       </td>",
"       <td>",
"        5.4",
"       </td>",
"       <td>",
"        4 to 6",
"       </td>",
"       <td>",
"        2.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7 to 9",
"       </td>",
"       <td>",
"        7.2",
"       </td>",
"       <td>",
"        7 to 9",
"       </td>",
"       <td>",
"        3.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10 to 12",
"       </td>",
"       <td>",
"        9.6",
"       </td>",
"       <td>",
"        10 to 12",
"       </td>",
"       <td>",
"        5.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13 to 15",
"       </td>",
"       <td>",
"        12.8",
"       </td>",
"       <td>",
"        13 to 15",
"       </td>",
"       <td>",
"        6.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16 to 18",
"       </td>",
"       <td>",
"        16.6",
"       </td>",
"       <td>",
"        16 to 18",
"       </td>",
"       <td>",
"        9.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        19 to 21",
"       </td>",
"       <td>",
"        22.0",
"       </td>",
"       <td>",
"        19 to 21",
"       </td>",
"       <td>",
"        12.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        22 to 24",
"       </td>",
"       <td>",
"        28.5",
"       </td>",
"       <td>",
"        22 to 24",
"       </td>",
"       <td>",
"        16.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25 to 27",
"       </td>",
"       <td>",
"        36.4",
"       </td>",
"       <td>",
"        25 to 27",
"       </td>",
"       <td>",
"        21.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        28 to 30",
"       </td>",
"       <td>",
"        45.7",
"       </td>",
"       <td>",
"        28 to 30",
"       </td>",
"       <td>",
"        27.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        31 to 33",
"       </td>",
"       <td>",
"        56.1",
"       </td>",
"       <td>",
"        31 to 33",
"       </td>",
"       <td>",
"        35.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        34 to 36",
"       </td>",
"       <td>",
"        67.0",
"       </td>",
"       <td>",
"        34 to 36",
"       </td>",
"       <td>",
"        44.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        37 to 39",
"       </td>",
"       <td>",
"        77.5",
"       </td>",
"       <td>",
"        37 to 39",
"       </td>",
"       <td>",
"        54.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;40",
"       </td>",
"       <td>",
"        83.9",
"       </td>",
"       <td>",
"        &ge;40",
"       </td>",
"       <td>",
"        61.6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Marchioli R, Avanzini F, Barzi F. Eur Heart J 2001; 22:2085.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_13_44252=[""].join("\n");
var outline_f43_13_44252=null;
var title_f43_13_44253="Curves from unacceptable FVC";
var content_f43_13_44253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Unacceptable spirometry",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 250px; height: 220px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flow-volume curve patterns from unacceptable forced vital capacity maneuvers. Curve A (red) hesitating start; curve B (blue) submaximal blast (poor peak flow effort); curve C (green) excessive coughing at the beginning of the maneuver; curve D (orange) premature termination of effort.",
"    <div class=\"footnotes\">",
"     FVC: forced vital capacity.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_13_44253=[""].join("\n");
var outline_f43_13_44253=null;
var title_f43_13_44254="Toe stand video";
var content_f43_13_44254=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1070px;\">",
"  <div class=\"videoplayer\" h264=\"./images/PC/73796/Toe_stand_video.mp4?title=Toe+stand+video\" style=\"width:480px;height:336px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Strength exercise video: Toe stand",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This exercise will help make walking easier by strengthening your calves and ankles. For an added challenge, you can modify the exercise to improve your balance.",
"    <br>",
"     <ol>",
"      <li>",
"       Stand behind a sturdy chair, feet shoulder-width apart, holding on for balance. Breathe in slowly.",
"      </li>",
"      <li>",
"       Breathe out and slowly stand on tiptoes, as high as possible.",
"      </li>",
"      <li>",
"       Hold position for one second.",
"      </li>",
"      <li>",
"       Breathe in as you slowly lower heels to the floor.",
"      </li>",
"      <li>",
"       Repeat 10 to 15 times.",
"      </li>",
"      <li>",
"       Rest; then repeat 10 to 15 more times.",
"      </li>",
"     </ol>",
"     As you progress, try doing the exercise standing on one leg at a time for a total of 10 to 15 times on each leg.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: file://go4life.niapublications.org (Accessed December 2, 2011).",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_13_44254=[""].join("\n");
var outline_f43_13_44254=null;
var title_f43_13_44255="Contents: Hospital pulmonary, critical care, and sleep medicine";
var content_f43_13_44255=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?2/63/3070\">",
"       Hospital Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Hospital pulmonary, critical care, and sleep medicine",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Hospital pulmonary, critical care, and sleep medicine",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/16/22792\">",
"           Acute interstitial pneumonia (Hamman-Rich syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/16/10505\">",
"           Acute respiratory distress syndrome: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/33/13850\">",
"           Advanced cardiac life support (ACLS) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/14/36068\">",
"           Advanced emergency airway management in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/48/38664\">",
"           Air embolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/37/8794\">",
"           An overview of asthma management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/24/20870\">",
"           Anticholinergic agents in the management of acute exacerbations of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/5/25690\">",
"           Anticoagulation in acute pulmonary embolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/10/16553\">",
"           Approach to the patient with dyspnea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/21/8538\">",
"           Arrhythmias in COPD",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/33/15894\">",
"           Arterial blood gases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/30/21991\">",
"           Assessment of respiratory distress in the mechanically ventilated patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/34/23079\">",
"           Basic airway management in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/25/36248\">",
"           Basic life support (BLS) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/26/8618\">",
"           Beta agonists in asthma: Acute administration and prophylactic use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/26/27050\">",
"           Catheter-induced upper extremity venous thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/14/30954\">",
"           Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/30/24040\">",
"           Clinical presentation and diagnosis of ventilator-associated pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/40/12938\">",
"           Communication in the ICU: Holding a family meeting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/1/29\">",
"           Complications of central venous catheters and their prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/4/40008\">",
"           Control of ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/57/16281\">",
"           Corticosteroid therapy in septic shock",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/55/25466\">",
"           Devices for difficult emergency airway management in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/57/6042\">",
"           Diagnosis of acute pulmonary embolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/7/16505\">",
"           Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/23/12663\">",
"           Diagnostic thoracentesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/14/28906\">",
"           Direct laryngoscopy and tracheal intubation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/48/15111\">",
"           Emergency airway management in acute severe asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/48/11014\">",
"           Emergency airway management in the geriatric patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/54/20329\">",
"           Emergency airway management in the morbidly obese patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/11/15545\">",
"           Endotracheal tube management and complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/45/4826\">",
"           Epiglottitis (supraglottitis): Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/16/12553\">",
"           Epiglottitis (supraglottitis): Treatment and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/22/24934\">",
"           Ethics in the intensive care unit: Responding to requests for futile or potentially inappropriate therapies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/60/26565\">",
"           Ethics in the intensive care unit: Informed consent",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/24/14727\">",
"           Etiology and evaluation of hemoptysis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/51/21306\">",
"           Evaluation and management of severe sepsis and septic shock in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/49/14105\">",
"           Evaluation of severe asthma in adolescents and adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/18/38183\">",
"           Extubation management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/47/35576\">",
"           Fever in the intensive care unit",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/23/28023\">",
"           Glycemic control and intensive insulin therapy in critical illness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/26/13735\">",
"           Identifying patients at risk for fatal asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/56/21384\">",
"           Imaging of pleural effusions in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/19/22838\">",
"           Imaging of pneumothorax",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/18/10535\">",
"           Invasive mechanical ventilation in adults with acute exacerbations of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/13/32984\">",
"           Malignant hyperthermia: Clinical diagnosis and management of acute crisis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/50/37673\">",
"           Management and prognosis of patients requiring prolonged mechanical ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/5/23641\">",
"           Management of acute exacerbations of chronic obstructive pulmonary disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/61/9176\">",
"           Management of the difficult-to-wean patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/30/17898\">",
"           Management of the patient with severe COPD and cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/13/26838\">",
"           Massive hemoptysis: Causes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/47/30454\">",
"           Massive hemoptysis: Initial management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/42/2730\">",
"           Mechanical ventilation in acute respiratory distress syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/59/8120\">",
"           Mechanical ventilation in acute respiratory failure complicating COPD",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/5/14423\">",
"           Methods of weaning from mechanical ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/48/43784\">",
"           Modes of mechanical ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/3/16441\">",
"           Needle cricothyroidotomy with percutaneous transtracheal ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/39/19063\">",
"           Nocturnal ventilatory support in COPD",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/51/1850\">",
"           Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/32/13831\">",
"           Nutrition support in critically ill patients: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/17/34073\">",
"           Nutrition support in critically ill patients: Enteral nutrition",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/58/8102\">",
"           Nutrition support in critically ill patients: Parenteral nutrition",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/22/4456\">",
"           Overview of acute pulmonary embolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/22/19817\">",
"           Overview of anesthesia and anesthetic choices",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/32/44553\">",
"           Overview of central venous access",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/21/31066\">",
"           Overview of inpatient management in the adult trauma patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/55/29558\">",
"           Overview of massive hemoptysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/1/13336\">",
"           Overview of mechanical ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/10/11434\">",
"           Overview of the management of postoperative pulmonary complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/61/40920\">",
"           Pain control in the critically ill adult patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/27/28089\">",
"           Parapneumonic effusion and empyema in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/31/27127\">",
"           Permissive hypercapnia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/28/16840\">",
"           Placement of inferior vena cava filters and their complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/14/3306\">",
"           Placement of jugular venous catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/27/1466\">",
"           Placement of subclavian venous catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/40/38537\">",
"           Postoperative complications among patients undergoing cardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/2/32810\">",
"           Postoperative management of the critically ill obese patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/55/38775\">",
"           Pretreatment agents for rapid sequence intubation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/51/34618\">",
"           Procedural sedation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/10/39078\">",
"           Prone ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/31/27128\">",
"           Pulmonary artery catheterization: Indications and complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/10/44199\">",
"           Pulmonary artery catheterization: Interpretation of tracings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/10/32934\">",
"           Pulmonary barotrauma during mechanical ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/55/1912\">",
"           Rapid sequence intubation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/7/10360\">",
"           Role of systemic glucocorticoid therapy in COPD",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/31/25082\">",
"           Sedative-analgesic medications in critically ill patients: Properties, dosage regimens, and adverse effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/29/15833\">",
"           Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/10/24744\">",
"           Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/62/6120\">",
"           Shock in adults: Types, presentation, and diagnostic approach",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/51/13113\">",
"           Strategies to reduce postoperative pulmonary complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/21/18776\">",
"           Stress ulcer prophylaxis in the intensive care unit",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/54/9065\">",
"           Supportive care and oxygenation in acute respiratory distress syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/3/36921\">",
"           Susceptibility to malignant hyperthermia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/12/22726\">",
"           The decision to intubate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/7/18552\">",
"           The difficult airway in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/51/18228\">",
"           The failed airway in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/34/6695\">",
"           The ventilator circuit and ventilator-associated pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/56/5002\">",
"           Treatment of acute exacerbations of asthma in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/32/42503\">",
"           Treatment of acute pulmonary embolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/17/3354\">",
"           Treatment of severe asthma in adolescents and adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/20/13639\">",
"           Treatment of severe hypovolemia or hypovolemic shock in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/49/793\">",
"           Use of blood products in the critically ill",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/35/13877\">",
"           Venous blood gases and other alternatives to arterial blood gases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/51/16182\">",
"           Ventilator-associated lung injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/39/21112\">",
"           Weaning from mechanical ventilation: Readiness testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/41/21140\">",
"           Weaning from mechanical ventilation: The rapid shallow breathing index",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/7/32887\">",
"           Ethics in the intensive care unit: Withholding and withdrawing life-support",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-8425D9DD01-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f43_13_44255=[""].join("\n");
var outline_f43_13_44255=null;
   